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2Abstract
v-Jun, a mutated derivative of the c-Jun transcription factor, is the transforming 
oncoprotein of an avian sarcoma virus. v-Jun is thought to cause cell transformation and 
tumorigenesis by the mis-regulation of certain target gene promoters. v-Jun can both 
activate and repress gene transcription compared to c-Jun, however little is known about 
the underlying mechanisms and the identity of the critical “effector” target gene(s) 
responsible for cell transformation and tumorigenesis by v-Jun.
To investigate the mechanisms of transcriptional regulation by v-Jun, a comparative study 
was undertaken of two gene promoters, bkj and collagenase, which are respectively 
activated or repressed by v-Jun. Promoter mutagenesis experiments were performed to 
investigate the effects of Jun binding site position and core promoter element sequences on 
transcriptional regulation by v-Jun. The primary conclusion was that these factors alone 
did not determine whether target promoters were activated or repressed by v-Jun.
However, alterations in the level of transcriptional activation and fold induction of the 
variant promoters by v-Jun implied that binding site position and core promoter sequences 
did influence transcriptional regulation by Jun proteins. This analysis also suggested that v- 
Jun regulated transcription by different mechanisms at different target promoters.
Further work investigated the relationship between transcriptional activation of v-Jun 
target promoters and cell transformation using AvJ-hER, an amino-terminally truncated v- 
Jun protein fused to the hormone-binding domain of estrogen receptor-a. This chimaeric 
protein was previously shown to induce activation of v-Jun target genes and cell 
transformation in an estradiol-dependent manner, despite lacking the v-Jun transcriptional 
activation domain. The estrogen receptor activating function-2 (AF-2) domain was 
proposed to substitute for this v-Jun domain, implying that estradiol-dependent 
transcriptional activation of v-Jun target gene promoters by AvJ-hER was required for cell 
transformation.
To test this hypothesis, an inactivating mutation was introduced into helix 12 of the AF-2 
domain, which mediates estrogen receptor binding to co-activator proteins. The mutant 
AvJ-hER protein was inactive in transcription and cell transformation assays, confirming 
that these processes required AF-2 function. Many estrogen receptor co-activator proteins 
have histone acetyltransferase activity, however the p300 histone acetyltransferase domain
3was unable to substitute for the estrogen receptor AF-2 domain function to induce either 
transcriptional activation or cell transformation.
In conclusion, while the mechanisms responsible for transcriptional activation and 
repression by v-Jun remain unclear, these results support the hypothesis that transcriptional 
activation of positive v-Jun target gene promoters is required for cell transformation.
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1 Introduction
1.1 Discovery and characterisation of the Jun proteins.
1.1.1 Background
Avian sarcoma viruses are retroviruses which induce tumour formation upon infection. The 
viral genes responsible for tumorigenesis were found to be similar to sequences found in 
avian genomic DNA (Stehelin et al., 1976), suggesting that these viral oncogenes were 
derived by transduction of cellular genes. Identification of some of these cellular proto­
oncogenes revealed that many are involved in the regulation of normal cell growth. 
Transforming retroviruses such as avian sarcoma viruses were used in the search for more 
cellular proto-oncogenes, in the hope that this would reveal more information about the 
control of cell growth and the mechanisms of tumorigenesis.
1.1.2 Discovery of v-Jun.
In one such search for novel proto-oncogenes, avian sarcoma virus 17 (ASV17) was 
isolated from a spontaneous chicken sarcoma (Cavalieri et al., 1985). The virus caused the 
formation of fibrosarcomas in vivo, and transformed chicken embryo fibroblasts (CEFs) in 
culture. The ASV17 transformed phenotype is defined by a characteristic cell morphology 
in culture (Cavalieri et al., 1985; Maki et al., 1987); anchorage independence and the 
formation of foci on solid substrate (Bos et al., 1990); enhanced cyclin E-cdk2 activity, 
resulting in an increased rate of cell growth, and continued cell cycle progression 
accompanied by high levels of apoptosis in the absence of serum growth factors (Clark et 
al., 2000; Clark and Gillespie, 1997). The viral genome did not contain sequences similar 
to known proto-oncogenes (Cavalieri etal., 1985; Maki etal., 1987), indicating that the 
transforming ability of the virus was due to the activity of a novel oncoprotein. Subsequent 
analysis of the ASV17 genome identified a putative oncogene with no sequence homology 
to any previously identified proto-oncogene. The novel gene was named jun, from the 
Japanese word for 17 (Maki et al., 1987).
Viral Jun (v-Jun) is expressed as a fusion with the viral Gag protein (Bos et al., 1988). 
Expression of Gag-v-Jun, or the v-Jun sequences alone, transformed CEFs in culture (Ball 
et al., 1988; Bos et al., 1990) and caused tumour formation (Wong et al., 1992), . 
confirming that v-jun is the transforming oncogene of ASV17.
1.1.3 Discovery of the cellular Jun proteins.
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During initial analysis of the ASV17 genome, sequences similar to v-jun were detected in 
genomic DNA from chickens and other vertebrate species (Maki et al., 1987), indicating 
that v-jun was, like other viral oncogenes, derived from a cellular proto-oncogene. Chicken 
cellular jun (c-jun) was subsequently cloned and sequenced (Ball et al., 1988; Nishimura 
and Vogt, 1988). c-Jun is essential for embryonic development and cell proliferation in 
culture (Johnson et al., 1993). Additional members of the jun family, junB and junD, have 
also been identified (Hirai et al., 1989; Ryder et al., 1988); however, based on sequence 
homology, c-jun is the cellular progenitor of the v-jun oncogene.
Comparison of the c-jun and v-jun sequences revealed structural differences between the 
genes (see Figure 1.1). As well as the fusion of v-jun to gag, the viral oncogene lacks the 
c-jun 3’ untranslated region (UTR), which is thought to destabilise c-jun mRNA. Deletion 
of this region from v-jun contributes to the high levels of expression of the viral protein 
(Bos et al., 1990). Amino acids 32 to 58 of c-Jun are absent from v-Jun; this 27 amino acid 
sequence is known as the delta domain. v-Jun also contains two amino acid substitutions 
compared to c-Jun: a serine to phenylalanine substitution at c-Jun amino acid position 222, 
and a cysteine to serine substitution at position 248.
Over-expression of c-Jun causes transformation of CEFs in culture, albeit at a lower 
efficiency than v-Jun (Bos et al., 1990; Wong et al., 1992). However, only v-Jun is 
tumorigenic in vivo (Morgan et al., 1994; Wong et al., 1992). Therefore there are 
differences in the effects of the two proteins which are not due solely to the higher level of 
expression of v-Jun. The contributions of the mutations within the v-Jun protein to cell 
transformation and tumorigenesis have been studied in some detail. Deletion of the delta 
region had the most significant effect on the induction of cell transformation, with the 
double amino acid substitution of secondary importance (Bos et al., 1990). The minor 
effect of the double substitution may be due to neutralisation of the opposing effects of the 
individual mutations; introduction of the serine to phenylalanine mutation into c-Jun 
decreased, while the cysteine to serine substitution increased, the efficiency of focus 
formation (Morgan etal., 1993). The delta deletion and the double amino acid substitution 
both contributed to tumour formation by v-Jun (Morgan et al., 1994). These results imply 
that the mutations within v-Jun are responsible for its altered function and oncogenic 
activity.
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TAD
v-Jun
c-Jun
63 73 222 248
F SS S
Gag
Zip
65kD
39kD
s s s c
JunB: 45% homology zip 38kD
s s s c
JunD: 53% homology A ! | | zip 38kD
Figure 1.1
Comparison of the Jun family proteins.
The Jun transcriptional activation domain (TAD), delta (A) domain, basic (b) DNA 
binding domain and leucine zipper (zip), and the ASV17 Gag domain, are shown.
S: serine; F: phenylalanine; C: cysteine.
Amino acid positions are derived from the c-Jun sequence.
Protein molecular weights and amino acid homologies to c-Jun are shown.
The mutations within v-Jun compared with c-Jun alter the post-translational 
regulation of the viral protein and contribute to the mis-regulation of transcription 
and cell transformation -  see text for details.
1.1.4 v-Jun as a transcription factor.
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The function of the Jun proteins was first suggested by the observation that the C-terminal 
region of v-Jun shares 45% sequence homology with the sequence-specific DNA binding 
domain (DBD) of Gcn4, a yeast transcription factor (Vogt et al., 1987). The implication 
that v-Jun could also bind specifically to DNA was confirmed in experiments which 
demonstrated that replacement of the Gcn4 DBD with the homologous region of v-Jun 
complemented a gcn4 null phenotype (Struhl, 1987). Complementation required a 
functional Gcn4 binding site in a target promoter, suggesting that the DNA recognition 
sequence of v-Jun was similar to that of Gcn4. Later observations that full-length v-Jun 
could replace Gcn4 function suggested that v-Jun also contained a transcriptional 
activation domain (TAD); progressive N-terminal deletions localised this domain to two 
acidic regions between amino acids 15 and 102 of v-Jun (Struhl, 1988).
1.1.5 c-Jun as a component of AP-1.
The DNA recognition sequence of Gcn4, ATGACTCAT, is similar to an element found in 
the promoters of genes induced by tumour-promoting phorbol esters such as 12-0- 
tetradecanoyl-phorbol-13-acetate (TPA) (Angel et al., 1987b). These TPA response 
elements (TREs) have the consensus sequence TGAG/CTCA and are bound by Activator 
Protein-1 (AP-1), which activates transcription from TRE-containing promoters in 
response to TPA (Angel et al., 1987b; Lee et al., 1987). The similarity between the AP-1 
and Gcn4 recognition sequences suggested that c-Jun may be related to AP-1.
Antibodies raised against N- and C-terminal domains of v-Jun specifically recognised 
human AP-1 in Western blots, and tryptic peptide fragments of AP-1 were found to 
correspond in amino acid sequence to regions of c-Jun (Angel et al., 1988; Bohmann et al., 
1987). In DNA footprinting analysis, v-Jun and human c-Jun protected consensus TRE 
sequences, but not mutated derivatives, with a similar pattern to human AP-1 (Angel et al., 
1988; Bohmann et al., 1987; Bos et al., 1988). v-Jun was also shown to activate 
transcription from TRE-containing promoters (Angel et al., 1988). Taken together, these 
data showed that c-Jun and v-Jun bind specifically to TREs, and that c-Jun comprises a 
major component of the cellular AP-1 transcription factor.
1.1.6 Post-translational regulation of c-Jun and v-Jun.
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The expression and activity of cellular proto-oncogenes such as c-jun are tightly regulated 
to prevent inappropriate cell growth. Identification of c-Jun as a major component of AP-1 
placed the protein at the end of signal transduction pathways induced by phorbol esters 
such as TPA (Angel et al., 1987b; Lee et al., 1987), and the activation of oncogenes such 
as Ha-ras and v-src (Schonthal et al., 1988; Wasylyk et al., 1988). This discovery enabled 
investigation of the way in which c-Jun is regulated by extra-cellular signals, and how v- 
Jun may escape regulation and so cause cell transformation and tumorigenesis.
Treatment with phorbol esters, or activation of Ha-Ras, increased the level of c-Jun 
phosphorylation at serine residues at positions 63 and 73 (Adler et al., 1992; Binetruy et 
al., 1991; Pulverer etal., 1991; Smeal etal., 1991). Phosphorylation of these residues, in 
particular serine 73, correlated with increased transcriptional activation of TPA-responsive 
genes such as collagenase (Binetruy et al., 1991; Black et al., 1994; Hibi et al., 1993; May 
et al., 1998; Pulverer et al., 1991; Smeal et al., 1991), and with the ability of c-Jun to 
increase the efficiency of cell transformation by Ha-Ras (Smeal et al., 1991). In contrast, 
the level of phosphorylation of v-Jun was not increased by these stimuli (Adler et al.,
1992; Black et al., 1994; Black et al., 1991; May et al., 1998; Smeal et al., 1991), and 
mutation of the serine residues corresponding to positions 63 and 73 of c-Jun did not affect 
the transcriptional activity of v-Jun (Black et al., 1994). This difference between the Jun 
proteins was found to be a result of the deletion of the delta region from v-Jun (Adler et al., 
1992; Black etal., 1991; Derijard etal., 1994).
c-Jun N-terminal kinase (JNK) was identified as a novel member of the mitogen activated 
protein kinase (MAPK) family (Derijard et al., 1994; Hibi et al., 1993). JNK proteins are 
activated by cellular stress such as ultra-violet (UV) light, phorbol esters, or activation of 
Ha-Ras, and phosphorylate c-Jun on serines 63 and 73 (Derijard et al., 1994; Hibi et al., 
1993). The JNK binding domain of c-Jun encompasses the delta domain, with the result 
that JNK binds c-Jun, but not v-Jun (Hibi et al., 1993; Kilbey et al., 1996; May et al., 
1998). The lack of phosphorylation of v-Jun at N-terminal serine residues renders the 
oncoprotein refractory to signal transduction pathways induced by JNK agonists such as 
UV light, TPA and activated Ha-Ras (Hibi et al., 1993; Kilbey et al., 1996; May et al., 
1998; Tsang etal., 1994).
The point mutations within the C-terminal half of v-Jun also alter the regulation of the 
protein by signal transduction cascades. The serine to phenylalanine mutation at position
22
222 abolishes phosphorylation of the site, which releases v-Jun from inhibition of DNA 
binding (Boyle et al., 1991; Lin et al., 1992). The cysteine to serine mutation at position 
248 has also been shown to increase the affinity of DNA binding by v-Jun in oxidising 
conditions, due to insensitivity of the serine residue to redox regulation (Abate et al.,
1990). However, an equivalent mutation has been shown to decrease the DNA binding 
activity of c-Jun homodimers in reducing conditions (Oehler et al., 1993). Regulation of 
the DNA binding activity of c-Jun is clearly complex, but the double point mutation in the 
C-terminal half of v-Jun has been shown to permit specific DNA binding by the viral 
protein in conditions where binding by c-Jun was abolished (Oehler et al., 1993).
Interestingly, the v-Jun cysteine to serine mutation subjects the protein to an additional 
level of regulation. Amino acid position 248 is contained within the Jun nuclear localistion 
signal, and introduction of a serine residue at this site has been shown to cause cell-cycle 
dependent nuclear translocation; unlike c-Jun, which was constitutively nuclear, the 
nuclear translocation of v-Jun was specifically increased during the G2 phase of the cell- 
cycle (Chida and Vogt, 1992). This was due to phosphorylation of v-Jun at serine 248 
during G1 and S phase (Tagawa et al., 1995). The significance of this phenomenon is not 
known, but represents a further example of how the mutations within v-Jun alter its 
regulation compared to c-Jun.
c-Jun is also regulated by other pathways. For example, an increase in intracellular calcium 
levels stimulated the phosphorylation of the protein, at sites other than serines 63 and 73, 
and independently of JNK activation (Cruzalegui et al., 1999). In addition, c-Jun, but not 
v-Jun, has been shown to be phosphorylated at tyrosine 170 by c-Abl (Barila et al., 2000). 
Little is known about the regulation of v-Jun by these mechanisms, and how the mutations 
within the protein may alter the effects of such signal transduction pathways in v-Jun 
transformed cells. Further investigation of these pathways may reveal further examples of 
the phenotypic effects of the mutations within v-Jun, possibly with implications for cell 
transformation and tumorigenesis.
1.1.7 Interaction of Jun with other proteins.
1.1.7.1 Fos and other bZip proteins.
Early attempts to purify AP-1 revealed that the transcription factor consists of more than 
one protein (Angel etal., 1987b; Lee etal., 1987). The product of the c-fos proto-oncogene 
was known to bind DNA sequences similar to a TRE, and was indeed shown to associate
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with Jun proteins as part of the AP-1 complex bound to TREs (Halazonetis et al., 1988; 
Rauscher et al., 1988a; Rauscher etal., 1988c; Sassone-Corsi etal., 1988).
v-Jun, c-Jun, JunB and JunD have all been shown to bind TREs in the absence of any other 
protein (Halazonetis et al., 1988; Nakabeppu et al., 1988; Rauscher et al., 1988b; Ryseck 
and Bravo, 1991; Turner and Tjian, 1989). While c-Fos alone could not bind TREs, co­
expression of c-Fos or the related proteins FosB and Fos-related antigen-1 (Fra-1) 
increased the affinity of DNA binding by each of the Jun proteins (Halazonetis et al., 1988; 
Kouzarides and Ziff, 1988; Nakabeppu et al., 1988; Rauscher et al., 1988b; Ryseck and 
Bravo, 1991; Turner and Tjian, 1989). This was due to stabilisation of the protein-DNA 
complex (Rauscher et al., 1988b; Ryseck and Bravo, 1991). Co-translation of full-length 
and truncated forms of Jun and Fos revealed that Jun proteins could form homodimers 
(Halazonetis et al., 1988; Nakabeppu et al., 1988; Turner and Tjian, 1989), and 
heterodimers with other Jun proteins (Nakabeppu et al., 1988) or with c-Fos and related 
proteins (Gentz et al., 1989; Halazonetis et al., 1988; Kouzarides and Ziff, 1988; 
Nakabeppu et al., 1988; Turner and Tjian, 1989). In contrast, c-Fos could not form stable 
homodimers (Turner and Tjian, 1989). The ability of proteins to bind DNA therefore 
correlated with the presence of stable Jun / Jun or Jun / Fos dimers. Dimerisation occurred 
in the absence of DNA (Halazonetis et al., 1988; Nakabeppu et al., 1988), suggesting that 
dimerisation was required for DNA binding.
The Jun dimerisation domains were localised by various studies to the C-terminal halves of 
the proteins. Deletion and site directed mutagenesis studies with Jun and Fos proteins 
revealed that dimerisation was mediated by the leucine zipper motif adjacent to the basic 
DBD (Gentz et al., 1989; Kouzarides and Ziff, 1988; Schuermann et al., 1989; Turner and 
Tjian, 1989). This combination of a basic region and leucine zipper, responsible for DNA 
binding and dimerisation, is known as a bZip domain. The specific orientation of binding 
between two leucine zippers brings together the basic regions of the two components of the 
dimer (Gentz et al., 1989), to form a bi-partite DNA-binding domain.
A conserved element similar to a TRE is found in the promoters of many genes activated in 
response to increased levels of cyclic AMP (cAMP) (Comb et al., 1986). This cAMP 
response element (CRE) has the sequence TGACGTCA and is bound by members of the 
activating transcription factor (ATF) / CRE binding protein (CREB) family. These 
transcription factors contain bZip domains with limited sequence homology to the Jun and 
Fos families. This, and the similarity between the TRE and CRE sequences, led to 
investigation of the relationship between the AP-1 and ATF / CREB families.
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Protein complexes bound to TREs were also capable of binding to oligonucleotides 
containing various CREs (Hoeffler et al., 1989). c-Jun, JunB and JunD homodimers have 
been shown to directly bind certain CREs, depending on the flanking sequences, with a 
lower affinity than to TREs (Chatton et al., 1994; Ivashkiv et al., 1990; Macgregor et al., 
1990; Nakabeppu eta l., 1988; Ryseck and Bravo, 1991). In contrast, v-Jun homodimers 
bound preferentially to CREs (Kataoka et al., 1994). Jun proteins heterodimerise via 
leucine zipper motifs with certain members of the ATF/CREB family, including CRE-BP2, 
CRE-BPa, ATF-2, -3, -4, ATF-a, B-ATF, and Jun dimerisation proteins (JDP) -1 and -2, 
but not with CREB or ATF-1 (Aronheim et al., 1997; Benbrook and Jones, 1990; Chatton 
etal., 1994; Hai and Curran, 1991; Ivashkiv etal., 1990; Macgregor etal., 1990; Nomura 
et al., 1993).
Interestingly, while Jun / Jun or Jun / Fos dimers bind preferentially to TREs, dimers of c- 
Jun with members of the ATF/CREB family generally bind specifically to CREs 
(Benbrook and Jones, 1990; Chatton etal., 1994; Hai and Curran, 1991; Ivashkiv etal., 
1990; Macgregor et al., 1990; Nomura et al., 1993). Some combinations, such as Jun / 
ATF-2, Jun / ATF-4, and Jun / ATFa, can also bind to TREs, but with a lower affinity than 
to CREs (Chatton et al., 1994; Hai and Curran, 1991). JunB / B-ATF dimers are highly 
unusual in binding to TREs with a higher affinity than to CREs (Echlin et al., 2000). The 
implications of this alteration in binding site preference are discussed below. Jun and Fos 
proteins also dimerise with members of the Maf family, bZip oncoproteins which bind to 
sequences containing TREs and CREs (Kataoka et al., 1994), and c-Jun and c-Fos dimerise 
with the nuclear factor for interleukin-6 expression (NF-IL6) transcription factor in 
response to IL-6 (Hsu et al., 1994).
The ability of Jun proteins to form dimers with such a wide range of bZip transcription 
factors has implications for their role as transcriptional regulators. Opposing effects of 
different heterodimer combinations on transcription have been demonstrated. For example, 
co-expression of CRE-BP2 or B-ATF interfered with the activation of TRE-containing 
promoters by Jun / Fos dimers (Benbrook and Jones, 1990; Echlin et al., 2000), by 
formation of dimers with Jun which do not activate transcription from TREs. As described 
above, dimerisation of Jun with different partners also alters the DNA binding preference 
of the complex, directing Jun / AP-1 family dimers to TREs and a sub-set of CREs, and 
Jun / ATF/CREB family dimers predominately to CREs. This would be expected to direct 
different dimers to bind and regulate distinct but overlapping spectra of target promoters in
vivo.
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Convincing evidence for distinct roles of Jun / AP-1 family and Jun / ATF/CREB family 
heterodimers in transcriptional regulation and cell transformation has been obtained, by 
manipulation of the Jun leucine zipper motif to create c-Jun and v-Jun mutants which 
dimerise preferentially with either Fos or ATF proteins (van Dam et al., 1998). Jun-mO 
proteins, which preferentially dimerised with c-Fos and Fra-2, specifically bound and 
activated transcription from a consensus TRE, while Jun-ml proteins, which formed 
dimers with ATF-2, did not. The mutant proteins induced different aspects of the v-Jun 
transformed phenotype in CEFs; v-Jun-mO mediated anchorage independent growth in soft 
agar, while expression of v-Jun-ml enabled growth in low serum. Co-expression of both 
proteins reconstituted the full v-Jun transformed phenotype. These results suggested a 
model of v-Jun transformation whereby v-Jun / Fos family dimers regulate TRE-containing 
promoters to induce anchorage independent growth, and v-Jun / ATF family dimers 
regulate promoters containing CREs to enable growth-factor independence.
This hypothesis is supported by data from various studies. Over-expression of Fra-2, but 
not ATF-2, induced some degree of anchorage independent growth (van Dam et al., 1998), 
although with a lower efficiency than v-Jun. Co-expression of ATF-2 with v-Jun-ml, and 
to a lesser extent with wild-type v-Jun, enhanced tumorigenesis and growth in low serum, 
but decreased the efficiency of colony formation in soft agar, possibly by sequestration of 
v-Jun from complexes containing Fos family proteins (Huguier et al., 1998). Over­
expression of ATF-3 in CEFs caused the characteristic change in cell morphology seen in 
v-Jun transformed cells, and enhanced growth in low serum (Perez et al., 2001). However, 
ATF-3 did not induce anchorage independent growth, and regulated (by repression) only a 
sub-set of v-Jun target genes, further supporting the model described above. Forced 
expression of v-Jun homodimers, which bind TREs and CREs (Kataoka et al., 1994), 
caused growth factor independence, anchorage independent growth, and tumorigenesis 
(Jurdic et al., 1995). Similarly, formation of c-Jun homodimers, which bind TREs and 
certain CREs (Nakabeppu et al., 1988; Ryseck and Bravo, 1991), led to both growth-factor 
independence and anchorage independent growth (Castellazzi et al., 1993).
Even within the Fos family, different dimerisation partners can modify the function of Jun 
proteins. This was first suggested due to the changes in composition of the protein complex 
bound to TREs observed in rodent fibroblasts in the 24hr following stimulation with serum 
or specific mitogens (Cook et al., 1999; Kovary and Bravo, 1991; Kovary and Bravo,
1992; Lallemand et al., 1997). The composition of the complex varied with differences in 
the relative levels of expression of the Jun and Fos proteins. The JunD / Fra-2 dimers 
predominant in quiescent cells were rapidly replaced, initially by dimers of JunB with c-
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Fos and FosB, and then by c-Jun and JunB with Fra-1 and Fra-2. In contrast, TREs in 
asynchronous cultures of exponentially growing cells were bound predominantly by dimers 
of c-Jun and JunD with Fra-2 and some Fra-1 (Kovary and Bravo, 1992; Lallemand et al.,
1997). Distinct roles for the different Fos proteins were suggested by micro-injection of 
specific inhibitory antibodies. Simultaneous inhibition of c-Fos and FosB function had the 
greater effect on DNA synthesis during serum stimulation of cells, while inhibition of Fra- 
1 and Fra-2 function had the greater effect in exponentially growing cells (Kovary and 
Bravo, 1992).
Evidence exists that the distinct roles of different Fos proteins are due to the highly 
specific regulation of transcription by different dimer combinations. For example, c-Jun / 
c-Fos and c-Jun / Fra-2 dimers have similar DNA binding properties, but c-Jun / c-Fos 
dimers activated, while c-Jun / Fra-2 dimers repressed, a promoter driven by the 
collagenase TRE (Suzuki et al., 1991). The differences between the Fos proteins were 
largely attributable to sequence divergence in their C-terminal halves. c-Fos and Fra-2 also 
have distinct roles in mouse keratinocyte differentiation in response to different stimuli 
(Rutberg et al., 1997). c-Fos expression was induced specifically by TP A, and c-Fos 
activated transcription from certain TRE-containing promoters, while Fra-2 expression was 
induced by calcium treatment and was shown to reduce transcription from a promoter 
strongly activated by c-Fos. This difference between the proteins is thought to contribute to 
the activation of overlapping but distinct sets of target genes in response to the different 
stimuli.
1.1.7.2 Unrelated transcription factor families.
As described above, dimerisation of c-Jun and v-Jun with different members of the bZip 
transcription families can significantly alter their DNA binding preference and 
transcriptional effects. c-Jun is also known to interact with members of many structurally 
unrelated transcription factor families, providing a further level of transcriptional 
regulation. The recent trend towards investigation of combinatorial transcriptional 
regulation by multiple factors from complex enhanceosome elements has yielded much 
information about the interactions of the AP-1 family with other regulatory factors, and 
only a few well-characterised examples are discussed below; for a more comprehensive 
review, see (Chinenov and Kerppola, 2001).
One example involves certain members of the signal transducer and activator of 
transcription (Stat) family. In response to cytokines such as IL-6, c-Jun and Stat proteins
interact and synergistically activate transcription from promoters containing a Stat 
recognition sequence, with or without a TRE (Schaefer et al., 1995; Schuringa et al., 2001; 
Zhang et al., 1999). c-Jun and c-Fos also interact with the nuclear factor of activated T 
cells (NFAT) family to activate transcription from promoters containing a NFAT 
recognition sequence adjacent to a TRE. NFAT proteins bound to DNA form a complex 
with Jun / Jun or Jun / Fos dimers (Jain et al., 1993), which has been shown to increase the 
affinity of binding of a c-Jun / c-Fos dimer to a non-consensus TRE (Peterson et al., 1996). 
Similarly, interaction between c-Jun and the retinoblastoma (Rb) tumour suppressor 
protein led to synergistic activation of transcription from target promoters and increased 
the affinity of c-Jun binding to a consensus (Nead et al., 1998; Nishitani et al., 1999) or 
non-consensus (Slack et al., 2001) TRE. Interactions such as these clearly have 
consequences for target promoter selection as well as regulation by c-Jun.
Jun proteins also undergo a complex series of interactions with Smad proteins in response 
to transforming growth factor-p (TGF-p). TGF-P induced a strong interaction between c- 
Jun and Smad-3, and the two proteins co-regulated promoters containing a Smad binding 
element (SBE) and TRE (Zhang et al., 1998). Promoters containing overlapping TRE / 
SBE sequences, as well as promoters such as c-jun, which contain a TRE and SBE some 
distance apart, were activated by TGF-p, with DNA binding by the Smad and AP-1 
families required for full activation (Qing et al., 2000; Wong et al., 1999). However, TGF- 
p-induced activation of certain SBE-containing promoters by Smad-3 was inhibited by 
JNK activation of c-Jun and JunB (Dennler et al., 2000; Verrecchia et al., 2001), 
suggesting the existence of complex cross-talk networks linking the Smad and AP-1 family 
pathways. The induction of the c-jun promoter by TGF-p may therefore provide a negative 
feedback mechanism.
The examples discussed above represent only a fraction of the known interactions of c-Jun 
with a wide range of structurally diverse transcription factors. While this area of research is 
expanding, little is known about the interaction of v-Jun with these regulatory factors. It 
would be expected that the structural differences between v-Jun and c-Jun could alter the 
interaction of v-Jun with some c-Jun-binding proteins, possibly affecting the selection and 
regulation of a diverse range of target promoters. Any such alterations may be found to 
contribute to the v-Jun transformed phenotype.
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1.2 Transformation as a result of altered transcriptional 
regulation: the search for v-Jun target genes.
As described in Chapter 1.1, v-Jun and c-Jun have been characterised as transcription 
factors which dimerise with a variety of proteins via the leucine zipper, bind a specific 
recognition sequence in promoter DNA, and regulate the transcription of a range of target 
genes in a highly complex manner. Structural differences exist between v-Jun and c-Jun, 
and these have been shown to contribute to cell transformation and tumorigenesis by the 
viral protein (See Chapter 1.1.3). The role of the Jun proteins as transcription factors 
suggests that tumorigenesis and the increased efficiency of cell transformation by v-Jun are 
due to the altered expression of target genes, via mis-regulation of their promoters by the 
viral protein. Evidence for cell transformation as a consequence of altered transcriptional 
regulation by v-Jun, and a review of the search for target genes relevant to this process, are 
presented below.
1.2.1 Transcriptional regulation and cell transformation.
In the context of over-expressed murine c-Jun, deletion of the DBD or leucine zipper 
abolished transcriptional regulation from TREs and cell transformation, while point 
mutations in these domains decreased transcriptional activation and the efficiency of cell 
transformation (Morgan et al., 1992). Deletion of the v-Jun TAD similarly abolished 
transcriptional activation and cell transformation by the viral protein. These results suggest 
that sequence-specific DNA binding and the activation of transcription are required for cell 
transformation by c-Jun and v-Jun, supporting the hypothesis that the phenotypic effects of 
the proteins are due to their role as regulators of transcription.
Manipulation of the v-Jun DBD to alter its binding specificity from the TRE to the 
unrelated c/EBP recognition sequence further supported this hypothesis (Basso et al.,
2000). v-Jun proteins with a mutated DBD failed to alter the expression of known v-Jun 
target genes, and did not induce deregulated cell growth, anchorage independence or 
release from contact inhibition. This strongly suggests that the specific binding and 
regulation of promoters containing TREs is required for cell transformation by v-Jun.
v-Jun has been shown to down-regulate the endogenous c-Jun protein and thereby replace 
c-Jun as a major component of the complex bound to TREs and CREs in v-Jun 
transformed CEFs (Kilbey et al., 1996). Various studies have investigated the effect of this
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alteration on the transcriptional regulation of promoters containing these elements. Initial 
observations with a promoter driven by four copies of the TRE sequence in an in vitro 
assay suggested that v-Jun was a stronger activator of transcription than c-Jun (Bohmann 
and Tjian, 1989). Deletion of a region similar to the delta domain increased the 
transcriptional activity of c-Jun in this system, implying that the delta deletion was largely 
responsible for the increased activity of v-Jun. This was supported by the study in CEFs of 
transcriptional activation from a promoter containing five binding sites for the yeast Gal4 
transcription factor. A fusion of v-Jun to the Gal4 DBD was a stronger activator of 
transcription than the equivalent Gal4-c-Jun protein (Black et al., 1994). Again, the 
different activities of c-Jun and v-Jun were reported to be due to the deletion of delta from 
v-Jun.
In the murine F9 embryonal carcinoma cell line, which expresses low levels of the 
endogenous AP-1 family proteins, c-Jun has been shown to be a more potent activator than 
v-Jun of the natural coliagenase I promoter (Morgan et al., 1993), which contains a 
consensus TRE (Angel et al., 1987b). Systematic analysis revealed that while the 
introduction of the serine to phenylalanine mutation into c-Jun increased transactivation of 
the coliagenase promoter, the cysteine to serine or double mutation decreased transcription 
to the levels obtained with v-Jun (Morgan et al., 1993). These v-Jun C-terminal point 
mutations also had opposing effects on the efficiency of cell transformation, further 
supporting the relationship between transcriptional mis-regulation and cell transformation. 
Deletion of the delta domain from c-Jun also decreased transcriptional activation of the 
coliagenase I promoter, but to a lesser degree than introduction of the cysteine to serine 
mutation.
A decreased transcriptional activity of v-Jun compared to c-Jun has also been observed in 
CEFs, which have a much higher basal level of AP-1 family activity than do F9 cells. 
Various artificial promoters containing a TRE, as well as the natural coliagenase I 
promoter, were specifically repressed in v-Jun transformed CEFs compared to control cells 
(Kilbey et al., 1996), and co-expression of c-Jun or v-Jun with the coliagenase I promoter 
confirmed that c-Jun activates this promoter more strongly than does v-Jun (Gao et al.,
1996). In a comparison between a minimal c-jun promoter driven by multiple copies of the 
c-jun TRE or of a consensus CRE, c-Jun activated the TRE-containing promoter more 
strongly than did v-Jun, while v-Jun was the more potent activator of transcription from the 
CRE-driven promoter (Gao et al., 1996).
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Taken together, these results suggest that v-Jun can both activate and repress transcription 
compared with c-Jun, depending on the promoter context, cell type, and transcription assay 
utilised. It has been reported that the delta deletion is largely responsible for the increased 
transcriptional activity of v-Jun at certain promoters (Black et al., 1994; Bohmann and 
Tjian, 1989), while the cysteine to serine point mutation appears more important for 
transcriptional repression by v-Jun (Morgan et al., 1993). This has not been specifically 
investigated by direct comparison in the same system of promoters activated or repressed 
by v-Jun. It therefore remains unclear whether this represents a genuine difference between 
the two modes of transcriptional regulation by v-Jun. However, it is clear that the 
replacement of c-Jun with v-Jun in transformed cells mis-regulates, by activation or 
repression, various target promoters containing TREs or CREs, due to the structural 
differences between the proteins.
1.2.2 v-Jun target genes.
1.2.2.1 Identification of v-Jun targets.
In accordance with the observations described above, methods such as subtractive 
hybridisation have identified examples of both activated and repressed targets of v-Jun. 
Examples of negative v-Jun targets include C06, a transmembrane protein with homology 
to a subunit of calcium-activated potassium channels (Oberst et al., 1997); apolipoprotein 
A-l, whose down-regulation is associated with certain cancers (Hadman et al., 1998); the 
endogenous c-jun gene (Hussain et al., 1998); and secreted protein, acidic and rich in 
cysteine (SPARC), which is associated with tissue remodelling and cell cycle control (Vial 
and Castellazzi, 2000; Vial et al., 2000).
Many up-regulated v-Jun targets have also been identified, including p-keratin in jun- 
transformed cells (Bkj), a highly hydrophobic protein related to p-keratins (Hartl and 
Bister, 1995; Hartl and Bister, 1998); a putative cysteine protease related to cathepsin O 
(Hadman et al., 1996); glutaredoxin, which is involved in DNA synthesis (Goller et al.,
1998); heparin-binding epidermal growth factor-like growth factor (HB-EGF) (Fu et al.,
1999); homologues of cytokine-inducible SH2-containing proteins, reversion-induced LIM 
protein, MAPK phosphatase 2, and other targets with no homology to known genes (Bader 
et al., 2000; Fu et al., 2000).
A more recent study has utilised emerging micro-array technology to identify a large 
number of genes (more than 200) either activated or repressed by v-Jun, including a
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putative tumour suppressor, Src-suppressed C kinase substrate (SSeCKS), which is 
repressed by v-Jun (Cohen et al., 2001). This approach necessitates the expression of v-Jun 
in murine fibroblasts, as chicken micro-arrays are not yet commercially available. This 
may be found to limit the value of the technique for the identification of target genes 
associated with cell transformation by v-Jun in its natural CEF target cells. However, at 
present, this appears to be an extremely useful approach to large-scale identification of v- 
Jun target genes.
Many genes mis-regulated in v-Jun transformed cells will not be direct transcriptional 
targets of v-Jun, but may be activated or repressed in response to the altered expression of 
other, direct, targets. A small number of genes have been identified as direct v-Jun targets 
by cloning and analysis of their promoters. For example, the activation of Bkj and the 
repression of c-Jun have been shown to be due to direct transcriptional regulation by v-Jun, 
via TREs in the respective gene promoters (Hartl and Bister, 1998; Hussain et al., 1998). 
However, this approach, while potentially informative about the transcriptional regulation 
of specific v-Jun target promoters, is not practical with the advent of technologies such as 
micro-array analysis. The large amount of data now being generated requires a screening 
approach simultaneously applicable to many putative target genes.
One such possibility is the use of a quail cell system, in which the expression of v-Jun and 
subsequent transformation of the cells are controlled by the addition of doxycycline (Bader 
et al., 2000). bkj, a known direct target of v-Jun, was activated in this system with kinetics 
consistent with rapid induction by v-Jun. The expression of a novel up-regulated v-Jun 
target gene was also dependent on the induction of v-Jun expression, indicating that it may 
also be a direct transcriptional target. However, the dependence of this system on the 
kinetics of gene induction to discriminate between direct and indirect v-Jun targets 
represents a potential problem, as this approach could lead to ambiguity in certain cases.
A more reliable system involves a protein with hormone-inducible v-Jun function (Kruse et 
al., 1997). Previous fusion of c-Jun, JunD and Fos family proteins to the hormone-binding 
domain of human estrogen receptor-a (ER-a) had been shown to induce the characteristic 
regulation of known target genes only in the presence of the agonist ligand estradiol 
(Fialka etal., 1996; Francis etal., 1995; Kim etal., 1996; Schuermann etal., 1993; 
Superti-Furga etal., 1991). Fusion of the ER-a hormone-binding domain to c-Jun or JunD 
proteins lacking a functional TAD enabled hormone-dependent transcriptional activation 
(Francis et al., 1995; Kim et al., 1996). This suggested that the ER-a activating function 2 
(AF-2) domain, a hormone-dependent TAD which overlaps the hormone-binding domain,
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contributed to the activation of Jun target promoters in the presence of its activating ligand. 
The ER-a hormone-binding domain was therefore fused to full-length v-Jun, to create a 
hormone-inducible v-Jun protein (vJl-hER), and to an amino-terminally truncated v-Jun 
protein lacking its TAD, to investigate the contribution of the AF-2 domain to hormone- 
dependent transcriptional activation by the chimaeric protein (Kruse et al., 1997).
Both vJl-hER and the truncated AvJ-hER protein initiated hormone-dependent activation 
of bkj, a direct transcriptional target of v-Jun. The level of activation by AvJ-hER was 
lower than that obtained with vJl-hER, suggesting that the ER-a AF-2 domain contributed 
to, but was not completely responsible for, hormone-dependent transactivation (Kruse et 
al., 1997). Both ER-a fusion proteins induced cell transformation in the presence of 
estradiol. AvJ-hER also mediated hormone-dependent cell-cycle progression in the absence 
of serum growth factors (Clark et al., 2000). This indicated that the ER-a fusion proteins 
regulated at least some of the same critical transformation effector genes as v-Jun. Of the 
two fusion proteins, the function of AvJ-hER was regulated more tightly by estradiol, 
probably due to degradation of vJl-hER to release full-length functional v-Jun protein even 
in the absence of estradiol (Kruse et al., 1997).
AvJ-hER, with its strictly hormone-dependent v-Jun function, represents an excellent 
system for discrimination between direct and indirect v-Jun target genes. As the addition of 
hormone activates a pre-existing protein, simultaneous treatment of cells with estradiol and 
a protein synthesis inhibitor such as cyclohexamide leads to the activation only of direct v- 
Jun target genes. Indirect targets, which may depend on the increased synthesis of a 
regulatory factor in response to v-Jun, are less likely to be activated. Hormone-inducible v- 
Jun systems have been used to identify glutaredoxin, HB-EGF and MAPK phosphatase 2 
(Fu et al., 1999; Fu et al., 2000; Goller et al., 1998), but not other v-Jun target genes (Fu et 
al., 2000), as probable direct v-Jun targets. This system is not ideal. Hormone-dependent 
transcriptional activation by AvJ-hER is thought to be due to the ER-a AF-2 domain, a 
transcriptional activator, and the effect on down-regulated v-Jun target genes has not been 
investigated. However, for genes up-regulated by v-Jun, this is an excellent system for 
discrimination between direct and indirect transcriptional targets.
1.2.2.2 v-Jun effector genes.
The altered expression of only a sub-set of v-Jun target genes is thought to be necessary for 
cell transformation and tumorigenesis. Both direct and indirect transcriptional targets of v-
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Jun may be relevant for these processes. Identification of these “effector genes” is of 
primary importance in the investigation of the mechanisms of cell transformation and 
tumorigenesis by v-Jun.
One approach has been to investigate the effects of over-expression of individual up- 
regulated v-Jun target genes in control cells, or of re-expression of negative target genes in 
v-Jun transformed cells. This had yielded some extremely interesting results. For example, 
over-expression of HB-EGF, a gene directly up-regulated by v-Jun, induced anchorage 
independent growth and release from contact inhibition, albeit with a lower efficiency than 
v-Jun (Fu et al., 1999). This marks HB-EGF as an extremely good candidate v-Jun effector 
gene. A further putative effector gene is SSeCKS. Co-expression of this protein with v-Jun 
in murine fibroblasts strongly decreased the efficiency of cell transformation, indicating 
that repression of SSeCKS by v-Jun is necessary for the activity of the oncoprotein (Cohen 
et al., 2001).
A potential limitation of this approach is demonstrated by the example of SPARC. Re­
expression of this protein in v-Jun transformed CEFs increased the rate of cell division and 
efficiency of anchorage independent growth (Vial and Castellazzi, 2000). This was 
unexpected, as SPARC is a negative target of v-Jun. However, co-expression with SPARC 
was shown to decrease the efficiency of tumorigenesis by v-Jun. The analysis of gene 
expression in cultured cells may therefore prove inadequate if potential v-Jun effector 
genes are not to be overlooked.
Analysis of the effects of individual target genes presents a further difficulty. It is likely 
that v-Jun induces cell transformation and tumorigenesis by the simultaneous mis- 
regulation of a number of effector genes. Alteration of the expression of an individual v- 
Jun effector gene may not therefore induce any phenotypic effect, as the activity of the 
protein may require the co-ordinate mis-regulation of other targets.
In summary, while analysis of individual v-Jun target genes has the potential to be highly 
informative, this approach is not a practical proposition for large-scale investigation of the 
mechanisms of cell transformation and tumorigenesis. As with the discrimination between 
direct and indirect transcriptional targets of v-Jun, screening procedures have been 
developed which may facilitate management of the large amounts of data currently being 
generated. These involve determination of the expression of putative v-Jun effector genes 
in a panel of cell lines, expressing mutated Jun proteins with varying transformation 
efficiencies (Basso et al., 2000; Havarstein et al., 1992). Such screening approaches have
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correlated the degree of mis-regulation of HB-EGF (Fu et al., 1999) and reversion-induced 
LIM protein (Fu et al., 2000), but not homologues of cytokine-inducible SH2-containing 
proteins, MAPK phosphatase 2 (Fu et al., 2000), cathepsin O, or apolipoprotein A -l 
(Basso et al., 2000) with transformation potential. This technique is suitable for positive 
and negative, direct and indirect v-Jun target genes, and is potentially highly important as a 
method of identifying novel targets worthy of investigation as putative v-Jun effector 
genes.
1.3 Mechanisms of transcriptional regulation by v-Jun.
As described in Chapter 1.2.2, many positive and negative target genes of v-Jun have been 
identified, with a number known to be direct transcriptional targets. However, only a few 
v-Jun target promoters have been studied in any detail. While such studies have provided 
information about the effect of v-Jun on specific TRE-containing promoters such as bkj 
(Hartl and Bister, 1998) and c-jun (Hussain et al., 1998), little is known about the 
mechanisms of transcriptional regulation by v-Jun. Elucidation of these mechanisms is 
important to our understanding of the relationship between target gene regulation and cell 
transformation by v-Jun. The mechanisms responsible for the differential regulation of 
target promoters by v-Jun and c-Jun are of particular interest.
After discussion of general mechanisms of transcriptional regulation, a review of the 
literature concerning the regulation of transcription by the Jun proteins will be presented.
1.3.1 General mechanisms of transcriptional regulation.
It is commonly believed that most sequence-specific DNA binding transcription factors 
regulate transcription by control of the affinity of binding of the pre-initiation complex to 
core gene promoters. The pre-initiation complex is an extremely large complex containing 
RNA polymerase II, its associated general transcription factors (TFIIs) and other proteins 
necessary for the initiation of transcription. As discussed below, transcription factors can 
increase the affinity of binding of the pre-initiation complex at core promoters directly, by 
binding to components of the complex, or indirectly, by alteration of the chromatin 
environment surrounding the promoter.
1.3.1.1 Direct recruitment of the pre-initiation complex.
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The pre-initiation complex binds sequences known as core promoter elements situated 
close to the transcriptional start site. The best characterised element is the TATA box. This 
element is generally located 25-30bp upstream of the transcriptional start site, and has the 
loose consensus sequence TATAAAA. However, various non-consensus A/T-rich 
sequences have been shown to enable basal levels of transcription in an in vitro assay 
(Hahn et al., 1989), and considerable sequence variation between naturally occurring, 
functional TATA boxes has been observed.
The TATA box provides the initial binding site for TATA binding protein (TBP), a 
component of TFIID, and is the most important core promoter element for the transcription 
of many promoters. The TATA box also contributes to the selection of the transcriptional 
start site. It has been shown that the majority of transcriptional events initiate from sites 
25-30bp downstream of the TATA box, independently of its position with respect to other 
core promoter elements (O'Shea-Greenfield and Smale, 1992).
The Initiator (Inr) element, with the consensus sequence PyPyANPyPyPy (Javahery et al., 
1994; Lo and Smale, 1996), surrounds the major transcriptional start site of many 
promoters. In the absence of a TATA box, an Inr is sufficient for the initiation of basal and 
activated transcription from a specific start site (Smale and Baltimore, 1989). In promoters 
containing TATA box and Inr sequences, both elements contribute to transcriptional start 
site selection. A distance of 25bp between the elements is optimal for the initiation of high 
levels of transcription from a site within the Inr (O'Shea-Greenfield and Smale, 1992). An 
increase in the distance between the elements decreased the overall level of transcription. 
The majority of the remaining transcriptional initiation events occurred from sites 25-30bp 
downstream of the TATA box, with additional events initiating from a site within the Inr. 
This suggests that, while both elements can independently influence the selection of the 
transcriptional start site, optimal spacing allows the elements to co-operate to activate high 
levels of transcription from a specific site.
More recently, a conserved sequence known as the downstream promoter element (DPE) 
has been characterised as a common core promoter element. A consensus DPE has the 
sequence A/G G A/T CGTG and is located between positions +29 and +32 relative to the 
transcriptional start site (Burke and Kadonaga, 1996). Like the TATA box, the DPE 
provides a binding site for TFIID (Burke and Kadonaga, 1996; Burke and Kadonaga,
1997) and is dependent on an optimal distance from the Inr for full activity (Burke and
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Kadonaga, 1997; Kutach and Kadonaga, 2000). Analysis of 200 Drosophila promoters 
revealed that around 30% of promoters contained a TATA box, a similar number contained 
a DPE, and an additional 15% contained both elements (Kutach and Kadonaga, 2000). 
While introduction of a consensus DPE could partially rescue basal transcription from a 
promoter with a mutated TATA box (Burke and Kadonaga, 1996), mutational analysis 
revealed that the TATA box is the more important sequence in promoters containing both 
elements (Burke and Kadonaga, 1997).
As described above, the TATA box and DPE provide binding sites for TFIID. Components 
of TFIID also contact the Inr (Chalkley and Verrijzer, 1999; Kaufmann and Smale, 1994). 
However, most studies have investigated the role of the TATA box, and recruitment of the 
pre-initiation complex to TATA boxes will be discussed below. It should be noted that 
evidence exists for the recruitment of components of the pre-initiation complex in a step­
wise manner, and also as a pre-formed complex or series of complexes. The step-wise 
model will be followed below for convenience.
TFIID contains TBP and a number of TBP-associated factors (TAFus). Binding of TFIID 
has been shown to be the first stage in the assembly of the pre-initiation complex at core 
promoters (Buratowski et al., 1989), with the addition of TFIIA increasing the affinity of 
TFIID binding at some promoters (Buratowski et al., 1989; Emami et al., 1997; Kaufmann 
and Smale, 1994; Maldonado et al., 1990). TBP / TFIID can bind consensus and non­
consensus TATA boxes (Hahn et al., 1989; Patikoglou et al., 1999), in the minor groove of 
the DNA helix (Lee et al., 1991a; Starr and Hawley, 1991). The assembly of the pre­
initiation complex proceeds in the order TFIID / A, TFIIB, TFIIF / RNA polymerase II, 
TFIIE / H (Buratowski et al., 1989; Ha et al., 1993; Maldonado et al., 1990); see 
(Orphanides et al., 1996) and (Pugh, 2000) for reviews.
Various studies have shown, by fusion of TBP to transcriptionally inactive sequence- 
specific DBDs or by a 2-hybrid approach, that recruitment of components of the pre­
initiation complex by upstream binding factors enhanced transcriptional activation 
(Chatteijee and Struhl, 1995; Keaveney and Struhl, 1998; Klages and Strubin, 1995; Xiao 
et al., 1995). A functional TATA box and the TBP DBD were required for full activation 
(Chatteijee and Struhl, 1995; Klages and Strubin, 1995). Fusion of TBP to the Gal4 DBD 
directed the binding of TBP to a non-consensus TATA box close to the Gal4 binding site 
(Xiao et al., 1995), suggesting that transcriptional activation occurred by direct recruitment 
of the pre-initiation complex to core promoter elements. The fusion of acidic TADs to TBP 
or TAFus did not increase the level of transcription from a core promoter (Keaveney and
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Struhl, 1998). This ruled out an effect on the transcriptional activity of the pre-initiation 
complex by the binding of TADs to component proteins. This supports the hypothesis that 
recruitment of the pre-initiation complex to core promoters is responsible for the activation 
of transcription by factors binding to sites within the promoter.
Various transcription factors are known to bind components of the pre-initiation complex. 
For example, members of the nuclear hormone receptor family, such as steroidogenic 
factor 1, the progesterone receptor and ER-a, bind TFIIB (Ing et al., 1992; Li et al., 1999). 
TFIIB bound the AF-2 domain of ER-a, but not the N-terminal AF-1 domain (Ing et al.,
1992). The AF-2 domain also bound TAFn30 in a hormone-independent manner; depletion 
or inactivation of TAFn30 specifically decreased transcriptional activation by the AF-2 
domain, suggesting that this interaction had functional significance (Jacq et al., 1994). 
Over-expression of TAFn28 has been shown to enhance transcriptional activation by the 
AF-2 domains of the retinoid X receptor, retinoic acid receptor-y, ER-a and the vitamin D 
receptor (May et al., 1996), suggesting that interaction with TAFU proteins is a common 
mechanism of transcriptional activation by nuclear hormone receptors.
The Herpes simplex virus VP 16 protein has been shown to bind TFIID, TFIIB and TFIIH 
(Gupta et al., 1996; Stringer et al., 1990; Xiao et al., 1994). Interestingly, mutations in the 
VP 16 TAD which impaired its ability to activate transcription decreased its binding to 
TFIIH (Xiao et al., 1994), but not to TFIIB (Gupta et al., 1996). This implies that binding 
to some components of the pre-initiation complex may be more important than others in 
the activation of transcription.
p53 has been shown to bind TFIIH (Xiao et al., 1994) and has also been shown to increase 
the affinity of TFIID binding to the TATA box, especially in the presence of TFIIA (Xing 
et al., 2001). A transcriptionally inactive p53 protein had a much smaller effect on the 
affinity of TATA box binding. This further strengthens the relationship between binding to 
components of the pre-initiation complex and activation of transcription.
1.3.1.2 Histone modification and chromatin remodelling.
In vivo transcription occurs from DNA bound by histone proteins, and packaged into 
nucleosomes and higher-order chromatin structures. This has a general repressive effect on 
transcription by denying access to the DNA by sequence-specific binding proteins such as 
transcription factors and the pre-initiation complex. RNA polymerase II is associated with
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proteins involved in covalent histone modification and chromatin remodelling, linking 
these processes to transcriptional regulation.
Covalent modification of the histone components of nucleosomes, by acetylation, 
phosphorylation or methylation, is associated with transcriptional regulation (see below). 
The best characterised mode of modification is by acetylation and deacetylation of lysine 
residues in the N-terminal histone tail regions, mediated by enzymes known as histone 
acetyltransferases (HATs) and histone deacetylases (HDACs). Acetylation of these 
residues is proposed to decrease the affinity of histone-DNA binding, and so increase the 
accessibility of DNA to other proteins. TAFn250 has been identified as a HAT, 
preferentially acetylating histones 3 and 4 (H3 and H4) (Mizzen et al., 1996). TAFn250 
HAT activity was found to be required for transcription of the promoters of cyclin A and 
cyclin D l, and therefore for cell cycle progression (Dunphy et al., 2000). The RNA 
polymerase II holoenzyme has also been shown to contain various other HATs (Cho et al.,
1998).
The yeast (Wilson et al., 1996) and human (Cho et al., 1998) RNA polymerase II 
holoenzymes contain various mating-type switch / sucrose non-fermenter (SWI/SNF) 
proteins. The SWI/SNF complex is involved in ATP-dependent nucleosome structure 
disruption, and is implicated in transcriptional activation. The yeast and human RNA 
polymerase II holoenzymes could both remodel chromatin, and this function in yeast was 
dependent on SWI/SNF proteins and ATP (Wilson et al., 1996).
As well as their presence within the RNA polymerase II holoenzyme, other evidence links 
histone modification and chromatin modelling proteins to transcription. For example, 
TFIIIA, a co-factor in the activation of 5S rRNA gene promoters, could only bind a target 
promoter assembled into nucleosomes containing hyper-acetylated histones (Lee et al.,
1993). Removal of the N-terminal histone tails also permitted binding of TFIIIA to a 
nucleosome template, indicating that these domains restrict DNA binding within chromatin 
templates. As mentioned above, N-terminal histone tails are the targets for modification by 
HATs and other enzymes, and modification of these domains is proposed to regulate 
transcription by altering the accessibility of DNA to binding factors.
A chromatin immuno-precipitation (ChIP) assay using an antibody specific for acetylated 
H3 revealed that estrogen treatment caused histone hyper-acetylation in a region of 
chromatin containing a promoter activated by ER-a, and enabled TBP to bind the promoter 
(Sewack et al., 2001). Rapid and specific histone phosphorylation in response to heat
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shock has similarly been shown to occur at Drosophila chromosome regions containing 
multiple heat-shock response genes (Nowak and Corces, 2000). Conversely, specific 
regions of DNA known to be transcriptionally silent in certain yeast strains were associated 
with hypo-acetylation of H4 proteins in vivo (Braunstein et al., 1993). Treatment with 
trichostatin A (TSA), an inhibitor of HD AC enzymes, activated the transcription of various 
viral promoters (Dressel et al., 2000), suggesting a role for HDACs in transcriptional 
repression. These findings strengthen further the relationship between histone modification 
and transcriptional regulation.
Further evidence for this relationship came with the discovery that transcriptional co­
activators, which enhance transcriptional activation by a wide range of transcription 
factors, have intrinsic HAT activity. These co-activators include Gcn5 (Brownell et al., 
1996), CREB binding protein (CBP) (Bannister and Kouzarides, 1996; Ogryzko et al.,
1996), the highly similar p300 protein (Ogryzko et al., 1996), p300/CBP associated factor 
(PCAF) (Yang et al., 1996), and steroid receptor co-activator-1 (SRC-1) (Spencer et al.,
1997). Binding between p300/CBP, PCAF and SRC-1 (Spencer et al., 1997; Yang et al., 
1996) suggested the presence of co-activator complexes. A chimaeric protein consisting of 
the Gal4 DBD and CBP HAT domain acted as a HAT-dependent transcriptional activator 
at certain promoters (Martinez-Balbas et al., 1998). The ability of Gcn5, p300 and PCAF 
to acetylate histones has been shown to correlate with their transcriptional co-activator 
function (Chakravarti et al., 1999; Kuo et al., 1998; Lau et al., 2000; Wang et al., 1998). 
The relationship between histone modification and transcriptional regulation is therefore 
well established.
Nucleosome disruption and chromatin remodelling by the SWI/SNF complex are also 
associated with transcriptional activation. Mutations in yeast SNF2, SNF5 or SNF6 
reduced the accessibility of core promoter DNA to binding proteins, and decreased 
transcription from certain promoters. However, this phenotype was partially rescued by a 
further mutation which reduced the production of H2A and H2B (Hirschhorn et al., 1992), 
suggesting a link between the function of the SNF proteins, nucleosome structure and 
transcription. Addition of a large SWI/SNF complex with DNA-dependent ATPase activity 
increased the affinity of binding of Gal4 or TBP/TFIIA to sites contained within a 
nucleosome (Cote et al., 1994; Imbalzano et al., 1994; Kwon et al., 1994). This suggests 
that, like histone modification, ATP-dependent chromatin remodelling by SWI/SNF 
proteins causes transcriptional activation by increasing the accessibility of promoter DNA.
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As discussed in Chapter 1.3.1.1, transcription factors can activate transcription by direct 
recruitment of the pre-initiation complex to core promoters. There is now a great deal of 
evidence that transcription factors can also regulate transcription by indirect control of the 
binding of the pre-initiation complex to core promoters, via recruitment of factors involved 
in histone modification and chromatin remodelling.
One of the better characterised examples of this kind of transcriptional regulation involves 
the manipulation of histone acetylation status by members of the nuclear hormone receptor 
family. These proteins contain a conserved AF-2 domain, which mediates activation of 
target promoters in the presence of agonist ligand (Danielian et al., 1992), and 
transcriptional repression when unliganded or bound to antagonist ligand. The search for 
effectors of hormone-dependent transcriptional regulation by nuclear hormone receptors 
identified various co-activator and co-repressor proteins. Co-activators such as p300, CBP, 
PCAF, SRC-1 and activator of thyroid and retinoic acid receptors (ACTR) bind members 
of the nuclear hormone receptor family in a ligand-dependent manner (Chakravarti et al., 
1996; Chen etal., 1997; Hanstein etal., 1996; Korzus etal., 1998; Yao etal., 1996) and 
have been shown to be involved in hormone-dependent transcriptional activation 
(Chakravarti et al., 1996; Chen et al., 1997; Hanstein et al., 1996; Henttu et al., 1997; 
Korzus et al., 1998; Smith et al., 1996).
Nuclear hormone receptor co-repressors include N-CoR (Horlein et al., 1995) and 
silencing mediator for retinoid and thyroid hormone receptors (SMRT) (Chen and Evans, 
1995). These proteins formed complexes with nuclear hormone receptors bound to DNA, 
but were released upon addition of agonist ligand (Chen and Evans, 1995; Horlein et al., 
1995). N-CoR has also been shown to bind ER-a specifically in the presence of a 
tamoxifen-derived antagonist ligand (Lavinsky et al., 1998). A Gal4-N-CoR protein acted 
as a transcriptional repressor (Horlein et al., 1995), and N-CoR and SMRT were both 
associated with transcriptional repression by unliganded or antagonist-bound nuclear 
hormone receptors (Chen and Evans, 1995; Horlein et al., 1995; Lavinsky et al., 1998).
Structural studies have shown that ligands bind to a deep hydrophobic pocket within the 
nuclear hormone receptor C-terminal half (Bourguet et al., 1995; Renaud et al., 1995). 
Comparison between unliganded and agonist-bound receptors revealed a major 
conformational change upon ligand binding; helix 12 folded back towards the ligand- 
binding pocket, and the AF-2 domain assumed a generally more compact structure 
(Bourguet etal., 1995; Renaud etal., 1995). The integrity of helix 12 and associated 
protein domains was found to be essential for binding to co-activators and hormone-
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dependent transcriptional activation (Feng et al., 1998; Henttu et al., 1997; Renaud et al., 
1995).
It has been proposed that the conformational change induced by agonist ligand provides a 
hydrophobic surface for co-activator binding (Feng et al., 1998). Comparison between ER- 
a  hormone-binding domains bound to agonist or antagonist ligand confirmed that both 
ligands bound within the same hydrophobic pocket (Shiau et al., 1998). However, different 
contacts formed between each ligand and its binding domain caused distinct effects. In the 
presence of agonist ligand, helix 12 moved to form a hydrophobic cleft with residues from 
helices 3, 4, and 5. This cleft was bound by a peptide derived from a co-activator protein. 
However, binding of antagonist ligand did not induce movement of helix 12 to form this 
hydrophobic cleft. Structural differences between unliganded, agonist- and antagonist- 
bound nuclear hormone receptors therefore appear to account for the binding of different 
proteins in response to different stimuli.
ChIP assays have shown that ER-a rapidly recruited co-activators, including p300, CBP, 
PCAF and SRC-1, to target promoters in the presence of estradiol, whereas N-CoR and 
SMRT were recruited upon addition of tamoxifen (Shang et al., 2000). This suggests a 
functional role for co-activators and repressors in the regulation of transcription by nuclear 
hormone receptors.
As described above, many nuclear receptor co-activators have been identified as HATs, 
providing a link between histone modification and hormone-dependent transcriptional 
regulation. The dependence on p300 for enhancement of estradiol-induced transcription by 
ER-a was limited to chromatinised templates (Kraus and Kadonaga, 1998); this 
enhancement was shown to be dependent on the HAT activity of p300 (Kraus et al., 1999). 
PCAF HAT activity has also been shown to be essential for hormone-dependent 
transcriptional activation by nuclear hormone receptors (Korzus et al., 1998). Direct 
evidence for a role for histone acetylation in transcriptional regulation by nuclear hormone 
receptors has been obtained using ChIP assays. These have shown that thyroid hormone 
receptor and ER-a mediated an increase in histone acetylation at target promoters in 
response to agonist ligand, correlating with the activation of transcription from these 
promoters (Sachs and Shi, 2000; Shang et al., 2000).
Similarly, the binding of co-repressors to unliganded or antagonist-bound nuclear hormone 
receptors has been shown to recruit HDACs such as Rpd3 and HDAC1 (Alland et al.,
1997; Heinzel et al., 1997; Nagy et al., 1997). HDAC function has been shown to be
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important for transcriptional repression by nuclear hormone receptor proteins (Heinzel et 
al., 1997; Lavinsky et al., 1998; Nagy et al., 1997; Sachs and Shi, 2000). Nuclear hormone 
receptors therefore represent an example of how the recruitment of histone modifying 
proteins can lead to the highly specific, tightly-controlled positive and negative regulation 
of transcription.
Many other transcription factors have been shown to recruit HATs and/or HDACs and so 
regulate transcription. Knowledge in this area is increasing rapidly, and only selected 
examples are discussed below. For example, the activation of a promoter driven by Spl 
and NF-kB p65 was enhanced by wild-type p300, but to a lesser extent by a p300 mutant 
protein with no HAT activity (Kraus et al., 1999), implicating histone acetylation in 
transcriptional activation by these factors. Transcriptional activation by E2F was also 
dependent on co-expression of CBP. However, a CBP mutant protein with no HAT 
activity, but competent for binding to E2F and TBP, could not co-activate transcription by 
E2F (Ait-Si-Ali et al., 2000). This suggests that CBP HAT activity, rather than any 
bridging role between the transcription factor and pre-initiation complex, is important in 
some cases. The importance of HAT activity has also been shown in a system assaying 
transcription from a chromatinised promoter containing a Gal4 site. Transcriptional 
activation by Gal4-VP16 required p300 and acetyl co-A; activation was decreased in the 
presence of a p300 inhibitor which specifically inhibits p300 HAT activity (Kundu et al., 
2000).
Examples are also known of transcription factors recruiting HDAC proteins. These include 
Rb, which bound HDAC1 and 2 and recruited the proteins to form a complex with E2F 
(Brehm et al., 1998). When recruited by Rb, HDAC1 was shown to repress transcription 
from E2F target promoters. Repression was relieved by treatment with TSA, supporting the 
role of histone deacetylation in transcriptional repression. Spl has also been shown to bind 
HDAC1 and repress transcription from a chromatinised promoter via histone deacetylation 
(Doetzlhofer et al., 1999).
Transcription factors are also known to regulate transcription by recruitment of 
components of the SWI/SNF chromatin remodelling complex. For example, human 
SNF2a and |3 homologues have been implicated in hormone-dependent transcriptional 
activation by ER-a (Ichinose et al., 1997). The AF-2 domain has also been shown to bind a 
SWI2 homologue and recruit it to target promoters, specifically in the presence of agonist 
ligand (DiRenzo et al., 2000). The function of the SWI2 protein was essential for
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hormone-dependent transcriptional activation, and also for the co-activation function of 
SRC-1 and CBP.
c-Myc also activates transcription by a mechanism involving chromatin remodelling, c- 
Myc bound directly to a SNF5 homologue, and a mutant SNF5 protein deficient for 
binding to other SWI/SNF complex components decreased transcriptional activation by c- 
Myc (Cheng et al., 1999). Similarly, Gcn4 bound SNF5 and other components of the 
SWI/SNF complex, and mutations in these proteins reduced transcription from Gcn4 target 
promoters (Natarajan et al., 1999). Gal4-VP16 also bound components of the SWI/SNF 
complex via the VP16 TAD, and recruited these proteins to target promoters (Neely et al., 
1999; Yudkovsky et al., 1999). This led to ATP-dependent chromatin remodelling at Gal4 
target promoters (Yudkovsky et al., 1999) and an increase in transcriptional activity (Neely 
et al., 1999).
As described above, the recruitment of histone modifying or chromatin remodelling 
activities is a regulatory mechanism utilised by many transcription factors. Examples are 
given above of factors such as ER-a which recruit HATs and components of the SWI/SNF 
complex in response to similar stimuli. Evidence exists that these two mechanisms can co­
operate in the regulation of certain promoters. CBP is known to interact with a protein 
related to Snf2 (Johnston et al., 1999); this interaction enhanced transcriptional activation 
by a Gal4-CBP protein (Johnston et al., 1999) and by activated CREB (Monroy et al.,
2001). Other factors are also thought to activate transcription by co-operative recruitment 
of histone modifying and chromatin remodelling proteins. For example, while the separate 
addition of SWI/SNF proteins or p300 each enabled some degree of hormone-dependent 
transcriptional activation by the retinoic acid receptor, their simultaneous addition 
synergistically activated transcription to a much higher level (Dilworth et al., 2000).
Co-operation between histone modification and chromatin remodelling has also been 
reported in the activation of transcription by Gal4-VP16 (Mizuguchi et al., 2001). Pre­
incubation of a chromatinised template with p300 or PCAF did not in itself induce 
chromatin remodelling, but increased the level of transcription observed upon the addition 
of Gal4-VP16 and a chromatin remodelling factor (Mizuguchi et al., 2001). Similarly, in 
the case of interferon-p enhancer-driven transcription, pre-incubation of the template with 
CBP or Gcn5 did not induce chromatin remodelling, but increased the ability of the 
enhanceosome to recruit a SWI/SNF protein (Agalioti et al., 2000). This led to a greater 
chromatin remodelling effect on pre-acetylated templates. Recruitment of TBP and 
TAFn250 to the promoter was dependent on this remodelling activity, and was enhanced
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by pre-acetylation of the chromatin. These examples show that recruitment of histone 
modifying and chromatin remodelling activities by transcription factors can lead to 
transcriptional activation, by an indirect increase in the affinity of binding of the pre­
initiation complex to target promoters. These are obviously extremely important 
mechanisms of transcriptional regulation within a chromatin context.
1.3.2 Mechanisms of transcriptional regulation by Jun proteins.
As described in Chapter 1.3.1, many transcription factors have been shown to regulate 
transcription via control of the affinity of binding of the pre-initiation complex to core 
promoters. This control can occur directly, by protein-protein interaction with components 
of the pre-initiation complex, or indirectly, via recruitment of proteins which alter the 
chromatin environment of target promoters and their accessibility to the pre-initiation 
complex. As discussed below, the relevance of these mechanisms for transcriptional 
regulation by Jun proteins has begun to be investigated.
1.3.2.1 Recruitment of the pre-initiation complex.
Jun proteins have been shown to bind components of the pre-initiation complex in vitro.
An initial study revealed that c-Jun bound TBP via the bZip domain (Ransone et al., 1993). 
This was later confirmed, and additional binding of TBP to the c-Jun TAD was also 
detected (Franklin et al., 1995). Phosphorylation of c-Jun at serines 63 and 73 did not 
affect the interaction between c-Jun and TBP. Interestingly, TBP also bound the N- 
terminal TADs of v-Jun, JunD and JunB, but with different affinities. TBP bound the v-Jun 
TAD with a higher affinity than to c-Jun; deletion of the delta domain from c-Jun increased 
the affinity of TBP binding. However, TBP and TFIIB bound to the C-terminal half of c- 
Jun with a higher affinity than to the equivalent region of v-Jun (Franklin et al., 1995). The 
relative affinities of binding of TBP and TFIIB to full-length c-Jun and v-Jun have not 
been determined. This is potentially an extremely significant result, as different affinities 
of binding to the pre-initiation complex could provide an explanation for the altered 
transcriptional regulation of certain promoters by v-Jun compared to c-Jun. The 
implication that the delta deletion and C-terminal point mutations within v-Jun alter the 
affinity of TBP binding is especially important, as these mutations are known to contribute 
to transcriptional mis-regulation and cell tranformation by the viral protein (see Chapter
1.1.3 and 1.2.1).
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Interactions between c-Jun and other components of the pre-initiation complex have also 
been reported. The bZip domain bound to components of TFIIE and TFIIF, with 
dimerisation to c-Fos increasing the affinity of binding (Martin et ah, 1996).
Transcriptional activation of a TRE-containing promoter was “squelched” at high levels of 
expression of the c-Jun / c-Fos dimer, suggesting that the over-expressed proteins 
sequestered factors required for transcription from the core promoter. Co-expression of 
TFIIE specifically relieved this squelching effect, suggesting that TFIIE was a limiting 
factor for transcriptional activation by c-Jun and c-Fos.
The functional significance of c-Jun binding to a component of the pre-initiation complex 
has been explored in one case. In an in vitro assay, TBP activated transcription to a higher 
level than TFIID (Lively et al., 2001). This was found to be due to the inhibition of TBP- 
TATA box binding by the N-terminal domain of TAFn250. c-Jun bound to this N-terminal 
region, and was found to enhance transcription by TFIID, but not TBP. Footprinting 
analysis revealed that the binding of c-Jun to TAFn250 derepressed TATA box binding by 
TBP. Binding between c-Jun and components of the pre-initiation complex therefore 
appears to be highly significant, at least in vitro.
The binding of v-Jun to TFIIE, TFIEF or TAFU250, and any contribution of these factors to 
transcriptional activation by v-Jun, have not been investigated. It may be that, as with TBP 
(Franklin et al., 1995), v-Jun binds these proteins with altered affinity compared to c-Jun. 
The differential regulation of certain promoters by v-Jun and c-Jun may, in that case, be 
due to the differing abilities of the proteins to recruit the pre-initiation complex to target 
promoters. Determination of the relative in vivo binding affinities of c-Jun and v-Jun to 
TBP and other components of the pre-initiation complex, and the abilities of the 
transcription factors to recruit the complex to target promoters, could potentially determine 
whether this is the case.
1.3.2.2 Histone modification.
Like many other transcription factors, members of the Jun and Fos families bind HATs. 
This was first suggested by the observation that micro-injection of inhibitory CBP 
antibodies abolished TPA-induced transcription from a TRE-containing promoter (Arias et 
al., 1994). c-Jun phosphorylated by JNK, but not phosphorylated at C-terminal sites by 
casein kinase II, bound directly to CBP in vitro (Arias et al., 1994). The binding of CBP to 
un-phosphorylated c-Jun was not determined. It has since been revealed that CBP binds to 
the N-terminal TAD of c-Jun and v-Jun (Bannister et al., 1995). Serine to alanine
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substitutions at c-Jun positions 63 and 73 decreased, but did not abolish, binding to CBP. 
Introduction of alanine residues at the equivalent positions within the v-Jun TAD had a 
similar effect on CBP binding. As v-Jun is not phosphorylated at these sites by JNK, this 
suggested that serines 63 and 73 were involved in binding to CBP, but that N-terminal 
phosphorylation of c-Jun did not affect the affinity of co-activator binding. However, this 
has not been specifically tested by comparison of the binding of CBP to c-Jun 
phosphorylated by JNK or treated with phosphatases.
p300, SRC-1 and the nuclear hormone receptor co-activator ASC-2 have also been shown 
to bind c-Jun (Lee et al., 1996; Lee et al., 1998; Lee et al., 2000b). However, the 
dependence of this binding on c-Jun phosphorylation, and the affinity of co-activator 
binding to v-Jun, have not been determined. In contrast, a putative transcriptional adaptor 
protein known as Jun-activation-domain binding protein (JAB1) has been shown to bind c- 
Jun, stabilise its binding to a TRE, and enhance transcription from TRE-containing 
promoters (Claret et al., 1996). However, JAB1 did not bind or enhance transcriptional 
activation by v-Jun. JAB1 has been shown to bind SRC-1 (Chauchereau et al., 2000) and 
may therefore recruit HAT activity to c-Jun, but not v-Jun. Differential recruitment of 
HAT proteins, whether direct or via selective binding to adaptors such as JAB1, may be 
found to be important for the differences in transcriptional regulation between c-Jun and v- 
Jun.
Co-expression of CBP, p300, SRC-1 or ASC-2 has been shown to enhance transcriptional 
activation by c-Jun (Bannister et al., 1995; Lee et al., 1996; Lee et al., 1998; Lee et al., 
2000b). p300 and SRC-1 co-operated to increase transcriptional activation by c-Jun (Lee et 
al., 1998), suggesting that, like nuclear receptor co-activators, Jun proteins may recruit co­
activator complexes. Transcriptional activation by a Gal4-v-Jun protein was enhanced by 
co-expression of CBP (Bannister et al., 1995), but the role of other co-activators in 
transcriptional activation by v-Jun has not been determined.
Interestingly, in an investigation into the interaction between ATF-2 and p300, it was 
discovered that ATF-2 possessed intrinsic HAT activity (Kawasaki et al., 2000). ATF-2 
specifically acetylated the N-terminal tails of H2B and H4. ATF-2 HAT activity was 
induced by JNK phosphorylation in response to UV light, and correlated with 
transcriptional activation of a promoter containing a CRE. As described in Chapter 1.1.7.1, 
ATF-2 forms heterodimers with Jun proteins and is implicated in the induction of growth 
factor independence by v-Jun. The contribution of ATF-2 HAT activity to this process is
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not known, but may be important in transcriptional regulation and cell transormation by v- 
Jun.
As described in Chapter 1.3.1.2, negative, as well as positive, regulation of transcription 
can occur by recruitment of histone modifying proteins. In line with this, c-Jun and c-Fos 
have been shown to bind SMRT (Lee et al., 2000a). In the case of c-Fos, co-expression 
with SMRT or HDAC1 decreased transcriptional activation from a TRE-containing 
promoter, and this repression was relieved by TSA. This suggests that c-Fos may repress 
transcription by recruitment of HD AC activity to target promoters. It would be interesting 
to determine whether c-Jun and v-Jun can repress transcription by a similar mechanism.
In summary, while c-Jun and v-Jun have been shown to bind proteins with HAT activity, 
the role of histone modification in the transcriptional regulation of Jun target promoters has 
not been established. ChIP and in vitro transcription assays have been used to demonstrate 
the involvement of HAT activity in transcriptional regulation by nuclear hormone 
receptors and Gal4-VP16 (Kundu et al., 2000; Sachs and Shi, 2000; Shang et al., 2000). 
Similar analyses could help to determine whether c-Jun and v-Jun activate transcription by 
recruitment of HAT activity.
The contribution of HAT co-activators and HD AC co-repressors, as well as proteins such 
as ATF-2, to the differential regulation of transcription by c-Jun and v-Jun also remains 
elusive. Determination of the relative in vivo binding affinities of these proteins to c-Jun 
and v-Jun may reveal differences in their ability to recruit histone modifying activity. 
Comparison of the acetylation status of the chromatin surrounding target promoters in 
control and v-Jun transformed cells may disclose whether histone modification has 
functional significance for the mis-regulation of target genes by v-Jun.
An interesting possibility is raised by the observation that hormone-dependent activation of 
certain nuclear hormone receptors repressed TPA-induced, but not basal, transcription 
from TRE-containing promoters. This repression is mutual, and could be relieved by 
expression of co-activators such as p300, CBP, SRC-1 and ASC-2 (Aarnisalo et al., 1998; 
Kamei et al., 1996; Lee et al., 1998; Lee et al., 2000b). One interpretation is that trans­
repression occurs via competition for a limiting amount of common HAT co-activators. 
Alternative models, such as the specific repression of JNK activity by ligand-bound 
glucocorticoid receptor (Caelles et al., 1997), have been proposed. However, the 
observation that over-expression of HAT co-activator proteins relieved repression implies 
that TPA-induced transcriptional activation from TREs occurs via the enhanced
48
recruitment of co-activators. Indeed, CBP function has been implicated in TPA-induction 
of transcription from a TRE-containing promoter (Arias et al., 1994).
This suggests a model whereby phosphorylation of c-Jun by JNK in response to TPA and 
other stimuli leads to increased transcriptional activation by recruitment of HAT co­
activators. This is an attractive model, as it would explain the inability of v-Jun, which is 
not phosphorylated by JNK, to activate transcription of TPA and UV-responsive promoters 
such as coliagenase, stromelysin and c-jun (Hussain et al., 1998; May et al., 1998; Tsang et 
al., 1994). While in vitro studies have implied that the phosphorylation of c-Jun serines 63 
and 73 may not be important for binding to CBP (Bannister et al., 1995), this has not been 
studied in vivo. Neither has the regulation of binding of other co-activators by c-Jun 
phosphorylation been investigated. Resolution of these issues may develop our 
understanding of the differential transcriptional responses of c-Jun and v-Jun to external 
stimuli.
1.3.2.3 Chromatin remodelling.
As described in Chapter 1.3.1.2, the recruitment of chromatin remodelling activity to target 
promoters is a mechanism employed by various transcription factors. In the case of c-Jun / 
c-Fos dimers, binding to a TRE can be sufficient to induce nucleosome disruption (Ng et 
al., 1997). A promoter fragment with a TRE at its centre was assembled into a nucleosome, 
using acetylated histones. The c-Jun / c-Fos dimer bound to a TRE within naked DNA with 
a higher affinity than to the site within the nucleosome. However, binding to the 
nucleosome site occurred when the c-Jun / c-Fos dimer was present at higher 
concentrations. This completely disrupted the structure of the nucleosome and led to the 
dissociation of histones from the promoter DNA. The c-Jun and c-Fos TADs were not 
required for disruption, suggesting that TRE binding by the proteins was sufficient to 
disrupt DNA-histone contacts. Disruption of the nucleosome structure by c-Jun / c-Fos 
enabled binding of a second factor to a site previously masked by the nucleosome, 
illustrating that TRE binding by these proteins increased the accessibility of the promoter 
DNA. This model has not been tested in vivo, but has potential implications for 
transcriptional activation by indirect recruitment of the pre-initiation complex.
c-Jun and c-Fos have also been shown to bind BAF60a, a component of the SWI/SNF 
complex (Ito et al., 2000). A c-Jun / c-Fos dimer bound BAF60a as well as other SWI/SNF 
proteins, including the DNA-dependent ATPase subunit, in vivo. While the interaction 
between BAF60a and v-Jun was not investigated, BAF60a did not bind JunD, or Fos
49
family proteins other than c-Fos. The ability of heterodimers consisting of different Jun 
and Fos family members to bind BAF60a correlated with their activation of a TRE- 
containing promoter in F9 cells. Re-constitution of a functional SWI/SNF complex in cells 
lacking this chromatin remodelling activity enhanced the ability of a c-Jun / c-Fos dimer to 
activate a TRE-containing promoter.
Taken together, this suggests a role for the SWI/SNF complex in transcriptional activation 
by c-Jun / c-Fos dimers. However, as with the recruitment of the pre-initiation complex 
and histone modifying proteins, the functional significance of chromatin remodelling 
activity in transcriptional activation by c-Jun has not been definitively verified, and its role 
in transcriptional activation by v-Jun has not been investigated.
1.3.2.4 Summary
As described above, there is evidence for recruitment of the pre-initiation complex, histone 
modifying proteins, and a chromatin remodelling complex in transcriptional regulation by 
c-Jun. However, the functional relevance of these interactions for the in vivo regulation of 
c-Jun target genes has not been established. As our understanding of these mechanisms of 
transcriptional regulation develops, this situation may be resolved.
Our understanding of the mechanisms of transcriptional regulation by v-Jun, and how these 
differ from c-Jun, is more limited still. Comparison of the ability of c-Jun and v-Jun to 
disrupt nucleosome structure, and to bind and recruit components of the pre-initiation 
complex, SWI/SNF complex and histone modifying proteins, may reveal important 
differences between the proteins. More detailed analyses could then follow, for example in 
vitro transcription assays and ChIP analysis to determine whether alterations in histone 
modification, ATP-dependent chromatin remodelling, pre-initiation complex recruitment, 
or a combination of mechanisms, are likely to be involved in the mis-regulation of specific 
target genes by v-Jun. Coupled with the identification of v-Jun effector genes, this would 
improve our understanding of the mechanisms of transcriptional regulation and cell 
transformation by v-Jun.
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2 Materials and Methods
2.1 Materials
2.1.1 Chemicals and reagents
Amersham Pharmacia Biotech
D-threo-[dichloroacetyl-l-14C]-ch\oramphenico\
Redivue adenosine 5’-[y-32P]-triphosphate, triethylammonium salt 
Redivue deoxycytidine 5’-[a-32P]-triphosphate, triethylammonium salt
BDH Laboratory Supplies
Ethyl acetate
Fisher Scientific
Acetic acid, glacial 
Ammonium persulphate (APS)
Boric acid 
Chloroform
Ethylene diaminetetra-acetate (EDTA), disodium salt 
Glycine
Hydrochloric acid 
Magnesium chloride 
Methanol 
Potassium chloride 
Propan-2-ol
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Sodium acetate
Sodium chloride
Sodium dodecyl sulphate (SDS)
Sodium hydrogen orthophosphate
Fisons
Glycerol
Gibco BRL
J/V-2-hydroxyethylpiperazine-A^’-2-ethanesulphonic acid (Hepes) buffer 
Tris
Ultra-pure agarose, electrophoresis grade 
James Burrough (F.A.D.) Ltd
Ethanol
Kramel Biotech
Bovine serum albumin (BSA)
New England BioLabs 
SDS sample buffer, 3x 
Pierce
Coomassie protein assay reagent
Premier Beverages
Marvel skimmed milk powder
Promega
Deoxyadenosine triphosphate (dATP)
Reporter lysis buffer, 5x
Roche
Biotin-16-dUTP 
Severn Biotech Ltd.
30%(w/v) acrylamide, 1.6%(w/v) bisacrylamide 
30%(w/v) acrylamide, 0.8%(w/v) bisacrylamide
Sigma
Acetyl coenzyme A, sodium salt
Adenosine 5’ triphosphate (ATP), disodium salt
Aprotinin
Benzamidine HC1
Bromophenol blue (BPB)
Dithiothreitol (DTT)
Ethidium bromide
Ethylene glycol-bis(p-aminoethyl ether)N,N,N’,N’-tetra-acetic acid (EGTA)
Leupeptin
Okadaic acid
Phenyl methyl sulphonyl fluoride (PMSF)
Polydeoxyinosinic-deoxycytidylic acid (Poly dl.dC)
Ponceau S solution
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Sodium fluoride 
Sodium orthovanadate 
Spermidine
N,N,N ’ ,N ’ -Tetramethylethylenediamine (TEMED)
Triton X-100 (t-Octylphenoxypoly-ethoxy ethanol)
Tween-20 (Polyoxyethylene sorbitan nonolaurate)
2.1.2 Enzymes and kits
Amersham Pharmacia Biotech
Enhanced chemiluminescence (ECL) Western detection agent 
Oligolabelling kit
Applied Biosystems Inc.
GeneAmp PCR core reagents
PRISM BigDye terminator cycle sequencing ready reaction kit 
Gibco BRL
All restriction enzymes with the exception of BstYI 
Kramel Biotech
Klenow fragment oiE.coli DNA polymerase I
New England BioLabs
BstYI
Qiagen
QIAGEN plasmid maxi kit
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QIAprep spin miniprep kit 
QIAquick gel extraction kit 
QIAquick PCR purification kit
Roche
Rapid DNA ligation kit 
Stratagene
QuikChange XL site-directed mutagenesis kit
Transgenomic
Alkaline phosphatase 
T4 DNA ligase
T4 polynucleotide kinase (PNK)
2.1.3 Oligonucleotides
2.1.3.1 Probes
NB Where the antisense strand is an exact complement, only the sense strand is shown. 
TREs are shown underlined.
bkj( D) 5’ GGA TGG GTG ACT CAG AGT GAG
bkj( P) 5’ CCA GGC CTG ACT CAG CAG CCT
M/mt(P) 5’ CCA GGC CAG ACC CAG CAG GCT
bkj-117 5’ CAC GTG GTG ACT CAG CCT CTC
bkj-610 5’ GCA GAG ATG AGT CAT GAA GCG
bkj-All 5’ ACA CAT CTG AGT CAC CTG CAG
bkj-323 5’ GGA GCC ATG ACT CAT GGG ATA
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bkj-169 5’ CGC AGC ATG ACT CAG GAG CCA
bkj-109 5’ CAG AGC TTGAGTCAC CAA AAT
bkj-65 5’ IT T  TTG CTG ACT CAG CTC CCT
Col TRE 5’ AAG CAT GAG TCA GAC ACC TC
ColEco sense 5’ AAT TAA GCA TGAGTCAGA CAC CTC
ColEco antisense 3’ IT  CGT ACT CAG TCT GTG GAG TTA A
2.1.3.2 Primers
Mutagenic bases shown in bold type; restriction enzyme sites underlined.
Hindlll bkj5’ 5’ TCC AAG CTT GCG TCT CAG GGT GCA TGT CTG GAA
AAA C
Xbal bkjV 5’ TGT TCT AGA ACG GCA GCA GGG AAT GGA GTG GCT
GG
mt(P)TRE bkj5’ 5’ TCC AGG CCA GAC CCA GCA GC
-777TRE bkj5’ 5’ GGT GAC TCA GCC TCT CCC C
-610TRE bkjS’ 5’ GAG TCA TGA AGC GGC CTG AC
-477TRE bkj5’ 5’ CTG AGT CAC CTG CAG AGG C
-323TRE M/5’ 5’ GAC TCA TGG GAT AGG GAG G
-169TRE My5’ 5’ ACG CAG CAT GAC TCA GGA GC
-109TRE bkjS’ 5’ TGA GTC ACC AAA ATC ACC C
-65TRE My5’ 5’ GTT TTT GCT GAC TCA GCT CC
HindIII-65TRE bkj5’ 5 ’TCC AAG CTT GCG CTG ACT CAG CTC CCT CGG
bkj Col TATA 5’ 5’ CCA TCA GGC GCA GTA TAT ATA GTC GCC TCA TCT CC
bkj Col TATA 3’ 3’ GGT AGT CCG CGT CAT ATA TAT CAG CGG AGT GAG
GG
bkj Col ILS 5’ 5’ CCT CAT CTC CCA GCC ACT ATA TTG GCT GCT GCA
GTG C
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bkj Col ILS 3’
Col bkj TATA 5’
Col bkj TATA 3’
Col bkj ILS 5’
Col bkj ILS 3’
AF2mt5’
AF2mt3’
Sail p3005’
Hindlll p3003’
2.1.4 Plasmids
ASVI7 provirus with flanking chicken genomic sequences from clone 241, cloned into 
EMBL3, and pV, the corresponding proviral DNA without flanking sequences, cloned into 
M13mpl9, have been described (Maki et al., 1987) and were a gift from Peter Vogt.
Clal2Nco has been described (Hughes et al., 1987) and was a gift from Stephen Hughes.
-73/+63 ColCAT has been described (Angel et al., 1987a). -60/+63 ColCAT is a deletion 
mutant lacking the TRE at position -72. Both plasmids were a gift from Peter Angel.
pBlueScript KS p300 WT and pBlueScript KS p300 MutAT2 contain the p300 WT and 
p300 MutAT2 constructs respectively (Kraus et al., 1999) and were a gift from W.Lee 
Kraus.
pCAT-Basic is commercially available from Promega.
p CAT -BKJ(WT), pCAT -BKJ(DV), pCAT-BK/(P), pCAT-BKJ (D) and pCAT-BKJ(0) have 
been described (Hard and Bister, 1998) and were a gift from Markus Hartl.
3’ GGA GTA GAG GGT CGG TGA TAT AAC CGA CGA CGT 
CAC G
5’ GCA AGG ACT CCA TAA ATA CAG AGG GAG C
3’ CGT TCC TGA GGT ATT TAT GTC TCC CTC G
5’ CCT AGC TGG GCC ATT CCA GCA GCA AGA GG
3’ GGA TCG ACC CGG TAA GGT CGT CGT TCT CC’
5’ GAC CTG CTG CTG GAG GCG GCG GAC GCC CAC CGC 
CTAC
3’ CTG GAC GAC GAC CTC CGC CGC CTG CGG GTG GCG 
GAT G
5’ ATT GCA TCC GAG TCG ACT TTG GAG GCA CTT TAC 
CGT CAG G
5’ GAT CCA TAG CAA GCT TCT AGC AGC CTG CTG GTT 
GTTGC
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pckGAPDH contains chicken GAPDH DNA (Hussain et al., 1998). 
pJC6 has been described (Han et al., 1992) and was a gift from Ron Prywes. 
pRc/RSV is commercially available from Invitrogen.
pRc/RSV-cJ3 and pRc/RSV-vJl have been described (Morgan et al., 1993) and were a gift 
from Iain Morgan.
pSPT19-J-D300 contains the chicken c-jun 3’ UTR sequence (Hussain et al., 1998).
RCAS has been described (Hughes et al., 1987) and was a gift from Stephen Hughes.
RCAS AV2 has been described (Schuur et al., 1993) and was a gift from Peter Vogt; see 
Figure 2.1.
RCAS AvJ-hER and RCAS hER have been described (Kruse et al., 1997) and were a gift 
from Ulrich Kruse; see Figure 2.1.
2.1.5 Bacteriology
Beatson Institute Central Services
L-Broth 
Sterile glycerol
Difco Laboratories
Bacto-agar 
Gibco BRL
E.coli DH5a competent cells
Sigma
Ampicillin
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Stratagene
XLIO-Gold p-mercaptoethanol mix 
XLIO-Gold ultracompetent cells
2.1.6 Cell culture
Chicken embryo fibroblasts (CEFs) are fibroblasts derived from 10.5-11 day-old White 
Leghorn chicken embryos.
Beatson Institute Central Services
Sterile phosphate-buffered serum (PBS)
Sterile PBS + EDTA (PE)
Bio Whittaker Molecular Applications
SeaPlaque agarose
Fisher Scientific
Dimethyl sulphoxide (DMSO)
Gibco BRL
Chicken serum
Dulbecco’s modified Eagle medium (DMEM)
L-glutamine 
New-born calf serum 
Trypsin solution 
Tryptose phosphate broth
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Harlan Sera-Lab Ltd.
Foetal calf serum 
Roche
Af-[l-(2,3-dioleoyloxyl)propyl]-JV,A,AMrimethylammoniummethyl sulphate (DOTAP) 
liposomal transfection reagent
Sigma
10 x DMEM
17p-estradiol (estradiol)
4-Hydroxy tamoxifen (tamoxifen)
Penicillin G 
Sodium bicarbonate 
Sodium pyruvate 
Streptomycin sulphate
2.1.7 Antibodies
599-3 is an affinity-purified rabbit polyclonal antibody, raised against a peptide spanning 
amino acids 60-77 of chicken c-Jun.
730-5 is a rabbit polyclonal antiserum, raised against a full-length chicken c-Jun protein 
expressed in E.coli.
Cell Signalling Technology
Anti-rabbit IgG (H&L), Horseradish Peroxidase (HRP)-linked.
Anti-mouse IgG (H&L), Horseradish Peroxidase (HRP)-linked.
Santa Cruz Biotechnology, Inc.
c-Fos(4)X: rabbit polyclonal, c-Fos
FosB(102)X: rabbit polyclonal, FosB
HC20: rabbit polyclonal, estrogen receptor a
K-25: rabbit polyclonal, pan Fos
KM-IX: mouse monoclonal, c-Jun
N-17X : rabbit polyclonal, Fra-1
Q-20X : rabbit polyclonal, Fra-2
VP16(1-21): mouse monoclonal, VP16
2.1.8 Miscellaneous
Alltech
Silica gel 60 thin liquid chromatography (TLC) plates 
Amersham Pharmacia Biotech 
Hybond-N+ nylon membrane 
BioRad
Bio-Spin 30 chromatography columns 
Fuji Film
Phosphorimager imaging plate 
Super RX medical X-ray film
Gibco BRL
lOObp DNA ladder
61
lkb DNA ladder 
Osmonics
Supported nitrocellulose membrane 
Pall Gel man
Nanosep MF 0.2pm filtration tubes 
Promega
Streptavidin MagneSphere paramagnetic particles 
Sigma
Prestained protein molecular weight markers 
Whatman International Ltd.
Whatman 3MM filter paper
2.2 Methods
2.2.1 Bacteriology
2.2.1.1 Transformation of DNA into bacterial hosts
DH5a cells were thawed on ice, and a 20pl aliquot added to 2pl DNA solution in a pre­
chilled polypropylene tube. A range of DNA concentrations was generally used. After 
incubation on ice for 45min, cells were subjected to heat-shock at 42°C for 40s. 80pi L- 
broth was added and the tubes were incubated for lhr at 37°C with shaking. The mixture 
was spread onto plates containing 1.5%(w/v) agar and lOOpg/ml ampicillin in L-broth. The 
plates were incubated overnight at 37°C.
For transformation of DNA into XLIO-Gold ultracompetent cells, the following 
modifications were made to the above procedure: a 45pi aliquot of cells was pre-incubated
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with 2\il XLIO-Gold p-mercaptoethanol mix for lOmin on ice; incubation on ice with 
DNA took place for 30min; heat-shock was for 30s; and 500pl L-broth, pre-warmed to 
42°C, was added after heat-shock.
2.2.1.2 Bacterial culture
Single bacterial colonies were picked from agar plates, and inoculated into an appropriate 
volume of L-broth containing 100pig/ml ampicillin. The culture was grown overnight at 
37°C with shaking.
2.2.1.3 Preparation of glycerol stocks
0.5ml of overnight bacterial culture was mixed with an equal volume of sterile glycerol 
and stored at -70°C.
2.2.1.4 Small-scale plasmid DNA preparation
lml overnight bacterial culture was pelleted by centrifugation for 5min at 5000rpm. The 
pellet was resuspended and processed using the QLAprep Spin Miniprep Kit (Qiagen) 
according to the manufacturer’s instructions.
2.2.1.5 Large-scale plasmid DNA preparation
500ml overnight bacterial culture was pelleted by centrifugation for 15min at 6000rpm, 
4°C. The pellet was resuspended and processed using the QIAGEN Plasmid Maxi Kit 
(Qiagen) according to the manufacturer’s instructions.
2.2.2 Cell culture
2.2.2.1 Maintenance and storage of cell lines
CEFs were grown as a monolayer at 41°C, 5% CO2 , in DMEM supplemented with 
10%(v/v) new-born calf serum, l%(v/v) heat-inactivated chicken serum, 10%(v/v) tryptose 
phosphate broth, 2mM glutamine, 5U/ml penicillin and 50p,g/ml streptomycin. 2pM 
estradiol, 200nM tamoxifen or an equivalent volume of ethanol was added as required.
Cells were routinely passaged every 3-4 days. Cells were washed once in PE, exposed 
briefly to 0.25%(v/v) trypsin solution in PE, and harvested by agitation in normal growth
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medium. For long-term storage, cells were pelleted by centrifugation for 5min at lOOOrpm. 
The pellet was resuspended in an appropriate volume of 10%(v/v) DMSO in foetal calf 
serum, aliquoted, and stored in liquid nitrogen.
2.2.2.2 Transfection of cells with plasmid DNA
Plasmid DNA was transfected using DOTAP liposomal transfection reagent. For each 
transfection, 2.5-10pg DNA in 170pl 200mM Hepes buffer was added to 30p,l DOTAP. 
After 5min, the mixture was added to sub-confluent cells. The cell medium was changed 
after 24hr.
2.2.2.3 Cell photography
Photographs were taken using a Fuji Fine pix digital camera attached to an Axiovert25 
light microscope (Zeiss).
2.2.2.4 Cell growth assays
Cells were set up at either 2xl05 cells per 60mm plate or 4xl05 cells per 90mm plate. Cell 
numbers were determined in duplicate every 24hr by trypsinisation of the cells and 
scraping into 2ml growth medium. Cells were counted automatically using a Casyl cell 
counter (Scharfe System).
2.2.2.5 Soft agarose growth assays
2 x complete growth medium was prepared using lOxDMEM in sterile water with the 
addition of 2mM sodium pyruvate, 0.375%(w/v) sodium bicarbonate, and all other growth 
medium components (see Chapter 2.2.2.1) at double the usual concentration. SeaPlaque 
agarose in sterile water was prepared at 2%(w/v) and 0.7%(w/v) and sterilised by 
autoclaving.
Assays were prepared in 30mm plates. The base layer, consisting of 1.5ml 1% agarose in 1 
x growth medium, containing 2|xM estradiol or an equivalent volume of ethanol as 
appropriate, was allowed to set at room temperature (RT). Growing cells were trypsinised 
and resuspended in 1 x growth medium as before, and counted using a haemocytometer. 
102,103 or 104 cells were suspended in 2ml 0.35% agarose in 1 x growth medium, 
containing 2p,M estradiol or an equivalent volume of ethanol as appropriate, and overlaid
onto the base layer. The agarose was allowed to set and the cells incubated at 41°C, 5% 
CO2 . Cells were fed every 3-4 days by overlaying with 1.5ml 1% agarose in 1 x growth 
medium, containing 2pM estradiol or an equivalent volume of ethanol as appropriate. 
Colonies were counted under a light microscope after 2 weeks.
2.2.2.6 Preparation of whole cell extracts (WCEs)
Cells were grown to approximately 90% confluence on 90mm or 140mm plates. On ice, 
growth medium was removed and the cells washed twice with ice-cold PBS. After draining 
well, the cells were scraped into 1ml PBS and pelleted by centrifugation at 4000 rpm. The 
pellet was resuspended in a suitable volume of WCE buffer (0.4M KC1, 20mM Hepes, 
10%(v/v) glycerol with lOmM EGTA, 5mM EDTA, 5mM NaF, ImM sodium 
orthovanadate, ImM DTT, 50(ig/ml PMSF, 5|ig/ml aprotinin, 5|ig/ml leupeptin, 50ng/ml 
okadaic acid, 0.4%(v/v) Triton X-100). After 20min on ice, cells were subjected to 2 
rounds of freeze-thaw (dry ice-37°C waterbath) and pelleted by centrifugation at 
14000rpm, 4°C. The supernatant was removed and stored at -70°C.
2.2.2.7 Chloramphenicol acetyltransferase (CAT) assays
Cells were plated at 2.5x105 cells per 60mm plate in 4ml growth medium, containing 2pM 
estradiol, 200nM tamoxifen or an equivalent volume of ethanol as appropriate. After 24hr, 
cells were transiently transfected with reporter plasmid, and co-expression plasmids as 
required (see Chapter 2.2.2.2 for details). Cells were harvested 24-48hr after transfection. 
Cells were washed twice with PBS, and 300pl 1 x reporter lysis buffer was added. After 
lOmin, cells were scraped and pelleted by centrifugation at 13000rpm. lOpl supernatant 
was retained for estimation of the protein concentration (see Chapter 2.2.4.1). 180pl 
supernatant was incubated at 37°C with 0.8mg/ml acetyl coenzyme A and 2pi D-threo- 
[dichloroacetyl-1 -14C] -chloramphenicol.
After 2-3hr, the reaction was stopped on ice and 300pl ethyl acetate was added. After 
mixing and separation by brief centrifugation at 13000rpm, 200p,l of the organic phase was 
removed to a clean tube and dried down by centrifugation under vacuum. The pellet was 
resuspended in lOpl ethyl acetate and spotted onto silica gel 60 TLC plates. TLC was 
performed in an air-tight glass tank in 95%(v/v) chloroform, 5%(v/v) methanol for lhr. 
Plates were then dried and exposed to a phosphporimager imaging plate. The plate was 
read using a Personal Molecular Imager FX (BioRad), and radio-labelled products were
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quantified using Molecular Analyst software (BioRad). Relative CAT activity was 
calculated by division of the percentage acetylation of D-threo-[dichloroacetyl-l-u C]~ 
chloramphenicol by the sample protein concentration.
2.2.3 Nucleic acid protocols
2.2.3.1 Oligonucleotide synthesis
Oligonucleotides were synthesised by Beatson Institute Technical Services staff, using 
Cruachem reagents in a 392 DNA/RNA oligonucleotide synthesiser according to the 
manufacturer’s instructions. DNA pellets were dissolved in sterile TE (lOmM Tris, ImM 
EDTA).
2.2.3.2 Quantitation of DNA concentration
DNA concentrations were calculated by determining the UV light absorbency of a DNA 
solution at 260 and 280nm, using a Beckman DU650 Spectrophotometer. Samples were 
read in duplicate against a suitable blank. The DNA concentration was calculated using de 
Beer’s law, which states that an optical density of 1 at 260nm corresponds to 50fxg/ml 
double-stranded DNA or 33jxg/ml single-stranded DNA.
2.2.3.3 Oligonucleotide annealing
Equal amounts of two complementary oligonucleotides in annealing buffer (67mM Tris 
pH8,13mM MgCb, 6.7mM DTT, 1.3mM spermidine, ImM EDTA) were heated to 95°C 
and cooled to RT.
2.2.3.4 Polyacrylamide gel electrophoresis (PAGE)
DNA samples were resolved on polyacrylamide gels, prepared by adding an appropriate 
volume of 30%(w/v) acrylamide, 1.6%(w/v) bisacrylamide to lxTBE buffer (90mM Tris, 
90mM boric acid, 2mM EDTA). The gel was polymerised by the addition of APS and 
TEMED. Samples, containing 10%(v/v) loading dye (10%(v/v) glycerol with BPB in 
lxTBE), were subjected to electrophoresis at 150V in lxTBE buffer. The gel was washed 
for 15min in ethidium bromide in lxTBE, and DNA was visualised and photographed 
under short-wave UV illumination.
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2.2.3.5 Agarose gel electrophoresis
0.7-l%(w/v) agarose gels were used, depending on the size of the DNA fragment of 
interest. The appropriate amount of agarose was heated in lxTAE buffer (40mM Tris, 
16mM acetic acid, ImM EDTA) and lug/ml ethidium bromide was added before setting. 
Samples, containing 10% loading dye (see Chapter 2.2.3.4), were loaded along with 
appropriate size markers and subjected to electrophoresis at 80-100V in lxTAE buffer. 
DNA fragments were visualised and photographed under short-wave UV illumination.
2.2.3.6 Extraction of DNA fragments from agarose gels
DNA fragments were excised from agarose gels and recovered using the QIAquick Gel 
Extraction Kit (Qiagen) according to the manufacturer’s instructions.
2.2.3.7 Restriction enzyme digests
DNA was generally digested at 37°C for lhr with an excess of enzyme, in the buffer 
supplied by the manufacturer. Double digests were carried out simultaneously in the buffer 
most suitable for both restriction enzymes. PCR products with restriction sites close to 
their ends were digested overnight at 37°C. Digests with the BstYI enzyme were carried 
out at 60°C for lhr with the addition of 10%(w/v) BSA.
2.2.3.8 De-phosphorylation reactions
Linearised plasmid DNA was de-phosphorylated by treatment with an excess of alkaline 
phosphatase at 37°C for lhr, in the buffer recommended by the manufacturer.
2.2.3.9 DNA ligation reactions
DNA fragments were ligated either by overnight incubation at 11°C with an excess of T4 
DNA ligase in the buffer supplied by the manufacturer, or at RT for 30min using the Rapid 
DNA Ligation Kit (Roche) according to the manufacturer’s instructions. A range of 
insert:vector ratios was generally used.
2.2.3.10 Polymerase chain reaction (PCR)
PCR was carried out using GeneAmp PCR Core Reagents (Applied Biosystems Inc). 
0.75ng plasmid DNA template was amplified by AmpliTaq DNA polymerase using
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primers at a concentration of 0.2pM (p300 templates) or 0.6pM (bkj templates) in 4mM 
MgCl2 . Reactions were carried out using thin-walled PCR tubes in a PTC-100 PCR 
machine (MJ Research, Inc). Reaction conditions were as follows: initial step 95°C, 2min; 
followed by 25 cycles of 95°C, lmin 30; 50°C, 2min; 72°C, 2min; final step 72°C, 7min.
2.2.3.11 Purification of PCR products
10% of each PCR reaction was resolved on an agarose gel and visualised. The remainder 
of each reaction was processed using the QIAquick PCR Purification Kit (Qiagen) 
according to the manufacturer’s instructions.
2.2.3.12 Site-directed mutagenesis by a PCR cassette method
A panel of bkj promoter mutants with TREs in different positions was created using a PCR 
cassette method. In the first stage, the flanking primer pair Hindlll bkj5’ and Xbal M/3’ 
was used to amplify the bkj promoter region from -929 to +13, using pCAT-5A7(WT) as a 
template (see Chapter 2.1.3.2 for details of all primer sequences). The PCR product was 
digested overnight with Hindlll and Xbal and ligated into the pCAT-Basic reporter vector.
This wt(P)TRE bkj plasmid was used as the template for the next stage, involving point 
mutation of the proximal TRE at position -815. The first round of PCR used the mutagenic 
primer mt(P)TRE bkj5’ with the Xbal M/3’ flanking primer. 50% of the purified first- 
round product was then used as the 3’ primer in the second round, along with the Hindlll 
M/5’ flanking primer, to amplify the full-length mutated PCR product. This was digested 
and ligated into pCAT-Basic as before.
The resulting mt(P)TRE bkj plasmid was used as the template in the third stage. Again, this 
involved the use of each mutagenic 5’ primer with the Xbal M/3’ flanking primer in the 
first round of PCR, and 10-50% of the purified first-round product with the Hindlll M/5’ 
flanking primer in the second. All full-length mutated products were digested and ligated 
into pCAT-Basic as before to create the panel of reporter vectors.
2.2.3.13 Site-directed mutagenesis by a one-stage PCR method
All other site-directed mutants were made using the QuikChange XL Site-Directed 
Mutagenesis Kit (Stratagene). PCR using 50ng template DNA and 125ng each of 2 
complementary mutagenic primers was carried out according to the manufacturer’s
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instructions (see Chapter 2.1.3.2 for details of all primer sequences). The original template 
DNA was degraded by incubation at 37°C for lhr with Dpnl endonuclease, which 
specifically cleaves methylated and hemimethylated DNA, and the resulting mutated 
product was transformed into XLIO-Gold ultracompetent cells (see Chapter 2.2.1.1).
2.2.3.14 Plasmid construction 
RCAS AvJ-hER mt
Due to the large size of the RCAS vector, the Clal fragment of RCAS AvJ-hER was cloned 
into the Clal2Nco adaptor plasmid to enable site-directed mutagenesis. The AF-2mt 
primer pair (see Chapter 2.1.3.2) was used to introduce the M543A / L544A mutation into 
Clal2Nco AvJ-hER (see Chapter 2.2.3.13). The Clal fragment was then cloned into RCAS 
to create RCAS AvJ-hER mt.
RCAS AvJ-p300 wt and mt
The Clal2Nco AvJ-hER plasmid (see above) was digested with Ncol and BamHI to 
remove the AvJ-hER construct. The resulting DNA fragment was digested further with 
BstYI, and the NcoI-BstYI fragment containing AvJ was cloned into Clal2Nco digested 
with Ncol and BamHI, to create the Clal2Nco AvJ plasmid. pBlueScript KS p300 WT and 
p300 Mut AT2 were each used as the template in PCR reactions using the Sail p3005’ and 
Hindlll p3003’ primers (see Chapter 2.1.3.2) to amplify the p300 HAT domain (amino 
acids 1062-1723). PCR products were digested with Sail and Hindlll, and cloned into Sall- 
Hindlll digested Clal2Nco AvJ, downstream of and in frame with AvJ. The resulting 
plasmids were digested with Clal and cloned into RCAS to create RCAS AvJ-p300 wt and 
mt; see Figure 2.1.
2.2.3.15 Automated DNA sequencing
All plasmids were sequenced using the PRISM BigDye Terminator Cycle Sequencing 
Ready Reaction Kit (Applied Biosystems Inc.). Approximately 500ng DNA was mixed 
with 3.2pmol appropriate primer in a 6pi volume, and 4pl BigDye terminator ready 
reaction mix was added. PCR reaction conditions were as follows: initial step 95°C, 2min; 
followed by 25 cycles of 95°C, 15s; 50°C, lmin; 60°C, 4min, then a 4°C soak. The PCR
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product was precipitated by incubation on ice with 2pl 3M sodium acetate pH4.5 and 50pl 
ethanol, followed by centrifugation and washing in 70%(v/v) ethanol.
Samples were loaded and run overnight on an Applied Biosystems 373A automated 
sequencer by Beatson Institute Technical Services staff.
2.2.3.16 Probing of Northern blots
Extraction of total RNA from cells, mRNA selection, RNA formaldehyde gel 
electrophoresis, and blotting onto nylon membrane were performed by Mr B. Clark of the 
Beatson Institute.
Nylon membranes were pre-hybridised at 65°C for at least 3hr in hybridisation buffer 
(0.25M Na2H P04 pH 7.2, ImM EDTA pH 8, 7%(w/v) SDS). Double-stranded DNA 
probes were boiled for 5min then cooled on ice. Probes were labelled by incubation at 
37°C for lhr with an excess of deoxycytidine 5’-[a-32P]-triphosphate using the 
Oligolabelling Kit (Amersham Pharmacia Biotech). Radio-labelled probes were collected 
by centrifugation in a Bio-Spin 30 chromatography column. Probes were boiled for 5min 
and cooled on ice before adding to pre-heated hybridisation buffer. The nylon membranes 
were hybridised overnight at 65°C in this mixture.
Membranes were washed at 65°C for 2xl0min in 20mM Na2HP04 pH 7.2, ImM EDTA 
pH8, 5%(w/v) SDS, then 3xl0min in 20mM Na2HP04 pH 7.2, ImM EDTA pH 8, 
l%(w/v) SDS. Bound probe was detected by autoradiography; membranes were exposed to 
X-ray film at -70°C and films developed using an X-OMAT 480 RA processor (Kodak). 
Membranes were stripped by washing at 65°C for 3xl0min in 0.1%(w/v) SDS, and then re­
probed.
2.2.4 Protein protocols
2.2.4.1 Estimation of protein concentrations
Protein concentration standards were prepared over a range of 0-4mg/ml using BSA in a 
suitable buffer. 10 pi of each standard was added to 1ml 50%(v/v) Coomassie protein assay 
reagent in a plastic cuvette. The light absorbencies of the protein standards were read at 
595nm, using a Beckman DU650 Spectrophotometer, and a standard curve was produced.
lOjxl of each protein sample was then treated in the same way, and the protein 
concentration estimated from the standard curve.
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2.2A.2 SDS-PAGE
10% polyacrylamide resolving gels were prepared using 30%(w/v) acrylamide, 0.8%(w/v) 
bisacrylamide in 375mM Tris pH8.8, 0.1%(w/v) SDS. 4.8% polyacrylamide stacking gel 
layers were prepared using 30%(w/v) acrylamide, 0.8%(w/v) bisacrylamide in 125mM Tris 
pH6.8, 0.1%(w/v) SDS. Gels were polymerised by the addition of APS and TEMED.
WCEs in lxSDS sample buffer were boiled for 2min, cooled on ice and loaded onto the gel 
along with 10pl prestained protein molecular weight markers. Electrophoresis was carried 
out at 250V in buffer containing 25mM Tris, 192mM Glycine, 0.1%(w/v) SDS.
2.2A.3 Western transfer of proteins
Proteins were transferred from polyacrylamide gels to supported nitrocellulose membrane 
using a semi-dry electroblotter (Millipore). Blot components were soaked in transfer buffer 
(48mM Tris pH, 39mM glycine, 1.3mM SDS, 20%(v/v) methanol) and assembled, from 
anode to cathode, in the order: 6 sheets Whatman 3MM filter paper, nitrocellulose 
membrane, polyacrylamide gel, 6 sheets Whatman 3MM filter paper. Electoblotting was 
performed at 20V, 200mA for lhr.
2.2.4.4 Immunological detection of blotted proteins
Nitrocellulose membranes were blocked for lhr at RT in 100ml Tris-buffered saline- 
Tween (TBST: lOmM Tris, lOOmM NaCl, 0.1%(v/v) Tween-20) containing 5%(w/v) 
skimmed milk powder. The membrane was then incubated in 5% milk powder in TBST 
containing an appropriate concentration of primary antibody. Incubation was carried out 
overnight at 4°C (599-3 antibody) or for lhr at RT (all other antibodies). The membrane 
was washed at RT for 3xl0min with TBST, and then incubated for lhr at RT with 5% milk 
powder in TBST containing a 1:5000 dilution of an HRP-linked secondary antibody. The 
membrane was washed as before, and incubated for lmin at RT with ECL Western 
detection agent. Proteins were visualised by autoradiography. Membranes were stripped by 
incubation in 0.2M glycine, l%(w/v) SDS for 30-60min at RT.
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2.2.4.5 Protein staining
Total protein was visualised by incubating membranes in Ponceau S solution for 10-20min 
and rinsing in df^O.
2.2.5 DNA binding assays
2.2.5.1 Oligonucleotide labelling
200ng double-stranded oligonucleotide was end-labelled by incubation with T4 PNK in the 
presence of an excess of adenosine 5’-[Y-32P]-triphosphate for 30min at 30°C. 10% loading 
dye (see Chapter 2.2.3.4) was added to the reaction, and the sample was loaded onto a 12% 
polyacrylamide gel. Electrophoresis was carried out at 150V in lxTBE buffer. The gel was 
wrapped and exposed to X-ray film to enable visualisation and excision of the labelled 
probe. The gel fragment was placed in a Nanosep MF 0.2^m filtration tube (Pall Gelman), 
minced, and 400pl sterile TE was added. After overnight incubation at RT, the probe was 
recovered by centrifugation and stored at -20°C until needed.
2.2.5.2 Electrophoretic mobility shift assays (EMSAs)
lOfxg WCE was added to 0.5jxg polydl.dC in 1 x binding buffer (lOmM Hepes, 4mM DTT, 
0.2mM EDTA, lOOnM NaCl, O.lmg/ml BSA, 4%(v/v) glycerol). The extract was pre­
incubated for 15min on ice with antibody or unlabelled competitor oligonucleotide as 
required, lng radio-labelled probe was added, and the extract was incubated for 30min on 
ice.
A 4.2% polyacrylamide gel was prepared and pre-electrophoresed at 150V in lxTBE 
buffer for 30min, 4°C. Samples were then loaded, along with 10% loading dye in 1 x 
binding buffer in a separate well. Electrophoresis was carried out at 150V in lxTBE buffer, 
4°C. The gel was then fixed by incubation in 10%(v/v) acetic acid, 10%(v/v) methanol for 
15-30min at RT, and dried under vacuum onto Whatman 3MM filter paper. DNA-binding 
complexes were visualised by autoradiography at -70°C.
2.2.5.3 Preparation of biotinylated concatenated probes
Double-stranded ColEco oligonucleotide, with 5’-overhanging EcoRI complementary 
ends, was phosphorylated by incubation with T4 PNK in the presence of an excess of ATP
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for 30min at 30°C. T4 DNA ligase was added, and the reaction was incubated for 2hr at 
RT. The concatenated probe was biotinylated by incubation with the Klenow fragment of 
E.coli DNA polymerase I, in the presence of an excess of dATP and biotin- 16-dUTP. After 
lhr at 37°C, the reaction was stopped on ice. The probe was collected by centrifugation in 
a Bio-Spin 30 chromatography column (BioRad). After each stage, a portion of the 
reaction was retained and checked by resolving on a 12% polyacrylamide gel.
2.2.5.4 Biotinylated oligonucleotide capture of DNA-binding complexes
WCEs were pre-cleared using lOpi streptavidin-conjugated paramagnetic particles in 1 x 
binding buffer (see Chapter 2.2.5.2), 1M NaCl. After incubation with mixing at 4°C for 
lhr, particles were pulled down using a magnetic stand (Promega). A portion of the 
supernatant was removed for analysis by EMSA.
0.5\ig biotinylated concatenated probe was bound to lOpl streptavidin-conjugated 
paramagnetic particles by incubation with mixing at 4°C for lhr in 1 x binding buffer, 1M 
NaCl. DNA-bound particles were pulled down, washed twice in 400pl 1 x binding buffer, 
and resuspended in the remaining supernatant from the pre-clearing stage. After incubation 
for lhr as before, particles were pulled down and a portion of the supernatant was removed 
for analysis by EMSA. The remaining supernatant was discarded. Particles were washed as 
before, then resuspended in 40pi 1 x SDS sample buffer. The particles were pulled down, 
and the supernatant, containing eluted DNA-binding complexes, was analysed by SDS- 
PAGE and Western blotting. The particles from the pre-clearing stage were also 
resuspended in 1 x SDS sample buffer, pulled down, and the supernatant removed for use 
as a negative control.
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Gag bZip v-Jun: 65kD
iwmmm AvJ-hER: 60kD
AP-2 hER: 35kD
VP16
AV2: 32kD
AvJ-p300: 99kD
Figure 2.1
Structure of RCAS expression constructs.
AvJ-hER consists of the v-Jun C-terminal region fused to the hormone binding / AF-2 
domain of human estrogen receptor-a (see Chapter 2.1.4)
hER consists of the hormone binding / AF-2 domain of human estrogen receptor-a 
(see Chapter 2.1.4)
AV-2 consists of the C-terminal region of v-Jun fused to the VP16 transcriptional 
activation domain (see Chapter 2.1.4).
AvJ-p300 consists of the v-Jun C-terminal region fused to the histone acetyl 
transferase (HAT) domain of human p300 (see Chapter 2.2.3.14).
Point mutation derivatives of AvJ-hER and AvJ-p300 were also constructed: see 
Chapter 2.2.3.14.
Linker regions are shown as hatched boxes.
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3 Results: Comparative studies of gene promoters 
activated or repressed by v-Jun.
3.1 Introduction and aims.
While many positive and negative targets of v-Jun have been identified (see Chapter 1.2.2), 
little is known about the mechanisms of transcriptional regulation by v-Jun. However, the 
transcriptional regulation of a number of specific v-Jun target genes has been studied, with 
bkj and collagenase I representing two of the better characterised promoters.
Expression of bkj ({3-keratin in Jun-transformed cells) was detected specifically in quail 
embryo fibroblasts (QEFs) transformed by v-Jun, c-Jun, or a chimaeric v-Jun / JunD 
protein (Hartl and Bister, 1995), CEFs transformed by v-Jun or v-Fos (Hartl and Bister, 
1998), and in RCAS-AvJ-hER infected QEFs treated with estradiol (Kruse et al., 1997). 
Two consensus TREs were identified at positions -1073 and -815 relative to the major 
transcriptional start site (Hartl and Bister, 1998). Transcription from the full-length bkj 
promoter in QEFs was activated strongly by v-Jun, and to a lesser degree by c-Jun and 
JunD. Deletion analysis of the promoter suggested that the proximal TRE was necessary 
for transcriptional activation by v-Jun (Hartl and Bister, 1998).
The collagenase I promoter contains a consensus TRE at position -72 relative to the 
transcriptional start site (Angel et al., 1987b). Mutation of this element abolished basal and 
TPA-induced transcription from the promoter (Auble and Brinckerhoff, 1991; Gutman and 
Wasylyk, 1990; Jonat et al., 1990; Westermarck et al., 1997). Other sites, including a non­
consensus TRE at position -186, have been shown to contribute to transcriptional 
regulation (Auble and Brinckerhoff, 1991; Chamberlain etal., 1993; Gutman and 
Wasylyk, 1990; Westermarck et al., 1997; White and Brinckerhoff, 1995). However, the 
TRE at position -72 appears to be sufficient for regulation by v-Jun, as transcription from 
the collagenase I promoter region -73/+63 has been shown to be repressed in v-Jun 
transformed CEFs compared to control cells (Kilbey et al., 1996).
bkj and collagenase, then, represent examples of gene promoters which are respectively 
activated or repressed by v-Jun. The transcriptional mechanisms responsible for the 
opposing effects of v-Jun on the two promoters are not known. The aim of this work was to 
further characterise transcription from the bkj and collagenase promoters in v-Jun
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transformed and control CEFs, with the emphasis on investigation of the differences 
between the promoters which determine the nature of their regulation by v-Jun.
3.2 bkj is activated by v-Jun, whereas collagenase is 
repressed.
3.2.1 Promoter regulation in control and v-Jun transformed CEFs.
A systematic analysis of the activity of bkj and collagenase promoters and deletion mutant 
derivatives was carried out in CEFs uniformly infected with ASV17 or the RCAS 
retroviral vector. Prior transfection with a construct consisting of the CAT reporter gene 
driven by the RSV long terminal repeat promoter established that the transfection 
efficiencies of the two cell types were equivalent (data not shown).
5^ig each of the pCAT-BKJ(WT), -BKJ(DP), -BKJ(P), -BKJ(D) and -BKJ(0) reporter 
plasmids was transfected in triplicate into CEFs and v-Jun transformed CEFs, and relative 
CAT activities were determined (see Chapter 2.22.1 for details). The results of a 
representative experiment are shown in Figure 3.1 A.
The full-length promoter, BKJ(WT), was more active in v-Jun transformed CEFs than in 
controls. The BKJ(DF) promoter, which retains both TREs but lacks 690bp of upstream 
sequence, was also more active in v-Jun transformed CEFs than in controls; however, the 
overall levels of promoter activity in both cell types were much higher than the 
corresponding values obtained with the BKJ(WT) promoter. Deletion of the distal TRE and 
flanking sequences from BKJ(DP), resulting in the BKJ{P) promoter, did not affect 
promoter activity in v-Jun transformed CEFs, but decreased transcription in control CEFs. 
Further deletion of the proximal TRE and flanking sequences, resulting in the BKJ(0) 
promoter, decreased promoter activity in v-Jun transformed CEFs to basal levels. Deletion 
of the proximal TRE and flanking sequences from BKJ(WT) resulted in the BKJ(D) 
promoter, which displayed low levels of activity in both v-Jun transformed and control 
CEFs.
These results are in line with previous observations in QEFs (Hartl and Bister, 1998) that 
the BKJ(WT) promoter was activated more strongly by v-Jun than c-Jun, the BKJ(DP) 
promoter was more active in v-Jun transformed cells than in controls, and that v-Jun 
activated the BKJ(DP) and BKJ(P) promoters more strongly than BKJ(WY), BKJ(D) and
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BKJ(0). The fact that the BKJ(DV) promoter was more active than BKJ(WT) suggests that 
there may be a negative regulatory element, for example a binding site for a transcriptional 
repressor, within the 690bp deleted sequence. The difference in activity between the 
BKJ{WT) and BKJ{DP) promoters was much more pronounced in CEFs (Figure 3.1A) 
than in QEFs (Hartl and Bister, 1998). The two promoters have not been compared in 
QEFs stably infected with ASV17, or by co-transfection with c-Jun and v-Jun in CEFs; the 
discrepancy may be due to the different approach used in each case, or to the species 
difference.
Previous studies have suggested that the proximal, rather than the distal, TRE is necessary 
for activation of the bkj promoter by v-Jun; this was based on a comparison between the 
BKJ(P) and BKJ(D) promoters (Hartl and Bister, 1998). However, unlike BK J(?\ BKJ(D) 
retains the 690bp sequence upstream of the distal TRE which, as described above, 
mediated down-regulation of the BKJ(WT) promoter in v-Jun transformed and control 
CEFs (Figure 3.1 A). Any transcriptional effect of the distal TRE may therefore be masked 
in this promoter context. Additionally, comparison of the BKJ(DV) and BKJ(P) promoters 
reveals that deletion of the distal TRE decreased promoter activity in control CEFs. The 
distal TRE may therefore contribute to bkj regulation. However, the most important 
conclusions for the purpose of this comparative study were that the BKJ(P) promoter is 
more active in v-Jun transformed CEFs than in controls, and that deletion of the proximal 
TRE from this construct decreases transcription to basal levels in v-Jun transformed CEFs.
5pg each of the -73/+63 ColCAT and -60/+63 Col CAT reporter plasmids was transfected 
in triplicate into CEFs and v-Jun transformed CEFs, and relative CAT activities were 
determined as before. The results of a representative experiment are shown in Figure 3.IB. 
The -13/+63 ColCAT promoter had a high level of basal activity in control CEFs, and was 
down-regulated approximately 10-fold in v-Jun transformed CEFs. This confirmed 
previous observations (Hussain et al., 1998; Kilbey et al., 1996). Deletion of the TRE at 
position -72, resulting in the -60/+63 ColCAT promoter, abolished basal promoter 
activity. The decreased activity of this promoter in v-Jun transformed CEFs compared with 
control CEFs was not reproducible, and therefore unlikely to be a transcriptional effect of 
v-Jun on the -60/+63 ColCAT promoter.
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Figure 3.1
Transcription from (A) the bkj promoter and deletion mutants thereof and (B) the 
collagenase promoter and a deletion mutant.
Black boxes represent consensus TRE sequences. Promoter diagrams are not 
to scale.
5pg each reporter plasmid was transfected in triplicate into CEFs and v-Jun 
CEFs. Fold activation of transcription in v-Jun CEFs compared to control CEFs 
is shown in each case.
Error bars denote standard deviations.
f*  -7 3 /+ 6 3  
ColCAT
r* -6 0 /+ 6 3  
ColCAT
3.2.2 Effect of ectopic v-Jun expression on the bkj and 
collagenase promoters.
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As described in Chapter 1.2.1, v-Jun replaces c-Jun as the major component of the protein 
complexes bound to TREs and CREs in v-Jun transformed CEFs, and this is thought to 
account for the altered transcription of certain target promoters in these cells. However, it 
was possible that the activation of bkj and repression of collagenase in v-Jun transformed 
CEFs were not direct effects of v-Jun expression and binding to TREs, but were caused by 
some other altered property of the transformed cells. Co-expression experiments were 
therefore carried out to analyse the effects of c-Jun and v-Jun protein expression on the bkj 
and collagenase promoters.
0.5|igZ?KJ(P) reporter plasmid, along with 2pg pRc/RSV-cJ3, -vJl or empty vector, was 
transfected in triplicate into CEFs, and relative CAT activities were determined as before. 
Figure 3.2A shows that, while co-expression of c-Jun had little or no effect on promoter 
activity, co-expression of v-Jun strongly activated the BKJ(P) promoter. This confirmed 
previous observations in QEFs (Hartl and Bister, 1998).
Similarly, 2pg -73/+63 ColCAT reporter plasmid, along with lpg  pRc/RSV-cJ3, -vJl or 
empty vector, was transfected in triplicate into CEFs, and relative CAT activities were 
determined as before. Figure 3.2B shows that, while co-expression of c-Jun activated the 
promoter slightly, co-expression of v-Jun repressed the basal activity of the promoter. This 
confirmed previous reports (Gao et al., 1996).
The results of bkj and collagenase promoter reporter assays in v-Jun transformed and 
control cells (Figure 3.1) therefore correlate well with experiments involving the ectopic 
expression of c-Jun and v-Jun (Figure 3.2; see also (Hartl and Bister, 1998)). This strongly 
suggests that the activation of bkj and repression of collagenase in v-Jun transformed CEFs 
are direct effects of the v-Jun protein on the two gene promoters.
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Figure 3.2
(A) Co-expression of c-Jun and v-Jun with the BKJ(P) promoter.
0.5pg reporter plasmid, along with 2pg pRc/RSV-cJ3, -vJ1 or empty vector, 
was transfected in triplicate into CEFs. Error bars denote standard 
deviations.
(B) Co-expression of c-Jun and v-Jun with the -73/+63 ColCAT promoter.
2pg reporter plasmid, along with 1pg pRc/RSV-cJ3, -vJ1 or empty vector, 
was transfected in triplicate into CEFs. Error bars denote standard 
deviations.
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3.3 The collagenase and bkj TREs are bound by similar 
protein complexes.
It has been shown that dimers consisting of different members of the Jun and Fos families 
have different transcriptional effects on certain promoters (see Chapter 1.1.7.1). It was 
therefore possible that dimerisation with different Fos family members contributed to the 
different effects of v-Jun on the bkj and collagenase promoters.
The collagenase TRE has been shown to be specifically bound by c-Jun / Fos dimers in 
CEFs, and by v-Jun / Fos dimers in v-Jun transformed CEFs (Hawker et al., 1993; Kilbey 
et al., 1996). The major Fos family component was thought to be Fra-2 in both cell types 
(Kilbey et al., 1996). The proximal bkj TRE has been shown to be specifically bound by 
recombinant chicken c-Jun protein (Hartl and Bister, 1998). Neither of the bkj TREs has 
previously been tested for binding using cell extracts.
An EMSA was carried out to visualise the protein complexes bound to the collagenase 
TRE, and the distal (D) and proximal (P) TREs of bkj, in v-Jun transformed and control 
CEFs (Figure 3.3A). lOpg of each WCE was incubated with radio-labelled oligonucleotide 
probes comprising the relevant TRE and flanking sequences (see Chapter 2.1.3.1 for 
details) and subjected to electrophoresis (see Chapter 2.2.5.2). The complex bound to each 
TRE in v-Jun transformed CEFs was of similar intensity, but lower electrophoretic 
mobility, than the corresponding complex in control cells. In the case of the collagenase 
TRE, this has been shown to be due to the greater size of the Gag-v-Jun protein (65kD) 
compared to c-Jun (39kD) (Kilbey et al., 1996).
These results suggested that all three TREs were bound by similar protein complexes. 
Competition assays were carried out to determine whether this was the case. lOpg of WCE 
from CEFs or v-Jun transformed CEFs was pre-incubated with a 100-fold excess of 
unlabelled competitor oligonucleotide before addition of radio-labelled probe. Results are 
shown in Figure 3.3B. It should be noted that the relatively low intensity of the complex 
bound to the bkj(P) TRE in v-Jun transformed CEFs was due to the reduced efficiency of 
the probe end-labelling reaction in this case.
In v-Jun transformed CEFs, each TRE competed complex bound to each of the other two 
probes. In CEFs, there was mutual competition between the collagenase and bkj{?) TREs. 
This suggests that identical complexes bound to these TREs in each cell type. However,
the complex bound to the bkj(D) TRE in CEFs was not fully competed by an excess of 
bkj{?) TRE; this suggests that a component of this complex may be unique to the bkj{D) 
TRE under these conditions. However, as self-competition by bkj{P) was not complete, this 
may reflect a technical fault rather than a genuine difference between the two TREs.
The complexes bound to each probe were analysed by super-shift experiments. WCEs 
from CEFs were pre-incubated with the c-Jun specific KM-IX antibody, or with the K-25 
antibody, which is broadly reactive to all Fos family members. WCEs from v-Jun 
transformed CEFs were pre-incubated with K-25, or the Jun 730-5 antibody (Black et al.,
1994). Results are shown in Figure 3.3C.
In CEFs, the majority of the complex bound to each probe was super-shifted by the c-Jun 
antibody, while in v-Jun transformed CEFs, each complex was almost completely 
disrupted by the Jun antibody. The K-25 pan Fos antibody completely shifted the complex 
bound to each probe in both cell types. This supports previous observations (Hawker et al., 
1993; Kilbey et al., 1996) that the major components of the complex bound to the 
collagenase TRE are c-Jun / Fos family dimers in CEFs and v-Jun / Fos family dimers in v- 
Jun transformed CEFs, and additionally suggests that the bkj(D) and bkj(P) TREs are 
bound by similar protein complexes in each cell type.
Further analysis was carried out using antibodies specific for the individual Fos family 
members (Figure 3.3D). A Fra-2 specific antibody shifted each bound complex; no other 
specific antibody had any discernible effect. It is important to note that the Fra-2 antibody 
effected only a partial shift of each complex. That the residual bound proteins contained 
Fos family members seems clear from the fact that the K-25 antibody completely shifted 
the same complexes. As only the c-Fos and Fra-2 proteins have so far been identified in 
chickens, it is possible that the residual bound complexes contained FosB and/or Fra-1 
proteins which were not recognised by the antibodies used in this experiment.
Within the limits of the materials used, however, Figure 3.3 suggests that the collagenase, 
bkj(D) and bkj(P) TREs are bound by highly similar protein complexes in v-Jun 
transformed CEFs, i.e. predominately v-Jun / Fra-2 dimers.
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Figure 3.3
(A) EMSA showing protein complexes bound to radio-labelled probes 
encompassing the collagenase (Col) or bkj (Distal and Proximal) TREs.
(B) EMSAs showing mutual competition for binding complexes between the 
three probes in CEFs (upper panel) and v-Jun CEFs (lower panel). Extracts 
were pre-incubated with a 100-fold excess of unlabelled competitor DNA, as 
indicated, before addition of radio-labelled probe.
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Figure 3.3
Analysis of protein complexes bound to collagenase and bkj TREs in 
CEFs and v-Jun CEFs, using antibodies directed against Jun / Fos (C) 
and Fos family proteins (D).
Extracts were pre-incubated with 3pl antibody, as indicated, before 
addition of radio-labelled probe.
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3.4 The effect of TRE position on transcriptional 
regulation by v-Jun.
As described above, the binding of different Jun / Fos complexes to the collagenase and 
bkj{P) TREs is unlikely to account for the different effects of v-Jun on the -73/+63 
ColCAT and bkj(P) promoters. It is possible that the effects of v-Jun may instead be 
mediated by the different position of the TRE relative to the transcriptional start site in the 
two promoters. At -72, the collagenase TRE is situated close to the transcriptional start 
site, whereas at position -815, the bkj(P) TRE is relatively distant.
It has been shown that the ability of a CRE at position -45 to mediate basal and cAMP- 
induced transcription from the tyrosine hydroxylase promoter was decreased upon its 
insertion at positions further from the transcriptional start site (Tinti et al., 1997). While 
this site was not bound by c-Jun (Lim et al., 2000), it is possible that TRE position is 
similarly important for the nature of target promoter regulation by v-Jun. It is interesting 
that the stromelysin (transin) and endogenous c-jun genes, which are, like collagenase, 
down-regulated by v-Jun (Gao et al., 1996; Hussain et al., 1998; Kilbey et al., 1996; Tsang 
et al., 1994), have a consensus TRE at position -71 and -72 respectively (Hattori et al., 
1988; Matrisian et al., 1986). In the case of the c-jun promoter, repression by v-Jun was 
shown to be mediated by the non-consensus TRE at position -72 (Hussain et al., 1998). 
Such close correlation in the positions of TREs close to the transcriptional start site in three 
v-Jun-repressed promoters suggests that TRE position may be critical for the nature of 
target promoter regulation by v-Jun.
To investigate this possibility, a panel of variant bkj promoters was constructed, each with 
its TRE in a different position relative to the transcriptional start site. The aim was to 
determine whether moving the TRE closer to the transcriptional start site would convert 
bkj from a v-Jun-activated to a v-Jun-repressed promoter.
3.4.1 Mutation of the proximal bkj TRE abolishes DNA binding 
and transactivation by Jun / Fra-2.
The first stage of the procedure was to mutate the bkj(P) TRE, to ensure that binding of Jun 
/ Fra-2 dimers to this element did not interfere with transcription from the introduced 
TREs. This was achieved using a PCR cassette site-directed mutagenesis protocol (see 
Chapter 2.2.3.12). A mutagenic primer was used to alter two bases of the bkj(P) TRE, from
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TGACTCA to AGACCCA. This mutation has been shown to abolish binding by 
recombinant chicken c-Jun protein (Hartl and Bister, 1998).
Oligonucleotides containing the wild-type or mutated bkj(P) TRE (see Chapter 2.1.3.1) 
were each used as radio-labelled probe and unlabelled competitor in an EMSA, to 
determine whether mutation of the bkj(P) TRE abolished binding by Jun / Fra-2 dimers. As 
shown in Figure 3.4A, the Mjmt(P) TRE failed to compete for the complex bound to the 
bkj(P) TRE in CEFs and v-Jun transformed CEFs. No complex was detected bound to 
radio-labelled bkjrntf?) TRE in either cell type. This confirmed that mutation of the bkj(P) 
TRE abolishes normal TRE binding by Jun / Fra-2 dimers.
The activities of the wt(P)TRE bkj and mt(P)TRE bkj promoters were compared in CEFs 
and v-Jun transformed CEFs. BKJ(P) and BKJ(0) were included as controls. 5 jig of each 
reporter plasmid was transfected in triplicate into CEFs and v-Jun transformed CEFs, and 
relative CAT activities were determined as before. Results from a representative 
experiment are shown in Figure 3.4B.
Like BKJ{P), wt(P)TRE bkj was activated much more strongly in v-Jun transformed CEFs 
than in CEFs. The difference in the overall level of activation of these two promoters was 
probably due to the slightly different promoter region used in each case (-886/+12 for 
BKJ(P) and -929/+13 for wt(P)TRE bkj). mt(P)TRE bkj was not activated in v-Jun 
transformed CEFs to the high levels seen with the wt(P)TRE bkj promoter, although basal 
transcription was not affected by mutation of the TRE. It is clear, therefore, that the bkj(P) 
TRE is essential for high levels of transcription of the bkj promoter in v-Jun transformed 
CEFs. This strongly supports the hypothesis that the high level of expression of bkj in v- 
Jun transformed CEFs is due to direct binding and regulation of the promoter by v-Jun.
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Figure 3.4
(A) EMSA showing that the mutated proximal TRE was not bound by Jun/Fos 
dimers in CEFs or v-Jun CEFs, and failed to compete bound complexes from the 
wild-type bkj(P) TRE. Extracts were pre-incubated with a 100-fold excess of 
unlabelled competitor DNA, as indicated, before addition of radio-labelled probe.
(B) Transcription from bkj promoters containing wild-type or mutated proximal TREs. 
Black boxes represent consensus TRE sequences; the hatched box represents the 
mutated proximal TRE at position -815. Promoter diagrams are not to scale.
5pg each reporter plasmid was transfected in triplicate into CEFs and v-Jun CEFs.
Error bars denote standard deviations.
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3.4.2 Introduction of TRE sequences into the bkj promoter.
The mt(P)TRE bkj promoter was used as the template to create a panel of variant 
promoters with TREs at different positions relative to the transcriptional start site. Site- 
directed mutagenesis was used to convert sites with sequence similarity to a TRE into the 
consensus TRE sequence (see Chapter 2.2.3.12). In this way, only the 1-4 nucleotides 
which diverged from the consensus TRE sequence at each site were altered, avoiding 
disruption of the sequences flanking each element. To avoid disruption of functional 
elements which may be involved in the regulation of bkj by factors other than Jun, the bkj 
promoter sequence was checked for potential binding sites of other transcription factors by 
the RGSiteScan programme (wwwmgs.bionet.nsc.ru/mgs/programs/yura/ 
RecGropScanStart.html). No consensus binding sites for other cellular transcription factors 
were found in the mt(P)TRE bkj promoter. Suitable sequences for conversion into a 
consensus TRE were found at positions -111, -610, -477, -323, -169, -109 and -65 relative 
to the transcriptional start site.
Before the effect of TRE position on transcription could be analysed, it was necessary to 
determine whether all introduced TREs were bound by c-Jun and v-Jun with comparable 
affinities. EMSAs were carried out to determine the efficiency with which each introduced 
TRE competed for complex bound to the bkj(P) TRE. 10pg of WCE was pre-incubated 
with increasing amounts of each introduced TRE and its flanking sequences (see Chapter 
2.1.3.1), before incubation with radio-labelled bkj(P) TRE. An example is shown in Figure 
3.5A. All probes were assayed for competition in CEFs and v-Jun transformed CEFs. After 
autoradiography, bound complexes were quantified using PDI Gel Scan software 
(Precision Digital Images Inc), and the percentage competition of bound complex was 
calculated. Full results are shown in Figure 3.5B.
The efficiencies with which the introduced TREs competed for bound complex varied to 
some degree. For example, the bkj-610 TRE competed for bound complex more efficiently 
than did bkj-411 in CEFs and in v-Jun transformed CEFs. The relative competition 
efficiencies of the TREs were not conserved between the two cell types in all cases. For 
example, the bkj-111 TRE competed less effectively for bound complex than did the bkj(P) 
TRE in CEFs, but bkj-111 was the more effective competitor in v-Jun transformed CEFs.
It was possible that the observed variations in competition efficiencies were due to the 
preferential binding of different Jun / Fos proteins to different probes. The composition of 
the complexes bound to each TRE in CEFs and v-Jun transformed CEFs was therefore
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analysed. Radio-labelled probes containing the relevant TRE were incubated with 10pg of 
WCE from CEFs or v-Jun transformed CEFs. The complex bound to each TRE was 
analysed by pre-incubation with antibodies specific for c-Jun (KM-1X) or Fra-2 in CEFs, 
and Jun (730-5) or Fra-2 in v-Jun transformed CEFs. Results are shown in Figure 3.5C.
Within each cell type, every probe was bound by a complex with an equivalent 
electrophoretic mobility. Pre-incubation with antibodies produced results similar to those 
seen with the bkj(P) TRE (see Figure 3.3C and D); the majority of the complex bound to 
each TRE in CEFs was super-shifted by the c-Jun specific antibody, and each complex 
from v-Jun transformed CEFs was almost completely disrupted by the 730-5 Jun antibody. 
The Fra-2 antibody super-shifted the majority of each complex in both cell types. This 
suggests that, like the bkj(P) TRE, each introduced TRE is bound predominately by c-Jun / 
Fra-2 dimers in CEFs and v-Jun / Fra-2 dimers in v-Jun transformed CEFs.
In conclusion, there were some minor variations in the affinity of binding of protein 
complexes to the panel of TREs. This was probably due to the different sequences flanking 
each site, as the core TRE was identical in each case. However, no major differences were 
detected in the composition of the complexes bound to the panel of TREs in v-Jun 
transformed and control CEFs.
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Figure 3.5
(A) Representative EMSA showing competition of bound complex from the b/cy'(P)TRE 
by the addition of increasing amounts of unlabelled competitor. Extracts were pre- 
incubated with competitor DNA, as indicated, before addition of radio-labelled probe.
(B) Graphical representation of EMSA data. All probes were tested for competition as 
in (A), in CEF and v-Jun CEF extracts.
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(C) Analysis of protein complexes bound to the panel of TRE position 
mutants in CEFs and v-Jun CEFs, using antibodies directed against Jun or 
Fra-2.
Extracts were pre-incubated with 3pl antibody, as indicated, before addition 
of radio-labelled probe.
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3.4.3 The effect of TRE position on transcription of bkj.
5 jig of each of the panel of bkj promoter mutants was transfected in duplicate into CEFs 
and v-Jun transformed CEFs, and relative CAT activities were determined as before. 
Results from a representative experiment are shown in Figure 3.6.
Compared to the wt(P)TRE bkj promoter, the activities of the -777TRE bkj and -610 TRE 
bkj promoters were decreased by approximately 50% in v-Jun transformed CEFs. A 
further, progressive, decrease was seen in the activities of -477TRE bkj and -323TRE bkj; 
transcription from the -323TRE bkj promoter was also decreased in CEFs. Indeed, -323 
TRE bkj was active at levels similar to mt(P)TRE bkj in both cell types. The -169 TRE bkj 
and -109TRE bkj promoters were both activated in v-Jun transformed CEFs to levels 
similar to wt(P)TRE bkj, while their activity in CEFs was increased. -109TRE bkj was 
almost as active in CEFs as in v-Jun transformed CEFs. -65TRE bkj, in contrast, was 
activated over 4-fold more in v-Jun transformed CEFs than in controls, although overall 
levels of activation were lower than for the wt(P)TRE bkj promoter.
These results show that alteration of TRE position affected the activation of the bkj 
promoter in CEFs and v-Jun transformed CEFs. The initial effect of movement of the TRE 
from its wild-type position at -815 towards the transcriptional start site was to decrease the 
activity of the promoter in v-Jun transformed CEFs. This held true until a TRE position of 
-323, from where transactivation by both c-Jun and v-Jun was almost completely 
abolished. However, this trend was not continued with further reduction of the distance 
between the TRE and the transcriptional start site. Instead, introduction of a TRE 169 or 
109bp from the transcriptional start site produced promoters which were activated strongly 
in both CEFs and v-Jun transformed CEFs. -65TRE bkj, the promoter with its TRE closest 
to the transcriptional start site, was activated more strongly in v-Jun transformed CEFs 
than in CEFs. It is important to note that the relative activities of the promoters did not 
correlate with the variations in the affinity of Jun / Fra-2 binding to each TRE seen in 
Figure 3.5B, in either cell type. The results shown in Figure 3.6 are therefore not due solely 
to differences in the affinity of Jun / Fra-2 binding to the different promoters.
Therefore, while TRE position influenced the transcriptional regulation of bkj, the 
introduction of a TRE close to the transcriptional start site did not result in transcriptional 
repression by v-Jun. In conclusion, TRE position alone does not account for the difference 
in regulation of the collagenase and bkj promoters by v-Jun.
92
EZL
ZZE
~ZL
ZZL
EZL
JZL
IZE
r
mt(P)TRE
bkj
_!-► wt(P)TRE 
3 bkj
_[“ ► -777TRE 
bkj
_T* -610TRE 
bkj
-477TRE
bkj
r -323TREbkj
-T
-109TRE 
bkj
-65TRE
bkj
b
b
-169TRE
bkj
4.2
n
□ CEF 
■ v-Jun CEF
50 100 150 200
Relative CAT activity
250
H
8.2
8.2
5.7 
3.0
3.8 
3.6
1.3
4.8
300
Figure 3.6
Transcription from a panel of bkj promoter mutants with TREs introduced at different 
positions.
Black boxes represent consensus TRE sequences; hatched boxes represent the 
mutated proximal TRE at position -815. Promoter diagrams are not to scale.
5pg each reporter plasmid was transfected in duplicate into CEFs and v-Jun CEFs. Fold 
activation of transcription in v-Jun CEFs compared to control CEFs is shown in each 
case.
Error bars denote standard deviations.
3.5 The effect of core promoter sequences on 
transcriptional regulation by v-Jun
93
As described in Chapter 1.3.2.1, c-Jun and v-Jun have both been shown to bind 
components of the pre-initiation complex, including TBP. The sequence of the TATA box 
and other core elements of target gene promoters may therefore be important for 
transcriptional regulation by v-Jun.
Previous studies have shown that exchange of core promoter elements between 
heterologous promoters affects activation by certain transcription factors. For example, the 
levels of transcriptional activation by ATF (Taylor and Kingston, 1990b), Varicella Zoster 
virus IE62 protein (Perera, 2000) and Herpes simplex virus ICP4 protein (Cook et al.,
1995) vary with TATA box sequence. However, other transcription factors, including CPI, 
Spl (Taylor and Kingston, 1990b), VP16 (Perera, 2000) and adenovirus E la  (Taylor and 
Kingston, 1990a) are not affected by TATA box sequence alterations. Variations in Inr 
sequence have been shown to affect the ability of Spl to activate transcription (Chalkley 
and Verrijzer, 1999).
Interestingly, ATF facilitated the recruitment of a pre-formed pre-initiation complex from 
one transcription template to another, while CPI, which functions regardless of TATA box 
sequence, did not (Taylor and Kingston, 1990b). This suggests that activators which 
interact with and recruit components of the pre-initiation complex are more likely to be 
affected by sequence variations in core promoter elements. A possible explanation for this 
is suggested by the observation that the highest levels of induction by ICP4 were seen from 
the TATA boxes with the lowest affinities for TBP and the lowest levels of basal 
transcription (Cook et al., 1995). ICP4 is known to form a complex with TFIIB, TFIID and 
the TATA box (Smith et al., 1993). This implies that ICP4 activates transcription by 
enhancing the binding of TFIID to the TATA box, with a greater effect therefore observed 
on promoters where the basal level of binding is naturally low.
Transcription from a promoter containing a TRE has previously been assayed with a panel 
of TATA box sequences (Taylor and Kingston, 1990b). No major variations were 
observed, but the overall levels of transcription were so low that any differences in 
activation may not have been detected.
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A comparison of the bkj (Hartl and Bister, 1998) and collagenase (Angel et al., 1987a) core 
promoter regions is shown in Figure 3.7A. Both promoters contain a non-consensus TATA 
box at position -25 relative to the transcriptional start site. The bkj promoter also contains 
a consensus Inr sequence surrounding the major transcriptional start site. As this sequence 
has not yet been functionally analysed, it has been designated as an Initiator-like sequence 
(ILS). The same region in the collagenase promoter differs from a consensus Inr by 3 
nucleotides, and from the bkj ILS by 4 nucleotides. The TATA boxes of the two promoters 
differ at two positions. Neither of the promoters contains a DPE or similar sequence.
To investigate the possibility that the bkj and collagenase TATA box and ILS elements 
contribute to the nature of promoter regulation by v-Jun, these sequences were exchanged 
between the two promoters. The -65TRE bkj promoter was mutated as well as wt(P)TRE 
bkj, to investigate any combined effect of TRE position and core promoter sequence on 
transcriptional regulation by v-Jun. The bkj Col TATA and bkj Col ILS mutagenic primer 
pairs (see Chapter 2.1.3.2 for all primer sequences) were used to convert the bkj TATA box 
and ILS, respectively, into the corresponding collagenase sequence (see Chapter 2.2.3.13 
for details). The Col bkj TATA and Col bkj ILS primer pairs were used to convert the 
collagenase TATA box and ILS into the corresponding bkj sequence. Promoters with 
double element exchanges were created by two sequential rounds of mutagenic PCR, 
plasmid selection and sequencing.
The effect of TATA box exchange on transcription in CEFs and v-Jun transformed CEFs 
was investigated. 5p,g each of wt(P)TRE bkj: Col TATA, -65TRE bkj: Col TATA and -73/ 
+63 ColCAT: bkj TATA, as well as each parent plasmid, was transfected in triplicate into 
CEFs and v-Jun transformed CEFs, and relative CAT activities were determined as before. 
Results from a representative experiment are shown in Figure 3.7B.
Introduction of the collagenase TATA box into the wt(P)TRE bkj promoter reduced 
promoter activity in CEFs and v-Jun transformed CEFs over 4-fold. A much smaller 
decrease in activity was observed upon introduction of the collagenase TATA box into -65 
TRE bkj. Both wt(P)TRE bkj: Col TATA and -65TRE bkj: Col TATA were activated more 
strongly in v-Jun transformed CEFs than in controls. Introduction of the bkj TATA box 
into -73/+63 ColCAT had no discernible effect on transcription in CEFs or v-Jun 
transformed CEFs.
The effect of ILS exchange was investigated in the same way. Results from a 
representative experiment are shown in Figure 3.7C. Introduction of the collagenase ILS
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into both b£;-derived promoters decreased their overall activity in CEFs and v-Jun 
transformed CEFs, while retaining the difference in activation between the two cell types. 
Again, introduction of the bkj ILS into -73/+63 ColCAT had no discernible effect on 
transcriptional regulation.
The combined effect of TATA box and ILS exchange was also investigated. Results from a 
representative experiment are shown in Figure 3.7D. Introduction of the collagenase 
TATA box and ILS into the wt(P)TRE bkj promoter increased transcriptional activation 
around 2-fold in v-Jun transformed CEFs, whereas no major effect of the double exchange 
was seen in the context of the -65TRE bkj promoter. Introduction of the bkj TATA box 
and ILS into -73/+63 ColCAT increased promoter activity in CEFs and v-Jun transformed 
CEFs over 3-fold; however, the promoter was still repressed in v-Jun transformed CEFs 
relative to controls.
Figures 3.7B and C show that the sequences of the TATA box and ILS are important for 
transcriptional regulation of the bkj promoter by v-Jun. Substitution of either element for 
the corresponding collagenase sequence decreased promoter activity in CEFs and v-Jun 
transformed CEFs. This suggests that the bkj ILS is a functional Initiator, as mutation to 
the non-consensus collagenase sequence reduced transcription from the wt(P)TRE bkj and 
-65TRE bkj promoters. However, a consensus Inr does not appear to be necessary or 
sufficient for transcriptional activation by v-Jun; wt(P)TRE bkj: Col ILS and -65TRE bkj: 
Col ILS remained more active in v-Jun transformed CEFs than in controls, and the 
introduction of the bkj ILS into -73/+63 ColCAT did not alleviate transcriptional 
repression by v-Jun. Likewise, as the effects of TATA box exchange were similar to those 
of ILS exchange, v-Jun can not be said to depend on a particular TATA box sequence for 
transcriptional activation of target promoters.
Unexpectedly, the combined exchange of the TATA box and ILS elements increased the 
activity of the wt(P)TRE bkj promoter in v-Jun transformed CEFs and of -73/+63 ColCAT 
in CEFs. The reason for this is not clear. It is possible that the core elements of a particular 
promoter evolve together to activate transcription most efficiently when combined, and 
that this combination may serve to increase the activity of a heterologous promoter. 
However, the reason why both of the reciprocal double exchanges between wt(P)TRE bkj 
and -73/+63 ColCAT should increase promoter activity is not known. It is interesting that 
no such effect was seen with the -65TRE bkj promoter.
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Overall, these results suggest that the differential regulation of the bkj and collagenase 
promoters by v-Jun can not be accounted for by the particular sequence of the TATA box 
or the ILS of either promoter. A combined effect of TRE position and core promoter 
sequences was also ruled out by the results of experiments involving core element 
exchanges between the collagenase and -65TRE bkj promoters.
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Figure 3.7
(A) Comparison of the bkj and collagenase core promoter sequences.
Putative core promoter elements are shown in bold type.
Arrows denote the major transcriptional start sites.
(B) Transcription from bkj and collagenase promoters with interchanged TATA box 
elements.
5pg each reporter plasmid was transfected in triplicate into CEFs and v-Jun CEFs. 
Fold activation of transcription in v-Jun CEFs compared to control CEFs is shown 
in each case.
Error bars denote standard deviations.
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Transcription from bkj and collagenase promoters with interchanged ILS elements (C) 
or interchanged TATA box and ILS elements (D).
5pg each reporter plasmid was transfected in triplicate into CEFs and v-Jun CEFs. 
Fold activation of transcription in v-Jun CEFs compared to control CEFs is shown in 
each case.
Error bars denote standard deviations.
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3.6 The contribution of upstream bkj promoter regions to 
transcriptional regulation by v-Jun.
As already described, the different effects of v-Jun on the bkj and collagenase promoters 
could not be explained by differences in the composition of the complex bound to each 
TRE, TRE position relative to the transcriptional start site, or core promoter sequences. To 
facilitate future comparisons between the two promoters, a derivative of the -65TRE bkj 
promoter was created, which lacks the bkj promoter regions upstream of its TRE. The 
Hindlll -65TRE bkj 5 ’ and Xbal bkj 3 ’ primers (see Chapter 2.1.3.2) were used to amplify 
the -65TRE bkj promoter region from -66 to +13. The resulting PCR product was digested 
and ligated into pCAT-Basic as before (see Chapter 2.2.3.12).
5pg each of -66/+13 -65TRE bkj and full-length -65TRE bkj (shown as -929/+13 -65 
TRE bkj for ease of comparison) was transfected into CEFs and v-Jun transformed CEFs, 
and relative CAT activities were determined as before. Results from a representative 
experiment are shown in Figure 3.8. -66/+13 -65TRE bkj, like the full-length plasmid, was 
activated more strongly in v-Jun transformed CEFs than in controls. However, its overall 
activity was much higher (more than 10-fold) than that of -929/+13 -65 TRE bkj. This 
suggests that, while the bkj promoter region from -929 to -67 has a general repressive 
effect on transcription, it is not responsible for the activation of the bkj promoter by v-Jun.
This result will simplify future comparative studies of gene promoters activated or 
repressed by v-Jun. As -66/+13 -65TRE bkj is, like the full-length wild-type bkj promoter, 
up-regulated in v-Jun transformed CEFs, it can be directly compared with the -73/+63 
ColCAT promoter without the risk of interference from upstream sequences.
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-66/+13 -65TRE 
bkj
14.0
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Relative CAT activity
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Figure 3.8
Transcription from the -65TRE bkj promoter and a mutant derivative lacking the 
upstream promoter region from -929 to -67.
Black boxes represent consensus TRE sequences; the hatched box represents 
the mutated TRE at position -815. Promoter diagrams are not to scale.
5pg each reporter plasmid was transfected in triplicate into CEFs and v-Jun CEFs. 
Fold activation of transcription in v-Jun CEFs compared to control CEFs is shown 
in each case.
Error bars denote standard deviations.
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4 Results: Cell transformation and activation of v- 
Jun target genes.
4.1 Introduction and aims.
As described in Chapter 1.2.2.1, fusion of the v-Jun bZip region to the hormone-binding 
domain of human ER-a created a protein which exhibited estradiol-dependent 
transcriptional activation and cell transformation (Kruse et al., 1997). This was thought to 
be due to activation of v-Jun target promoters by the ER-a AF-2 domain, as AvJ-hER lacks 
any other known TAD, and transcriptional activation and cell transformation by the 
chimaeric protein were not induced by tamoxifen, an AF-2 antagonist ligand.
While full-length v-Jun has been shown to both activate and repress target genes, the 
estradiol-activated ER-a AF-2 domain has not been shown to directly repress transcription. 
This suggests that cell transformation in the presence of estradiol is likely to be due to the 
activation of positive v-Jun target promoters by the AF-2 domain. This is supported by the 
observation that fusion of the strong transcriptional activation domain of VP16 to amino- 
terminally truncated v-Jun or c-Jun caused cell transformation and tumorigenesis (Schuur 
et al., 1993).
The aim of this work was to investigate the relationship between transcriptional activation 
of v-Jun target genes and cell transformation, in particular the role of the ER-a AF-2 
domain in hormone-dependent cell transformation by AvJ-hER.
4.2 Characterisation of cells expressing AvJ-hER.
4.2.1 Ligand-activated AvJ-hER down-regulates the endogenous 
c-Jun protein.
The first stage was to further characterise cells expressing the AvJ-hER protein. CEFs were 
transfected with lOpg RCAS-AvJ-hER, or RCAS-hER, expressing the ER-a hormone- 
binding domain (Kruse et al., 1997), as a control. Transfection with replication-competent 
RCAS vectors results in uniform infection of the cell culture due to viral production. Cells 
were passaged 5 times in the presence of estradiol before plating onto 140mm tissue
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culture dishes in the presence of estradiol, tamoxifen, or an equivalent volume of ethanol 
as a carrier control. WCEs were prepared after 48hr.
50pg of each WCE was resolved by SDS-PAGE, transferred to nitrocellulose membrane, 
and the membrane was probed with antibody specific for human ER-a (see Chapter 2.2.4.2 
-  2.2.4.4). The membrane was also probed with 599-3 antibody to monitor expression of 
the endogenous c-Jun protein. Results are shown in Figure 4.1.
As described previously (Kruse et al., 1997), the AvJ-hER protein ran with an apparent 
molecular weight of around 60kD, with higher mobility bands thought to represent protein 
degradation products also present. The hER protein ran as a single band of around 35kD. 
The addition of estradiol or tamoxifen did not affect the expression of either protein. 
Unexpectedly, the level of endogenous c-Jun protein was markedly reduced in AvJ-hER 
CEFs in the presence of estradiol, but not tamoxifen. This was a highly reproducible result, 
and was not due to ligand activation of the exogenous hER AF-2 domain or endogenous 
ER proteins, as treatment of hER CEFs with estradiol did not affect expression of c-Jun. 
Down-regulation of c-Jun, a negative target of v-Jun, therefore correlated with activation 
of the AF-2 domain of AvJ-hER.
Some degree of down-regulation of c-Jun has been demonstrated in CEFs expressing AvJ- 
hER or vJl-hER (Kruse et al., 1997), but this effect was not shown to be hormone- 
dependent. The fusion of c-Jun, JunD or Fos proteins to the ER-a ligand-binding domain 
has been shown to cause hormone-dependent down-regulation of natural repressed target 
genes (Crowe et al., 2000; Fialka et al., 1996; Francis et al., 1995; Schuermann et al.,
1993; Superti-Furga et al., 1991). However, this was in the context of the full-length Jun or 
Fos protein in each case, and hormone-dependent transcriptional repression was thought to 
be mediated by unmasking of the activity of the relevant Jun or Fos domain. In the case of 
AvJ-hER, the results shown in Figure 4.1 imply that the estradiol-bound AF-2 domain 
mediated target gene down-regulation, as the protein contains no other known TAD.
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Cell type 
Hormone
hER AvJ-hER
+
+
+
+
+
+
no hormone
estradiol
tamoxifen
68kD -
46kD -
46kD _
ER-a
c-Jun
Figure 4.1
Western blot showing expression of the hER, AvJ-hER and endogenous c-Jun 
proteins in CEFs infected with RCAS-hER or -AvJ-hER, treated with estradiol, 
tamoxifen, or carrier control.
Blots were probed with antibodies specific for human ER-a (upper panel) and 
chicken c-Jun (lower panel).
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4.2.2 AvJ-hER does not down-regulate c-Jun at the level of 
transcription.
v-Jun directly represses transcription from a non-consensus TRE at position -72 in the c- 
jun promoter (Hussain et al., 1998). It was important to determine whether the down- 
regulation of c-Jun protein in estradiol-treated AvJ-hER CEFs was also due to 
transcriptional repression, or to some other hormone-dependent mechanism. mRNA was 
isolated from AvJ-hER CEFs treated with estradiol, tamoxifen or carrier control, and a 
Northern blot was performed (see Chapter 2.2.3.16). The blot was probed using sequences 
from the c-jun 3’ UTR, or the GAPDH coding sequence as a loading control. Figure 4.2A 
shows that treatment with estradiol did not decrease the level of c-jun mRNA in AvJ-hER 
CEFs.
Transcription from the c-jun promoter was assayed using the pJC6 reporter plasmid, which 
contains the murine c-jun promoter region from -225 to +150 (Han et al., 1992). 5pg of 
the reporter vector was transfected in triplicate into AvJ-hER CEFs treated with estradiol, 
tamoxifen or carrier control, and relative CAT activities were determined as before. Figure 
4.2B shows that transcription from the c-jun promoter was not repressed in the presence of 
estradiol.
These results contrast with the regulation of c-Jun by v-Jun. c-jun mRNA is absent in v-Jun 
transformed CEFs, and transcription from the c-jun promoter is repressed by v-Jun (Gao et 
al., 1996; Hussain et al., 1998). Figure 4.2 suggests that the down-regulation of c-Jun 
protein in estradiol-treated AvJ-hER CEFs does not occur at the level of transcription. The 
mechanism of c-Jun protein down-regulation is not known, but may involve alterations in 
processes such as protein translation or degradation.
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Figure 4.2
(A) Northern blot showing expression of c-jun and GAPDH mRNA in AvJ-hER CEFs 
treated with estradiol, tamoxifen or carrier control.
Blots were probed with radio-labelled DNA containing chicken c-jun 3’ UTR (upper 
panel) or chicken GAPDH coding (lower panel) sequences.
(B) Activity of the c-jun promoter in AvJ-hER CEFS treated with estradiol, tamoxifen or 
carrier control.
5pg reporter vector was transfected in triplicate.
Error bars denote standard deviations.
4.2.3 AvJ-hER binds constitutively to TREs.
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Chimaeric proteins consisting of Jun or Fos fused to the ER-a hormone-binding domain 
have, in some cases, been shown to be regulated in a hormone-dependent manner at the 
level of nuclear translocation or DNA binding (Fialka et al., 1996; Francis et al., 1995;
Kim et al., 1996). If this is also the case for AvJ-hER, then cell transformation in the 
presence of estradiol may be an indirect effect of nuclear accumulation or binding of the 
protein to TREs, rather than a direct effect of AF-2 domain activation at v-Jun target 
promoters. The sub-cellular location and DNA binding activity of AvJ-hER were therefore 
investigated in cells treated with estradiol, tamoxifen or carrier control.
Confocal immunocytochemistry performed by Dr. E. Black of the Beatson Institute 
revealed that the hER and AvJ-hER proteins were predominately nuclear in the presence of 
estradiol, tamoxifen and carrier control (data not shown).
An EMSA was carried out to visualise the protein complexes bound to TREs in hER and 
AvJ-hER CEFs treated with estradiol, tamoxifen or carrier control. 10p,g of each WCE was 
incubated with radio-labelled probe containing the collagenase TRE (see Chapter 2.1.3.1). 
Results are shown in Figure 4.3A. Each complex ran with a similar electrophoretic 
mobility. A decrease was observed in the intensity of the complex bound to the collagenase 
TRE in AvJ-hER CEFs treated with estradiol. This was a highly reproducible result.
Bound complexes were analysed by antibody super-shifts. WCEs were pre-incubated with 
antibodies specific for c-Jun (KM-IX), human ER-a, or the broad-specificity Fos family 
antibody (K-25). Results are shown in Figure 4.3B. In hER CEFs, the majority of each 
complex was super-shifted by the c-Jun antibody, and complexes were completely shifted 
by the pan-Fos antibody. This is in line with previous observations in CEFs ((Hawker et 
al., 1993; Kilbey et al., 1996) and Figure 3.3C of this work), and indicates that expression 
of hER and treatment with estradiol or tamoxifen did not disrupt the usual c-Jun / Fos 
dimers bound to TREs. As expected, complexes from hER CEFs were not super-shifted by 
the ER-a antibody, indicating that hER can not bind to TREs in the absence of the v-Jun 
DBD.
Complexes from AvJ-hER CEFs treated with estradiol, tamoxifen or carrier control were 
also super-shifted by the c-Jun and pan-Fos antibodies. Pre-incubation with the ER-a 
antibody caused a slight decrease in the intensity of the bound complex in each case, and
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appeared to cause the formation of a low-mobility complex which did not migrate into the 
gel (Figure 4.3B, see arrows), suggesting that AvJ-hER might bind TREs in a hormone- 
independent manner. However, this putative complex was present in an area of the gel with 
some background radiation, due to retention of a fraction of each complex in the wells of 
the polyacrylamide gel, and therefore could not be identified with any certainty.
Complexes were analysed further using antibodies specific for the individual members of 
the Fos family. Figure 4.3C shows that the Fra-2 specific antibody super-shifted the 
complexes bound to the collagenase TRE in hER and AvJ-hER CEFs treated with estradiol 
or carrier control. No other specific antibody had any effect. These results show that the 
protein complexes bound to TREs in hER CEFs contain predominately c-Jun / Fra-2 
dimers. In AvJ-hER CEFs, the complex bound to TREs appears to consist of c-Jun / Fra-2, 
and possibly AvJ-hER / Fra-2 dimers, regardless of hormone treatment.
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Figure 4.3
(A) EMSA showing protein complexes bound to the collagenase TRE in CEFs 
infected with RCAS-hER and -AvJ-hER, treated with estradiol, tamoxifen, or carrier 
control.
(B) Analysis of protein complexes bound to the collagenase TRE in hER (upper 
panel) and AvJ-hER (lower panel) CEFs treated with estradiol, tamoxifen, or carrier 
control, using antibodies specific for c-Jun, ER-a or the Fos family.
Extracts were pre-incubated with 3pl antibody, as indicated, before addition of radio­
labelled probe.
Arrows indicate the putative complex super-shifted by the ER-a antibody.
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Figure 4.3
(C) Analysis of protein complexes bound to the collagenase TRE in hER and AvJ-hER 
CEFs treated with estradiol or carrier control, using antibodies specific for Fos family 
proteins.
Extracts were pre-incubated with 3pl antibody, as indicated, before addition of radio­
labelled probe.
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Biotinylated-oligonucleotide capture experiments were carried out to enable unambiguous 
identification of the proteins bound to TREs in hER and AvJ-hER CEFs treated with 
estradiol or carrier control. 500p,g of each WCE was pre-cleared by incubation with 
streptavidin-conjugated paramagnetic particles. Complexes bound to TREs were captured 
by incubation with particles bound to a biotinylated oligonucleotide containing multiple 
copies of the collagenase TRE (see Chapter 2.2.5.3 and 2.2.5.4). EMSA analysis of 
samples removed from the supernatant after pre-clearing and oligonucleotide capture 
revealed depletion of TRE-binding complexes from WCEs after incubation with the 
biotinylated oligonucleotide (Figure 4.4A), indicating that these complexes were 
successfully captured.
Proteins bound to the biotinylated oligonucleotide were eluted after washing and analysed 
by Western blotting (Figure 4.4B). AvJ-hER bound to TREs in a hormone-independent 
manner, while the hER protein, which lacks the v-Jun DBD, did not bind TREs. c-Jun 
bound TREs in a hormone-independent manner in hER CEFs. In AvJ-hER CEFs, 
detectable levels of c-Jun bound TREs in the absence, but not the presence, of estradiol. 
Equal amounts of Fra-2 bound to TREs in each case. The binding of all proteins was 
specific for the biotinylated oligonucleotide, as no protein was detected in samples eluted 
after the pre-clearing stage.
The results from Figure 4.4 show that c-Jun / Fra-2 dimers bind TREs in hER CEFs treated 
with estradiol or carrier control. This is in agreement with antibody supershift experiments 
(Figure 4.3B, C). In AvJ-hER CEFs, the AvJ-hER protein binds TREs in a hormone- 
independent manner. In untreated cells, c-Jun also binds TREs; however, no c-Jun was 
detected bound to TREs in estradiol-treated cells. This is consistent with the down- 
regulation of c-Jun in these cells (Figure 4.1), and provides an explanation for the 
estradiol-induced decrease in the intensity of the protein complex bound to the collagenase 
TRE (Figure 4.3A); both c-Jun / Fra-2 and AvJ-hER / Fra-2 dimers bind TREs in untreated 
cells, whereas treatment with estradiol decreases the c-Jun / Fra-2 component of the 
complex.
Previous experiments in estradiol-treated AvJ-hER CEFs clearly showed a super-shift of 
the complex bound to TREs with a c-Jun specific antibody (Figure 4.3B). This would 
suggest that down-regulation of endogenous c-Jun in the presence of estradiol is not 
complete, and that residual protein binds TREs at levels too low to allow detection by
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Western blot methods. However, the most important conclusion of this work is that the 
binding of AvJ-hER to TREs is hormone-independent.
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Figure 4.4
Biotinylated-oligonucleotide capture of DNA-binding complexes
(A) EMSA analysis of supernatants removed after the pre-clearing stage and after 
biotinylated-oligonucleotide capture of DNA-binding complexes. 4% of each 
supernatant was incubated with radio-labelled collagenase TRE.
(B) Western blot analysis of proteins eluted from paramagnetic particles after the 
pre-clearing stage and after biotinylated-oligonucleotide capture of DNA-binding 
complexes.
Blots were probed with antibodies specific for human ER-a (upper panel), chicken 
c-Jun (middle panel) or Fra-2 (lower panel).
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4.3 The role of the ER-a AF-2 domain in hormone- 
dependent transcriptional activation and cell 
transformation by AvJ-hER.
As described in Chapter 1.2.2.1, the ER-a AF-2 domain has been proposed to account for 
transcriptional activation by AvJ-hER in the presence of estradiol, but not the antagonist 
ligand tamoxifen. Since AvJ-hER binds constitutively to TREs (see Figure 4.4), cell 
transformation in the presence of estradiol is likely to be a direct effect of activation of the 
AF-2 domain at v-Jun target promoters. This hypothesis was investigated by the 
introduction of an inactivating mutation into the AF-2 domain of AvJ-hER. The M543A / 
L544A double amino acid substitution within helix 12 of the ER-a AF-2 domain has 
previously been shown to specifically abolish hormone-dependent transcriptional 
activation in the context of the full-length ER-a (Danielian et al., 1992) and a 
Gal4ERVP16 fusion protein (Stafford and Morse, 1998), without affecting hormone 
binding. This mutation was introduced into RCAS-AvJ-hER to create RCAS-AvJ-hER mt; 
see Chapter 2.2.3.14.
4.3.1 The mutant protein is expressed at a lower level than wild- 
type AvJ-hER.
CEFs were transfected with 10p,g RCAS-AvJ-hER wt; -AvJ-hER mt; -AV2, expressing a 
fusion of the v-Jun C-terminal domains to the VP16 TAD (Schuur et al., 1993); pV and 
RCAS, to reconstitute ASV17; or empty RCAS vector as control. AvJ-hER wt and mt 
CEFs were each maintained in the presence or the absence of estradiol. After 3-4 passages, 
cells were plated onto 140mm plastic tissue culture dishes, in the presence of estradiol or 
carrier control as appropriate. WCEs were prepared after 48hr.
40|ig of each WCE was resolved by SDS-PAGE and subjected to Western blotting as 
before. The AvJ-hER mt protein ran as a major band of around 60kD, with small amounts 
of a higher mobility product also detected (Figure 4.5, upper panel). The expression of the 
protein was not affected by passaging in the presence of estradiol. This is in contrast to 
AvJ-hER wt, where expression of the protein was higher in cells passaged in the presence 
of estradiol. As previously reported (Schuur et al., 1993), the AV2 protein ran as a single 
band of around 32kD (Figure 4.5, middle panel).
As described previously ((Gao et al., 1996; Hussain et al., 1998; Kilbey et al., 1996), 
Figure 4.1 of this work), the c-Jun protein was down-regulated in v-Jun transformed CEFs, 
and in AvJ-hER wt CEFs treated with estradiol (Figure 4.5, lower panel). Down-regulation 
of c-Jun was also observed in CEFs infected with RCAS-AV2. However, little if any 
decrease in c-Jun expression was observed in AvJ-hER mt CEFs treated with estradiol or 
carrier control. This suggests that hormone-dependent down-regulation of c-Jun by AvJ- 
hER wt requires a functional AF-2 domain.
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Figure 4.5
Western blot analysis of protein expression in CEFs infected with RCAS, RCAS- 
AV2, ASV17, or RCAS-AvJ-hER wt and mt, grown in the presence of estradiol (+) 
or carrier control (-).
Blots were probed with antibodies specific for human ER-a (upper panel), VP16 
(middle panel), or chicken c-Jun (lower panel).
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It is interesting to note that the expression levels of AvJ-hER mt were lower than those of 
AvJ-hER wt in cells passaged in the presence of estradiol (Figure 4.5, upper panel). This 
was a highly reproducible result, observed in four independent rounds of transfection with 
RCAS-AvJ-hER wt and mt. The expression of the two proteins during the infection process 
was determined. CEFs were transfected with lOpg RCAS-AvJ-hER wt or mt and passaged 
in the presence or absence of estradiol. A portion of the trypsinised cells was retained at 
each passage, and WCEs were prepared.
20pg of WCEs prepared from cells at passage numbers 3 to 5 were resolved by SDS- 
PAGE, subjected to Western blotting, and probed with antibody specific for human ER-a. 
Figure 4.6 shows that the expression level of AvJ-hER wt was consistently higher in cells 
passaged in the presence of estradiol, with a greater increase compared to controls 
observed at the later stages of transfection. This was a reproducible result.
As expression of AvJ-hER wt has been reported to increase the rate of cell proliferation in 
the presence of estradiol, but inhibit cell proliferation in the absence of ligand (Kruse et al., 
1997), it may be that high levels of expression of this protein in the presence of estradiol 
confer a selective advantage on RCAS-AvJ-hER wt infected cells. This could lead to an 
increased rate of spread of the RCAS-AvJ-hER wt virus in the presence of estradiol. The 
increased expression of the AvJ-hER wt protein seen in Figure 4.5 may therefore reflect a 
higher proportion of cells in the population expressing this protein, rather than higher 
levels of expression in each cell. The fact that passaging in the presence of estradiol did not 
increase the expression of AvJ-hER mt suggests that mutation of the AF-2 domain 
abolished the hormone-dependent increase in the rate of cell proliferation observed with 
AvJ-hER wt.
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46kD
Figure 4.6
Western blot analysis of AvJ-hER wt and mt expression in CEFs 3 to 5 passages post­
transfection in the presence of estradiol (+) or carrier control (-).
Blots were probed with antibody specific for human ER-a.
4.3.2 AvJ-hER mt binds constitutively to TREs.
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The introduction of AF-2 domain mutations into full-length ER-a did not affect binding of 
the protein to DNA (Danielian et al., 1992). However, the effect of such mutations on a 
heterologous DBD in the context of a fusion protein has not previously been determined. 
An EMSA was carried out to visualise the complexes bound to TREs in AvJ-hER mt CEFs 
treated with estradiol or carrier control. lOfxg of each WCE was incubated with radio­
labelled probe containing the collagenase TRE (Figure 4.7A). In contrast to the results of 
similar experiments with AvJ-hER wt CEFs, no decrease in the intensity of the bound 
complex was observed in the presence of estradiol.
Biotinylated-oligonucleotide capture experiments were carried out to identify the proteins 
bound to the collagenase TRE in AvJ-hER CEFs treated with estradiol or carrier control. 
265jig of each WCE was pre-cleared and then incubated with paramagnetic particles 
bound to a biotinylated collagenase TRE oligonucleotide, as before. Proteins were eluted 
and analysed by Western blotting (Figure 4.7B).
The AvJ-hER mt and c-Jun proteins bound specifically to the collagenase TRE in a 
hormone-independent manner. In contrast to AvJ-hER wt, the higher mobility groups 
thought to represent proteolytic degradation products did not appear to bind DNA 
(compare Figure 4.7B and Figure 4.4B). The reason for this difference is not known. 
However, it is clear that the full-length AvJ-hER mt protein bound DNA in a hormone- 
independent manner. The different appearance of the complexes bound to TREs in AvJ- 
hER wt and mt CEFs treated with estradiol (Figure 4.7A) is therefore likely to be due to 
down-regulation of c-Jun by ligand-activated AvJ-hER wt, but not its mutant derivative. 
These results show that introduction of the M543A / L544A mutation into the AF-2 
domain of AvJ-hER does not affect the ability of the protein to bind TREs.
119
A.
AvJ-hER wt mt
estradiol + - +
B.
Sample eluted after: pre-clearing oligo capture
estradiol - + - +
68kD _
ER-a
46kD _
46kD —
c-Jun
Figure 4.7
(A) EMSA showing protein complexes bound to the collagenase TRE in AvJ-hER wt 
and mt CEFs, treated with estradiol (+) or carrier control (-).
(B) Western blot analysis of proteins eluted from paramagnetic particles after pre­
clearing and after biotinylated-oligonucleotide capture of DNA-binding complexes 
from AvJ-hER mt CEFs treated with estradiol (+) or carrier control (-).
Blots were probed with antibodies specific for human ER-a (upper panel) or chicken 
c-Jun (lower panel).
120
4.3.3 AvJ-hER mt does not transactivate the bkj promoter in the 
presence of estradiol.
The role of the AF-2 domain in hormone-dependent transcriptional activation of v-Jun 
target promoters by AvJ-hER was investigated. 5p,g of the wt(P)TRE bkj reporter vector 
(see Chapter 2.2.3.12) was transfected in triplicate into AvJ-hER wt and mt CEFs, grown in 
the presence of estradiol or carrier control; AV2 CEFs; and RCAS and ASV17 CEFs as 
controls. Relative CAT activities were determined as before. Results from a representative 
experiment are shown in Figure 4.8.
As shown previously (Figure 3.4), the wt(P)TRE bkj promoter was activated more strongly 
in ASV17 CEFs than in RCAS controls. The bkj promoter was also strongly activated in 
AV2 CEFs, to a level around 60% of that observed in ASV17 CEFs. This contrasts with 
previous reports, in which AV2 only weakly activated transcription from v-Jun target 
promoters (Schuur et al., 1993). The discrepancy may be due to the different promoters 
studied in each case.
As previously reported (Kruse et al., 1997), transcriptional activation of bkj by AvJ-hER wt 
was hormone-dependent, with expression from the promoter induced around 8-fold in 
estradiol-treated cells. The overall level of transcriptional activation by ligand-activated 
AvJ-hER wt was around 30% of that induced in ASVI7 CEFs; this is consistent with 
previous reports (Kruse et al., 1997). In contrast, treatment with estradiol did not induce 
activation of the bkj promoter by AvJ-hER mt, indeed the promoter was reproducibly 
down-regulated in hormone treated cells. These results strongly support the hypothesis that 
the ER-a AF-2 domain is responsible for hormone-dependent activation of v-Jun target 
genes by AvJ-hER.
RCAS &
AvJ-hER wt: - [}
AvJ-hER wt: + _  
AvJ-hER mt: - ^ 
AvJ-hER mt: + | 
AV2 
ASV17
10 15 20 25 30
Relative CAT activity
35 40
Figure 4.8
Activity of the wt(P)TRE bkj promoter in CEFs infected with RCAS, RCAS-AvJ- 
hER wt in the presence (+) and absence (-) of estradiol, -AvJ-hER mt in the 
presence (+) and absence (-) of estradiol, -AV2 or ASV17.
5pg reporter plasmid was transfected in triplicate into each cell type.
Error bars denote standard deviations.
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4.3.4 AvJ-hER mt does not induce hormone-dependent cell 
transformation.
4.3.4.1 Cell morphology.
Cells infected with the ASV17 virus adopt a characteristic elongated morphology 
compared to control CEFs, are more refractile, and grow in parallel arrays ((Cavalieri et 
al., 1985; Maki et al., 1987), Figure 4.9A and B of this work). CEFs expressing AV2 adopt 
a similar morphology to ASV17 transformed cells (Figure 4.9C).
In the absence of estradiol, the morphology of AvJ-hER wt and mt CEFs resembles that of 
control cells (Figure 4.9D and F). Estradiol-treated AvJ-hER wt CEFs adopt a morphology 
similar to ASV17 infected cells (Figure 4.9E). However, CEFs expressing AvJ-hER mt do 
not undergo a change in morphology in the presence of estradiol; cells remain similar in 
appearance to control CEFs (Figure 4.9G). This suggests that a functional AF-2 domain is 
required for the change in morphology of cells expressing AvJ-hER wt in the presence of 
estradiol.
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Figure 4.9
CEFs infected with RCAS (A); ASV17 (B); RCAS-AV2 (C); -AvJ-hER wt in the 
presence of carrier control (D) or estradiol (E); -AvJ-hER mt in the presence of carrier 
control (F) or estradiol (G).
B.
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4.3.4.2 Rate of cell proliferation.
It has been reported that the AvJ-hER wt protein mediates a hormone-dependent increase 
in the rate of cell proliferation (Kruse et al., 1997). Cell growth assays were carried out to 
investigate the role of the ER-a AF-2 domain in this process. Equal numbers of CEFs 
infected with RCAS-AvJ-hER wt or mt, in the presence of estradiol; RCAS-AV2; ASV17 
or RCAS were plated onto 60mm plastic tissue culture dishes, and cell numbers 
determined every 24hr (see Chapter 2.2.2.4). Results of a representative experiment are 
shown in Figure 4.10.
As previously reported (Clark and Gillespie, 1997), ASV17 CEFs grew at a greater rate 
and reached a higher saturation density than control cells. AV2 CEFs also grew at an 
increased rate. AvJ-hER wt CEFs in the presence of estradiol grew at a similar rate to 
ASV17 CEFs, while estradiol-treated AvJ-hER mt CEFs proliferated at a rate similar to 
control CEFs.
These results suggest that a functional AF-2 domain is necessary for the increased rate of 
proliferation of estradiol-treated AvJ-hER CEFs, and may provide an explanation for the 
increase in expression of AvJ-hER wt in cells passaged in the presence of estradiol (see 
Chapter 4.3.1).
125
35
30
o 25
20JD
15
10
5
0
14012010080
-o-
Time (hr)
Figure 4.10
Rate of growth of CEFs infected with RCAS, RCAS-AvJ-hER wt (+ estradiol) 
-AvJ-hER mt (+ estradiol), -AV2 or ASV17.
Cells were counted in duplicate every 24 hours.
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AvJ-hER wt 
AvJ-hER mt 
AV2 
ASV17
4.3.4.3 Anchorage-independent growth.
126
AvJ-hER wt has been shown to induce anchorage-independent growth in the presence of 
estradiol, with an efficiency equivalent to v-Jun (Kruse et al., 1997). It was proposed that 
the transforming ability of the chimaeric protein was due to the function of the ER-a AF-2 
domain. To investigate this hypothesis, the ability of AvJ-hER wt and mt CEFs to form 
colonies in agarose was determined. Cells were suspended in agarose containing estradiol 
or carrier control as appropriate, at 104,103 and 102 cells per 30mm plastic tissue culture 
dish (see Chapter 2.2.2.5 for details). Colonies were counted and photographed after 2 
weeks. Results from a representative experiment are shown in Table 4.1 and Figure 4.11.
As previously described (Bos et al., 1990), ASV17 CEFs formed colonies in agarose with 
high efficiency (Table 4.1, Figure 4.1 IB), while control CEFs did not form colonies. AV2 
CEFs formed colonies with an approximately 2-fold greater efficiency than ASV17 CEFs. 
This contradicts a previous study reporting a relatively low efficiency of cell 
transformation by AV2 (Schuur et al., 1993). While ASV17 CEFs formed predominately 
large dispersed colonies, as well as compact colonies (Figure 4.1 IB), the colonies formed 
by AV2 CEFs were generally small and compact (Figure 4.11C).
AvJ-hER wt and mt CEFs did not form colonies in the absence of estradiol. However, 
estradiol-treated AvJ-hER wt CEFs formed colonies with an approximately 3-fold higher 
efficiency than ASV17 CEFs. The colonies resembled those formed by ASV17 CEFs, with 
many large dispersed colonies present as well as smaller, compact colonies (Figure 4.HE). 
In contrast, AvJ-hER mt CEFs did not form colonies in agar in the presence of estradiol. 
These results support the hypothesis that hormone-dependent cell transformation by AvJ- 
hER wt is dependent on a functional AF-2 domain.
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Infecting construct 
RCAS vector 
AS V I7 
RCAS-AV2
RCAS-AvJ-hER wt: no hormone 
RCAS-AvJ-hER wt: + estradiol 
RCAS-AvJ-hER mt: no hormone 
RCAS-AvJ-hER: + estradiol
Cells plated
104 103 102
0 0 0
131/159 14 /25  5 /3
301 / 265 3 6 /1 4  3 / 1 0
0 0 0
423/397 37 / 59  1 1 / 7
0 0 0
0 0 0
Table 4.1
Agarose colony formation by CEFs infected with RCAS v-Jun constructs. The number of 
colonies at each cell concentration is shown in duplicate.
Figure 4.11
Agarose suspension cultures of CEFs infected with RCAS (A); ASV17 (B); RCAS- 
AV2 (C); -AvJ-hER wt in the presence of carrier control (D) or estradiol (E); -AvJ- 
hER mt in the presence of carrier control (F) or estradiol (G).
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4.4 The role of a HAT co-activator in transcriptional 
activation of v-Jun target promoters and ceil 
transformation.
The results described in Chapter 4.3 show that introduction of an inactivating mutation into 
helix 12 of the AF-2 domain abolishes hormone-dependent transcriptional activation and 
cell transformation by AvJ-hER. As helix 12 provides a binding surface for HAT co­
activator proteins in the presence of agonist ligand (see Chapter 1.3.1.2), the deficiency of 
the AvJ-hER mt protein may be due to the disruption of co-activator binding.
It was decided to investigate whether direct recruitment of a HAT domain to v-Jun target 
promoters could substitute for the function of the v-Jun TAD or ER-a AF-2 domain in 
transcriptional activation and cell transformation. The p300 co-activator was selected for 
analysis, as there is evidence for a role of the protein in transcriptional activation by Jun 
proteins (Lee et al., 1996), and mutated derivatives of the protein exist which enable 
analysis of the role of the HAT domain in p300 function (Kraus et al., 1999)
Fusions were created of the v-Jun DBD and dimerisation domain to the HAT domain of 
wild-type p300, and of p300 Mut AT2, which lacks HAT function and has a reduced 
ability to co-activate transcription by ligand-activated ER-a (Kraus et al., 1999). A 
chimaeric protein consisting of the homologous region of CBP fused to the Gal4 DBD has 
been shown to retain HAT activity and to activate transcription from certain promoters 
containing Gal4 binding sites (Martinez-Balbas et al., 1998). It was expected that 
recruitment of the wild-type, but not the mutated, p300 HAT domain to TREs and CREs 
by the v-Jun DBD would activate transcription from v-Jun target promoters and induce cell 
transformation, as with ligand-activated AvJ-hER wt. The construction of RCAS-AvJ-p300 
wt and mt is described in Chapter 2.2.3.14.
4.4.1 Expression of the chimaeric proteins.
CEFs were transfected with lOpg RCAS-AvJ-p300 wt; -AvJ-p300 mt; or the empty RCAS 
vector as control. After 3 passages, cells were plated onto 140mm plastic tissue culture 
dishes. WCEs were prepared after 48hr.
40pg of each WCE was resolved by SDS-PAGE and subjected to Western blotting as 
before. The AvJ-p300 wt and mt proteins ran as a single band with an apparent molecular
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weight of around 99kD (Figure 4.12, upper panel). The predicted molecular weight of the 
840 amino-acid proteins was 93.3kD. The level of c-Jun protein was not affected by 
expression of AvJ-p300 wt or mt (Figure 4.12, lower panel).
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Figure 4.12
Western blot analysis of protein expression in CEFs infected with RCAS, RCAS-AvJ- 
p300 wt or -AvJ-p300 mt.
Blots were probed with chicken Jun antibodies 730-5 or 599-3.
4.4.2 The AvJ-p300 proteins bind to TREs.
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Biotinylated-oligonucleotide capture experiments were carried out to determine whether 
the AvJ-p300 proteins bound to TREs. 125pg of each WCE was pre-cleared before 
incubation with paramagnetic particles bound to a biotinylated collagenase TRE 
oligonucleotide, as before. Proteins were eluted and analysed by Western blotting (Figure 
4.13).
The AvJ-p300 wt and mt proteins both appeared to bind specifically to the collagenase 
TRE, showing that the p300 HAT domains were recruited to TREs by the v-Jun DBD. c- 
Jun bound to the collagenase TRE in both cell types. However, due to the poor technical 
quality of the Western blot, binding of the AvJ-p300 proteins to TREs can not be identified 
with absolute certainty.
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Sample eluted after: pre-clearing oligo capture
AvJ-p300 wt mt wt mt
97kD _  , ^  4 *  ^ Jun (730-5)
46kD _
c-Jun (599-3)
«* * £ ♦
Figure 4.13
Western blot analysis of proteins eluted from paramagnetic particles after pre-clearing 
and after biotinylated-oligonucleotide capture of DNA-binding complexes from AvJ- 
p300 wt or mt CEFs.
Blots were probed with chicken Jun antibodies 730-5 or 599-3.
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4.4.3 The AvJ-p300 proteins do not transactivate the bkj promoter.
The AvJ-hER mt protein does not activate transcription from the bkj promoter in the 
presence of estradiol, suggesting that the ER-a AF-2 domain is necessary for hormone- 
dependent transcriptional activation by AvJ-hER (see Chapter 4.3.3). Having determined 
that AvJ-p300 wt and mt bind to TREs, the contribution of the p300 HAT domain to the 
transcriptional activation of bkj was investigated. 5pg of the wt(P)TRE bkj promoter was 
transfected in triplicate into CEFs infected with RCAS AvJ-p300 wt and mt, ASV17, or 
RCAS, and relative CAT activities were determined as before. The results of a 
representative experiment are shown in Figure 4.14.
The bkj promoter was not activated above the basal level by AvJ-p300 wt or mt. This 
suggests that recruitment of the p300 HAT domain to a TRE-containing promoter could 
not substitute for the v-Jun TAD or ER-a AF-2 domain in transcriptional activation.
R C A S
AvJ-p300 wt
AvJ-p300 mt
ASV17
4 5 6 7
Relative CAT activity
Figure 4.14
Activity of the wt(P)TRE BKJ  promoter in CEFs infected with RCAS, RCAS-AvJ- 
p300 wt, -AvJ-p300 mt, or ASV17.
5pg reporter plasmid was transfected in triplicate into each cell type.
Error bars denote standard deviations.
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4.4.4 The AvJ-p300 proteins do not induce cell transformation.
4.4.4.1 Cell morphology.
The morphology of CEFs infected with AvJ-p300 wt and mt is shown in Figure 4.15.
These cells do not adopt the characteristic morphology of v-Jun transformed CEFs, or 
CEFs expressing AV2 or ligand-activated AvJ-hER wt, but appear similar in appearance to 
control CEFs (compare with Figure 4.9). The p300 HAT domain, therefore, can not 
substitute for the function of the v-Jun TAD or ER-a AF-2 domain in the induction of an 
altered cell morphology.
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Figure 4.15
CEFs infected with RCAS-AvJ-p300 wt (A) or -AvJ-p300 mt (B).
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4.4.4.2 Rate of cell proliferation.
The ligand-activated AF-2 domain of AvJ-hER mediates an increase in the rate of cell 
proliferation (Figure 4.10). The contribution of the p300 HAT domain to this process was 
investigated. CEFs infected with AvJ-p300 wt and mt, or the empty RCAS vector, were 
plated onto 90mm plastic tissue culture dishes, and cell numbers were determined every 
24hr (see Chapter 2.2.2.4). The results of a representative experiment are shown in Figure 
4.16.
Fusion of the p300 HAT domain to the v-Jun DBD did not induce an increase in the rate of 
cell growth; indeed, AvJ-p300 wt CEFs proliferated at a slightly lower rate than controls. 
AvJ-p300 mt CEFs grew at a similar rate to control CEFs. Again, therefore, the recruitment 
of a HAT domain to TRE-containing promoters was not sufficient to cause the increased 
rate of cell growth mediated by the v-Jun TAD and ligand-activated AF-2.
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Figure 4.16
Rate of growth of CEFs infected with RCAS, RCAS-AvJ-p300 wt or -AvJ-p300 
mt.
Cells were counted in duplicate every 24 hours.
4.4.4.3 Anchorage-independent growth.
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The AF-2 domain of AvJ-hER wt mediates hormone-dependent cell transformation (see 
Chapter 4.3.4). The ability of the p300 HAT domains to substitute for this function was 
investigated. AvJ-p300 wt and mt CEFs were suspended in agarose at 104, 103 and 102 cells 
per 30mm plastic tissue culture dish, as before. This experiment was performed alongside 
the analysis described in Chapter 4.3.4.3, to provide negative and positive controls.
Table 4.2 shows that AvJ-p300 wt and mt CEFs were unable to form colonies in agarose 
suspension. Recruitment of the p300 HAT domains to v-Jun target promoters was therefore 
not able to substitute for the function of the v-Jun TAD or ligand-activated AF-2 domain in 
cell transformation.
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Cells plated
Infecting construct 104 103 102
RCAS vector 0 0 0
AS V I7 131/159 14 /25  5 /3
RCAS-AvJ-p300 wt 0 0 0
RCAS-AvJ-p300 mt 0 0 0
Table 4.2
Agarose colony formation by CEFs infected with RCAS-AvJ-p300 constructs. The number 
of colonies at each cell concentration is shown in duplicate.
142
5 Discussion
5.1 General introduction
Identification of the v-Jun oncoprotein as a member of a family of cellular transcription 
factors suggested that cell transformation by v-Jun was a result of the mis-regulation of 
specific target genes. Many positive and negative targets of v-Jun have since been 
identified, with the altered expression of some having been shown to contribute to the 
transformed phenotype (see Chapter 1.2.2). However, much work remains to be done to 
elucidate the mechanisms by which v-Jun mis-regulates transcription, and to determine 
which of its many target genes are specifically involved in the transformation process. The 
work described in Chapters 3 and 4 aimed to better characterise the mechanisms of 
transcriptional activation and repression by v-Jun, and to relate these different processes to 
cell transformation.
5.2 Transcriptional regulation by v-Jun
5.2.1 Introduction
While v-Jun is known to activate some target genes and repress others, its transcriptional 
mechanisms are not well understood. This work sought to better understand these 
mechanisms by comparison of gene promoters activated or repressed by v-Jun. bkj, which 
is activated in v-Jun transformed cells, and collagenase, which is repressed, were chosen, 
as the promoters of these genes have been relatively well characterised.
5.2.2 Regulation of the bkj and collagenase promoters by v-Jun.
A systematic analysis of transcription from the bkj and collagenase promoters was carried 
out, to verify that the regulation of the two promoters in control and v-Jun transformed 
CEFs occurred as previously reported.
Transcriptional regulation of the human collagenase I promoter is known to be complex. A 
non-consensus TRE at position -186 (Chamberlain et al., 1993; White and Brinckerhoff,
1995) and a PEA3 binding site at position -81 (Gutman and Wasylyk, 1990) contribute to 
TPA induction of transcription, in co-operation with the TRE at position -72. Transcription 
factors such as ETS-1 and PU.l also regulate the collagenase promoter, with
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transcriptional repression by PU.l dependent on an intact TRE at position -72 
(Westermarck et al., 1997). Other sequences in the promoter region between -180 and +60 
have been implicated in TPA induction of transcription (Auble and Brinckerhoff, 1991). 
However, various studies have shown that the TRE at position -72 is the most important 
regulatory element in the collagenase promoter (Auble and Brinckerhoff, 1991; Gutman 
and Wasylyk, 1990; Jonat et al., 1990; Westermarck et al., 1997), and a promoter 
containing this site is repressed in v-Jun transformed CEFs (Kilbey et al., 1996). The 
importance of the TRE at position -72 for transcriptional repression by v-Jun was 
confirmed by transfection of -73/+63 ColCAT and -60/+63 into control and v-Jun 
transformed CEFs (Figure 3. IB), and also by co-transfection of c-Jun and v-Jun with -73/ 
+63 ColCAT in CEFs (Figure 3.2B).
The quail bkj promoter was previously shown to be up-regulated by v-Jun through the 
more proximal of two TREs (Hartl and Bister, 1998). This was confirmed by transfection 
of BKJ(P) and its deletion mutant BKJ(0) into control and v-Jun transformed CEFs (Figure 
3.1A), and also by co-transfection of c-Jun and v-Jun with BKJ(P) in CEFs (Figure 3.2A).
However, throughout this study, it became clear that the regulation of bkj is more complex 
than previously thought. As described in Chapter 3.2.1, comparison ofBX/(WT) and 
BKJ(DP) indicated that the sequence upstream of the distal TRE contains negative 
regulatory elements, possibly with a stronger effect in chicken cells than in quail cells. 
Also, the function of the distal bkj TRE has not been adequately investigated. Figure 3.1 A 
indicates that this element contributes to bkj regulation in control CEFs, and may have a 
role in transcriptional regulation by v-Jun that had been masked in previous studies.
Later studies revealed further complexities in the regulation of bkj. Comparison of the 
BKJ(P) and wt(P)TRE bkj promoters (Figure 3.4B) suggests that the region between -929 
and -886 may mediate an increase in the level of transcription (See Chapter 3.4.1). Figure 
3.8 indicates that the promoter region from -929 to -67 negatively regulates transcription 
from the -65TRE bkj promoter. Whether these effects are mediated by the binding of 
specific regulatory factors to the promoter, or by some other process, is not known.
Further characterisation of the bkj promoter, for example by a comprehensive search for 
transcription factor binding sites, finer deletion analysis, footprinting etc., would facilitate 
a better understanding of the transcriptional regulation of this gene, and the interaction of 
c-Jun and v-Jun with any other regulatory factors. The role of the distal TRE is o f 
particular interest. The construction of reporter vectors containing point mutations of the
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two TREs within the same promoter context would enable analysis of the contribution of 
each site to regulation by c-Jun and v-Jun. Further characterisation of the protein 
complexes bound to each TRE would also be beneficial, as any differences between them 
may contribute to the different roles of the two elements in transcriptional regulation.
However, the important conclusions for the purposes of the comparative study were that, 
as reported, the bkj promoters used are up-regulated by v-Jun through the proximal TRE, 
and that the -73/+63 ColCAT promoter is repressed by v-Jun through its TRE at position 
-72.
5.2.3 The effect of the protein complexes bound to different TREs.
The first stage in the comparison of the bkj and collagenase promoters was identification of 
the proteins bound to their TREs. EMSAs (Figure 3.3A) and antibody super-shift 
experiments (Figure 3.3C, D) showed the binding of similar protein complexes to each 
TRE within each cell type. As previously seen with the collagenase TRE in chicken cells 
(Hawker et al., 1993; Kilbey et al., 1996), the complex contained v-Jun in v-Jun 
transformed CEFs and predominately c-Jun in CEFs, with Fra-2 as the major dimerisation 
partner in each case.
The complex bound to each TRE in CEFs was not completely shifted by a c-Jun specific 
antibody (Figure 3.3C). The collagenase TRE has been shown to be bound by JunD in 
rabbit fibroblasts (White and Brinckerhoff, 1995), but not in CEFs (Kilbey et al., 1996). 
Further antibody super-shifts would determine whether JunD binds the bkj TREs in CEFs. 
In both cell types, a broad-specificity Fos family antibody completely shifted each 
complex, while a Fra-2 specific antibody effected only a partial shift. As discussed in 
Chapter 3.3, the residual complex may contain the chicken homologues of the FosB and 
Fra-1 proteins. Any differences between the TREs in the composition of this residual 
complex may be important for their function in transcriptional regulation.
However, competition assays showed that all three TREs were bound by an identical 
complex in v-Jun transformed CEFs (Figure 3.3B). Differences in the composition of the 
protein complex bound to each TRE are therefore unlikely to account for the different 
effects of v-Jun on the two promoters.
5.2.4 The effect of TRE position.
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Comparisons between the collagenase, stromelysin and c-jun promoters suggested that the 
position of the TRE relative to the transcriptional start site may have an effect on target 
promoter regulation by v-Jun (see Chapter 3.4). This was investigated by the creation of a 
panel of variant bkj promoters with TREs introduced at different positions relative to the 
transcriptional start site.
As shown in Figure 3.6, alteration of TRE position modified regulation of the bkj promoter 
by v-Jun. This was not due to different levels of co-operation of each introduced TRE with 
the wild-type proximal TRE at position -815, as prior point mutation had eliminated this 
element (Figure 3.4). Nor was the binding of different proteins likely to be responsible for 
the variations in transcriptional activity, as each TRE was, like the wt(P)TRE, bound 
predominately by c-Jun / Fra-2 dimers in CEFs and v-Jun / Fra-2 dimers in v-Jun 
transformed CEFs (Figure 3.5C). These proteins bound to each TRE with slightly different 
affinities (Figure 3.5B), probably due to the different sequences flanking the TRE in each 
case, which have been shown to contribute to the affinity of binding by Jun / Fos dimers 
(Ryseck and Bravo, 1991). However, TRE binding affinity did not correlate with the level 
of activation of the bkj promoters in either cell type. The variations in promoter activity 
seen in Figure 3.6 were therefore due primarily to the different TRE position in each case.
The reasons for these variations are unclear. There appear to be three phases: a progressive 
decrease in transcription in v-Jun transformed CEFs from TREs at positions from -815 to 
-323; high levels of transcription in both cell types from TREs at positions -169 and -109; 
and a pattern of activation resembling that of the wild-type promoter from TRE position 
-65. It would be interesting to investigate whether these three phases represent different 
transcriptional mechanisms of v-Jun from different TRE positions, for example by 
recruitment of different components of the pre-initiation complex, different HAT co­
activators or chromatin remodelling factors. The use of specific inhibitors could potentially 
determine which, if any, of the mutant promoters are activated by a mechanism involving 
HATs.
The principal conclusion from these experiments was that the introduction of a TRE close 
to the transcriptional start site did not convert a v-Jun activated to a v-Jun repressed 
promoter. However, an effect of TRE position on the nature of transcriptional regulation 
by v-Jun can not be ruled out. A major limitation of this study was the requirement for sites 
with sequence similarity to a TRE, to enable conversion into a consensus TRE using
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mutagenic PCR primers. In the attempt to create a TRE in a position closely corresponding 
to that of the site in the collagenase promoter, the nearest available site for conversion was 
at position -65. Repression of other promoters by v-Jun occurs from TREs at position -72 
(collagenase and c-jun) or -71 (stromelysin: see Chapter 3.4). Binding of v-Jun / Fra-2 to 
the -65TRE bkj promoter would therefore occur on the opposite face of the DNA helix 
(relative to the transcriptional start site) than on the three natural v-Jun repressed 
promoters. This difference may be crucial for the nature of transcriptional regulation by v- 
Jun, for example by affecting binding and assembly of the pre-initiation complex.
Certain transcription factors have been shown to depend on the stereospecific alignment 
between their binding site and the TATA box for their transcriptional activity at certain 
promoters. Examples include myoD and myogenin, which bind to the proximal E-box of 
the murine desmin gene promoter (Li and Capetanaki, 1994), and Spl within the SV40 
early promoter (Takahashi et al., 1986). Within the tyrosine hydroxylase promoter, 
insertions of full or half DNA helical turns between the CRE and the TATA box caused 
variations in the level of basal transcription, but did not affect the induction of transcription 
by cAMP (Tinti et al., 1997).
A possible role for a precise stereospecific alignment between the TRE and the TATA box 
is suggested by comparison of the -169TRE and -109TRE bkj promoters (Figure 3.6). 
These promoters contain TREs on the same face of the DNA helix relative to the 
transcriptional start site, and are regulated in a similar way, with high levels of activation 
in CEFs and v-Jun transformed CEFs. While other factors may contribute to the regulation 
of these promoters, their similarity suggests that the stereospecific alignment between the 
TRE and the TATA box may be important.
Introduction of a TRE at position -71 or -72 in the bkj promoter would be likely to alter 
the overall levels of transcription in CEFs and v-Jun transformed CEFs, but it is less clear 
whether the TRE would mediate repression by v-Jun. Mutation of the six bases at this site 
which differ from a consensus TRE would require two rounds of mutagenic PCR. 
Alternatively, a TRE could be introduced at this site by insertion, but this would cause 
greater overall sequence disruption than would site-directed mutagenesis. Construction of 
such a promoter would provide a better comparison with the collagenase promoter, and 
may yet provide evidence for TRE position as a determinant of transcriptional regulation 
by v-Jun.
5.2.5 The effect of core promoter sequence.
147
As described in Chapter 3.5, regulation by certain transcription factors has been shown to 
be influenced by the sequences of core promoter elements, such as the TATA box and Inr. 
These sequences were therefore exchanged between the bkj and collagenase core 
promoters, to investigate their possible role in determining the nature of target promoter 
regulation by v-Jun.
Figures 3.7B-D show the effect of TATA box and / or ILS exchange between the 
collagenase and bkj promoters. It is clear that the TATA box and ILS do not determine 
whether these target genes are activated or repressed by v-Jun. However, the overall levels 
of transcription from the bkj promoter, but not collagenase, were altered by interaction of 
c-Jun and v-Jun with different core promoter element sequences.
Figure 3.7C indicates a role for a consensus initiator in transcription from the bkj promoter. 
It would be interesting to analyse this element functionally, for example by analysis of the 
effect of point mutations on the choice of transcriptional start site. The bkj promoter 
contains two transcriptional start sites (Hartl and Bister, 1998). The minor site has no 
consensus Inr sequence and is not active in QEFs expressing c-Jun or v-Jun (Hartl and 
Bister, 1995; Hartl and Bister, 1998). However, this alternative site is used to initiate a 
small number of transcriptional events in ASV17-transformed CEFs (Hartl and Bister, 
1995; Hartl and Bister, 1998). It would be interesting to analyse the contribution of the ILS 
at the major transcriptional start site to this species difference in transcription initiation.
Another intriguing result is the difference between the wt(P)TRE bkj and -65TRE bkj 
promoters. Introduction of the collagenase ILS decreased transcription from both 
promoters (Figure 3.7C), implying that v-Jun activates transcription by a mechanism 
involving an Inr in both cases. However, introduction of the collagenase TATA box, alone 
or in combination with the collagenase ILS, affected transcriptional regulation from 
wt(P)TRE bkj, but had little or no effect in the context of the -65TRE bkj promoter (Figure 
3.7B, D). This suggests that, while alteration of TRE position does not convert bkj into a v- 
Jun repressed promoter, it may alter the mechanism whereby v-Jun activates the promoter. 
Figure 3.7B suggests that this may be by removing v-Jun’s dependence on TATA box 
sequence. This could provide an explanation for the three distinct phases of the variations 
in bkj promoter activity seen in Figure 3.6 (see Chapter 5.2.4).
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As described in Chapter 3.5, some studies have shown a link between a transcription 
factor’s dependence on TATA box sequence within a particular promoter, and its binding 
to components of the pre-initiation complex (Cook et al., 1995; Taylor and Kingston, 
1990b). This relationship could suggest distinct mechanisms for the regulation of different 
promoters by v-Jun, i.e. by direct recruitment of the pre-initiation complex to the core 
promoter of wt(P)TRE bkj, but not -65TRE bkj or collagenase. However, the correlation 
between TATA box sequence dependence and binding to the pre-initiation complex is not 
absolute. E la and VP16 each bind components of the pre-initiation complex (Gupta et al., 
1996; Horikoshi et al., 1991; Lee etal., 1991b; Stringer et al., 1990; Xiao etal., 1994), but 
have been shown to activate transcription independently of TATA box sequence (Perera, 
2000; Taylor and Kingston, 1990a). Further work, for example footprinting or template 
commitment assays with the wt(P)TRE bkj, -65TRE bkj and collagenase core promoters, 
may help to resolve this issue.
5.2.6 Future work.
A M/-derived promoter with a TRE at position -65 and none of the upstream sequence is, 
like wt(P)TRE bkj and -65TRE bkj, activated more strongly in v-Jun transformed CEFS 
than controls (Figure 3.8). This construct may provide a better comparison with -73/+63 
ColCAT, as both promoters contain a TRE at the extreme 5’ end of the promoter. While 
activation of -66/+13 -65TRE bkj by v-Jun may be found to differ in some respects from 
the regulation of the natural bkj promoter, comparisons between -66/+13 -65TRE bkj and 
-73/+63 ColCAT will serve as a useful model in further investigations of the 
transcriptional mechanisms responsible for the opposing effects of v-Jun on different 
promoters.
The first stage would be to determine whether the different effects of v-Jun on the two 
promoters are mediated through sequence variations in the TREs, or in the core promoters. 
Differences in the sequences of TREs, and flanking DNA up to lObp from the central base 
of the TRE, have been shown to affect the affinity and orientation of Jun / Fos heterodimer 
binding (Leonard et al., 1997; Rajaram and Kerppola, 1997; Ramirez-Carrozzi and 
Kerppola, 2001a; Ramirez-Carrozzi and Kerppola, 2001c; Ryseck and Bravo, 1991). 
Different orientations of heterodimer binding to a TRE affected DNA bending at the site 
and transcriptional synergy with NFAT proteins bound to a site adjacent to the TRE 
(Ramirez-Carrozzi and Kerppola, 2001a; Ramirez-Carrozzi and Kerppola, 2001b).
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The collagenase TRE, bkj proximal TRE and the TRE introduced at bkj position -65 are 
not predicted to show a strong preference for the orientation of Jun / Fos heterodimer 
binding (V.R. Ramirez-Carrozzi, personal communication), suggesting that the bkj and 
collagenase TRE flanking sequences are unlikely to determine the nature of transcriptional 
regulation by v-Jun. Exchange of the TRE and flanking sequences between the two 
promoters would verify this.
A more likely explanation for the different effects of v-Jun on the collagenase and bkj 
promoters is variation in core promoter sequences other than the TATA box and ILS. 
Exchange of whole core promoters between bkj and collagenase, followed by the exchange 
of smaller sequence blocks, would determine whether this is the case, and may identify the 
core promoter regions which are likely to determine the transcriptional effect of v-Jun. 
Possible candidates are the sequence blocks immediately flanking the TATA box, as 
exchange of these sequences between promoters has been shown to affect the level of 
transcriptional induction by a chimaeric Gal4-VP16 transcription factor (Wolner and 
Gralla, 2000).
However, it may be that this kind of dissection of the bkj and collagenase gene promoters 
will not identify the determinants of transcriptional regulation by v-Jun. The whole 
sequence of such natural promoters has evolved together to determine how the gene is 
regulated by transcription factors, and it may be that individual sequence elements can not 
function correctly outside the natural core promoter context. However, as with the 
experiments described in Chapter 3, further comparative studies between genes activated 
or repressed by v-Jun are likely to provide insights into the transcriptional mechanisms of 
v-Jun at specific target promoters. Such findings may be found to be applicable to other v- 
Jun target genes, and may lead indirectly to a better understanding of the transcriptional 
mechanisms responsible for the opposing effects of v-Jun on different target promoters.
5.3 Activation of v-Jun target genes and cell 
transformation.
5.3.1 Introduction
Fusion to the ligand-binding domain of ER-a is a widely used method to confer hormone- 
inducible function upon a heterologous protein. In the case of ER-a fusions to transcription 
factors such as Jun, activation of the ER-a AF-2 domain is thought to contribute to
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hormone-dependent transcriptional regulation of target promoters by the chimaeric protein 
(Francis et al., 1995; Kim et ah, 1996). Therefore, when constructing a hormone- 
regulatable v-Jun-ER fusion protein, an amino-terminally truncated v-Jun protein was also 
fused to the ER-a hormone-binding domain, to determine the contribution of the AF-2 
domain to the hormone-dependent functions of the v-Jun-ER protein (Kruse et al., 1997).
It was found that the ligand-activated AF-2 domain could substitute for the function of the 
v-Jun TAD, in transcriptional activation of v-Jun target promoters and induction of some 
of the characteristics of cell transformation. This observation suggested a common 
mechanism of cell transformation by v-Jun and AvJ-hER, with activation, rather than 
repression, of v-Jun target promoters thought to be important for the transformation 
process. The work described in Chapter 4 sought to better characterise the relationship 
between activation of v-Jun target genes and cell transformation.
5.3.2 Characterisation of cells expressing AvJ-hER.
The premise that hormone-dependent cell transformation by AvJ-hER is due to the 
activation of v-Jun target promoters by the ER-a AF-2 domain assumes that the chimaeric 
protein is recruited to TRE and CRE-containing promoters by the v-Jun DBD. It was not 
clear whether the addition of estradiol directly activated the AF-2 domain of AvJ-hER 
bound constitutively to target promoters, or caused transcriptional activation and cell 
transformation by regulation of the sub-cellular location or DNA binding activity of the 
protein.
Previous studies with Jun and Fos-ER proteins suggest that the level at which hormone 
regulates the function of such chimaeric proteins varies. For example, proteins consisting 
of JunD or Fos proteins fused to the ER-a ligand-binding domain were constitutively 
nuclear in location (Francis et al., 1995; Schuermann et al., 1993), while c-Jun-ER was 
expressed throughout the cytoplasm and nucleus in untreated cells, with the addition of 
estradiol stimulating nuclear accumulation of the protein (Fialka et al., 1996). Similarly, 
JunD-ER was strictly hormone-dependent for DNA binding (Francis et al., 1995), while c- 
Fos-ER has been shown to bind TREs in the absence of estradiol (Crowe et al., 2000), and 
DNA binding by a c-Jun bZip-ER protein was increased by estradiol treatment (Kim et al.,
1996). The regulation of AvJ-hER at these levels had not previously been studied.
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The results described in Chapter 4.2.3 show that AvJ-hER is not regulated by hormone at 
the level of sub-cellular location or DNA binding, but binds constitutively to TREs. The 
hormone-dependent effects of AvJ-hER are therefore likely to be a direct result of 
activation of the AF-2 domain at v-Jun target promoters.
One unexpected effect of AF-2 domain activation was down-regulation of the endogenous 
c-Jun protein (Figure 4.1). Antibody super-shift experiments suggested that this down- 
regulation was not complete, and that residual c-Jun protein bound TREs (see Chapter 
4.2.3). However, the level of residual c-Jun protein was below the limits of detection by 
Western blotting techniques. As described in Chapter 4.2.2, the levels of c-jun mRNA and 
transcription from the c-jun promoter were not decreased in AvJ-hER CEFs treated with 
estradiol. This suggested that, unlike the v-Jun TAD, the ligand-activated AF-2 domain of 
AvJ-hER does not directly repress c-jun at the level of transcription. It would be interesting 
to determine whether other negative targets of v-Jun, such as collagenase and SSeCKS, are 
also repressed in estradiol-treated AvJ-hER CEFs. The results described in Chapter 4.2.2 
suggest that direct transcriptional targets of v-Jun may not be repressed. The down- 
regulation of c-Jun at the translational or post-translational level is likely to be specific, 
possibly due to its homology with the v-Jun domains of AvJ-hER.
The mechanism of specific c-Jun protein down-regulation by ligand-activated AvJ-hER is 
unknown. One possibility is that the activated protein specifically decreases the rate of c- 
Jun translation. Evidence exists that chicken c-jun mRNA is translated by a mechanism 
involving internal initiation, due to a putative internal ribosome entry segment(s) within 
the 5’ UTR (Sehgal et al., 2000). Translation by internal initiation is not well understood, 
and it is not clear how ligand-activation of a protein such as AvJ-hER could specifically 
disrupt this process.
Perhaps a more likely explanation for the down-regulation of c-Jun in estradiol-treated 
AvJ-hER CEFs is specific protein degradation. In the presence of activating ligand, c-Jun 
was down-regulated by AvJ-hER wt, but not by the transcriptionally inactive AvJ-hER mt 
protein (Figure 4.5). c-Jun was also down-regulated in cells expressing AV2, a fusion of 
the v-Jun bZip domain to the VP16 TAD. Fusion of a functional TAD to the v-Jun bZip 
domain is therefore associated with down-regulation of the endogenous c-Jun protein.
Recently, there has been much interest in the link between transcriptional activation and 
protein degradation by the ubiquitin / proteasome pathway, initiated by the observation that
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the Myc “degron”, the region of the protein which signals its degradation, overlaps its 
TAD (Salghetti et al., 1999). This is now known to be a common feature of many 
transcription factors with acidic TADs, including Jun, Fos, and Gcn4 (Salghetti et al.,
2000). Studies with various wild-type and mutated TADs have shown a correlation 
between ubiquitin / proteasome-mediated protein degradation and transcriptional activation 
(Molinari et al., 1999; Salghetti et al., 1999; Salghetti et al., 2000).
Phosphorylation of yeast Gcn4 by SrblO, a component of the RNA polymerase II 
holoenzyme, signalled the ubiquitination and degradation of the transcription factor (Chi et 
al., 2001). Similarly, cdk7, a component of TFIIH, phosphorylated the E2F-1 TAD; this 
was thought to stimulate degradation of the protein (Vandel and Kouzarides, 1999). These 
observations have suggested the “Black Widow” model of transcription-linked protein 
degradation, whereby recruitment of the pre-initiation complex and activation of 
transcription by certain transcription factors signals their destruction, mediated by 
components of the transcription machinery (Tansey, 2001). This is proposed to provide an 
additional level of transcriptional regulation.
While recent studies suggest that, in some cases, ubiquitination regulates the activity of a 
transcription factor independently of its function in protein degradation (Salghetti et al.,
2001), the proteasome itself has been shown to be essential for transcriptional activation in 
the case of ER-a (Lonard et al., 2000). However, both mechanisms result in the 
degradation of the ubiquitinated transcription factor. Various studies have shown that 
proteins non-covalently bound to a ubiquitinated transcription factor are also targeted for 
degradation. For example, activation of the retinoid X receptor with specific ligand 
signalled the destruction of the receptor and its heterodimerisation partner, even when the 
partner protein was itself transcriptionally inactive (Osburn et al., 2001).
ER-a was ubiquitinated and degraded by the proteasome in the presence of estradiol, but 
not tamoxifen, while a transcriptionally inactive helix 12 mutant was not degraded 
(Nirmala and Thampan, 1995; Wijayaratne and McDonnell, 2001). The VP16 TAD was 
also ubiquitinated and degraded by the proteasome (Salghetti et al., 2001). This suggests a 
mechanism for the repression of c-Jun by AV2 and ligand-activated AvJ-hER. c-Jun could 
theoretically dimerise with these proteins via the v-Jun leucine zipper, and become 
degraded by the proteasome upon transcription-linked ubiquitination of its 
heterodimerisation partner. This is an attractive model, as it provides an explanation for the 
down-regulation of c-Jun by transcriptionally active AV2 and agonist-bound AvJ-hER wt,
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but not by transcriptionally inactive AvJ-hER mt, AvJ-p300 proteins, and unliganded or 
antagonist-bound AvJ-hER wt.
There are possible problems with this model. Figure 4.1 shows that the expression of AvJ- 
hER was not decreased by the addition of estradiol. However, any transcription-linked 
degradation of this protein may be masked by its high level of expression from the RCAS 
retroviral vector. Indeed, the level of a high-mobility degradation product of AvJ-hER was 
increased in the presence of estradiol (Figure 4.1), indicating some degree of protein 
degradation in the presence of activating ligand. This was not an effect of ligand binding, 
as the AvJ-hER mt protein was not degraded in estradiol-treated cells (Figure 4.5 and 4.6). 
Additionally, super-shift and biotinylated-oligonucleotide capture experiments show that, 
while AvJ-hER wt and c-Jun bound to TREs in untreated cells, both proteins appeared to 
dimerise with Fra-2, not with each other (Figure 4.3 and 4.4). However, this may not 
reflect the situation in vivo. Alternatively, AvJ-hER and c-Jun may dimerise in response to 
estradiol, promoting degradation of c-Jun.
Further investigation of this model is required. Firstly, it is important to determine whether 
c-Jun binds to AV2, and to AvJ-hER wt in the presence and absence of estradiol. 
Determination of the half-lives of AvJ-hER wt and mt in the presence and absence of 
estradiol would establish whether any degradation of these proteins correlates with their 
transcriptional activity. Time-course experiments would reveal the rate of c-Jun 
degradation in AvJ-hER CEFs upon addition of estradiol, and whether this process can be 
blocked by the inhibition of ubiquitination or proteasome function. These experiments may 
suggest a mechanism for the down-regulation of c-Jun by AV2 and ligand-activated AvJ- 
hER.
5.3.3 The role of the ER-a AF-2 domain in hormone-dependent 
transcriptional activation and cell transformation by AvJ- 
hER.
As described above, the ER-a AF-2 domain is proposed to contribute to hormone- 
dependent transcriptional activation by AvJ-hER and other Jun-ER fusion proteins.
Changes in the position of helix 12 within this domain are thought to regulate the binding 
of transcriptional co-activators and co-repressors in response to agonist or antagonist 
ligands (see Chapter 1.3.1.2). This motif is therefore critical for ligand-specific
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transcriptional activation and repression by nuclear hormone receptors. A double amino 
acid substitution was introduced into helix 12 of AvJ-hER, to determine whether hormone- 
dependent transcriptional activation and cell transformation by the chimaeric protein were 
mediated by the ER-a AF-2 domain.
Figure 4.5 and 4.6 show that, while passaging cells in the presence of estradiol increased 
the expression of the AvJ-hER wt protein, no such effect was observed with AvJ-hER mt. 
Cell growth assays confirmed a previous report (Kruse et al., 1997) that expression of AvJ- 
hER wt increased the rate of cell proliferation in the presence of estradiol, and showed that 
a functional AF-2 domain was required for this effect (Figure 4.10). This result suggests 
that in the presence of estradiol, expression of AvJ-hER wt, but not AvJ-hER mt, conferred 
a selective advantage on infected cells and specifically increased the rate of spread of the 
RCAS-AvJ-hER wt virus.
A JunD-ER fusion protein was reported to delay Gl-S transition, and therefore decrease 
the rate of cell proliferation, in the absence of hormone (Francis et al., 1995). In the 
attempt to isolate clonal JunD-ER cell lines by antibiotic selection, it was reported that 
expression of the fusion protein could only be detected if cells were selected in the 
presence of agonist ligand as well as antibiotic (Francis et al., 1995). Similarly, the 
efficiency of cell transformation induced by a panel of mouse c-Jun mutant proteins 
correlated with their level of expression from RCAS vectors in CEFs (Morgan et al.,
1992). This suggests that correlation between the level of expression of a protein and its 
ability to increase the rate of cell proliferation may be a common effect.
With this kind of correlation, it is difficult to distinguish between cause and effect. 
However, in the case of AvJ-hER, direct comparison between the wild-type and mutated 
proteins suggests that their levels of expression are a result of their effects on the rate of 
cell proliferation. Immunocytochemistry experiments performed at various stages 
throughout the infection process would determine the proportion of cells expressing AvJ- 
hER wt or mt in the presence of estradiol or carrier control. The relative levels of 
expression of the proteins in individual infected cells could also be compared. It may be 
possible by this method to begin to quantitate the rate of spread of the RCAS-AvJ-hER wt 
and mt viruses.
Introducti on of the M543A / L544A mutation into helix 12 of full-length ER-a or a 
Gal4 ER VP16 fusion protein abolished hormone-dependent activation of target promoters
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(Danielian et al., 1992; Stafford and Morse, 1998). It was expected that the equivalent 
mutation within AvJ-hER would have a similar effect on the transcription of v-Jun target 
promoters. Having determined that full-length AvJ-hER mt bound constitutively to TREs 
(Figure 4.7B), its ability to activate transcription from a v-Jun target promoter was 
determined. Transcription from the bkj promoter was assayed, as bkj is a direct 
transcriptional target of v-Jun ((Hartl and Bister, 1995; Hartl and Bister, 1998), Chapter 3 
of this work) and estradiol-induced AvJ-hER wt (Kruse et al., 1997).
As expected, AvJ-hER mt did not activate the bkj promoter in the presence of estradiol 
(Figure 4.8). In fact, AvJ-hER mt reproducibly repressed the basal level of bkj transcription 
in a hormone-dependent manner. A similar effect has been observed in the context of an 
ER-a protein with a deletion of the AF-2 domain. This protein repressed basal 
transcription from positive ER-a target promoters in the presence of estradiol (Jung et al.,
2001). Unlike wild-type ER-a, which interacts with co-repressor proteins only in the 
presence of antagonist ligands (Lavinsky et al., 1998; Shang et al., 2000), AF-2-deleted 
ER-a bound constitutively to SMRT, and estradiol-dependent transcriptional repression 
was relieved by TSA treatment (Jung et al., 2001). This suggests that the AF-2-deleted 
protein repressed basal transcription via histone deacetylation.
In contrast to AvJ-hER mt, the AF-2-deleted ER-a protein bound DNA in a hormone- 
dependent manner. This could account for hormone-dependent transcriptional repression 
by recruitment of HD AC activity to target promoters only in the presence of estradiol. As 
AvJ-hER mt binds constitutively to TREs, its mechanism of hormone-dependent 
transcriptional repression may differ from that of AF-2-deleted ER-a in some respects.
One possibility is that repression by AvJ-hER mt is an effect of the increased availability of 
co-repressor proteins upon estradiol treatment, due to their release by endogenous ER 
proteins. It would be interesting to determine whether TSA treatment relieves repression of 
the bkj promoter by estradiol-bound AvJ-hER mt, and whether the mutated protein binds 
co-repressors such as SMRT in the presence and absence of estradiol.
As full-length AvJ-hER mt bound constitutively to TREs, its failure to activate the bkj 
promoter is thought to be a direct transcriptional effect of AF-2 domain mutation. This 
supports the hypothesis that hormone-dependent transcriptional activation of v-Jun target 
promoters by AvJ-hER is mediated by the ER-a AF-2 domain. It would be expected that 
AvJ-hER mt is also deficient in the activation of other v-Jun target genes such as HB-EGF. 
However this has not yet been investigated.
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The ability of the AvJ-hER proteins to induce hormone-dependent cell transformation was 
determined. As described in Chapter 4.3.4, AvJ-hER wt induced hormone-dependent cell 
transformation based on three criteria: altered cell morphology, an increased rate of cell 
proliferation, and the induction of anchorage-independent growth. This confirms previous 
reports (Kruse et al., 1997). Unexpectedly, estradiol-bound AvJ-hER wt induced 
anchorage-independent growth approximately 3-fold more efficiently than v-Jun (Table 
4.1).
In contrast, the transcriptionally inactive AvJ-hER mt protein did not induce cell 
transformation in the presence of estradiol. This supports the hypothesis that hormone- 
dependent cell transformation by AvJ-hER wt is mediated by the ER-a AF-2 domain, and 
provides evidence for a relationship between activation of v-Jun target promoters and cell 
transformation (see Chapter 5.3.5).
5.3.4 The role of a HAT co-activator protein in transcriptional
activation of v-Jun target promoters and cell transformation.
As described in Chapter 1.3.1.2, there is a great deal of evidence that hormone-dependent 
transcriptional activation by the AF-2 domain of nuclear hormone receptors is mediated by 
the recruitment of HAT co-activator proteins. Thyroid hormone receptor proteins 
containing point mutations within the AF-2 domain have been shown to be defective for 
binding to SRC-1 and other co-activators (Liu et al., 1998; Tagami et al., 1998). The 
failure of AvJ-hER mt to mediate hormone-dependent transcriptional activation of a v-Jun 
target promoter may therefore be due to a similar disruption of co-activator binding.
While various co-activators bind nuclear hormone receptors, the nature of their 
contribution to hormone-dependent transcriptional activation has not, in many cases, been 
directly determined. However, the HAT activity of p300 has specifically been shown to 
mediate hormone-dependent transcriptional activation by ER-a (Kraus et al., 1999; Shang 
et al., 2000). There is also evidence for a role of p300 in transcriptional activation by c-Jun 
(Lee et al., 1996). The AvJ-p300 wt and mt fusion proteins were therefore created, to 
determine whether direct recruitment of HAT activity to v-Jun target promoters could 
substitute for the function of the v-Jun TAD or ligand-activated AF-2 domain in 
transcriptional activation and cell transformation.
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Although both AvJ-p300 wt and mt were expressed in CEFs and bound TREs (Figure 4.12, 
4.13), neither protein induced transcriptional activation of the bkj promoter or cell 
transformation (Figure 4.14, Chapter 4.4.4). The inactivity of the AvJ-p300 mt protein was 
expected, as its HAT domain was derived from p300 Mut AT2, which had negligible HAT 
activity in vitro and was deficient in the hormone-dependent co-activation of ER-a target 
promoters (Kraus et al., 1999). However, AvJ-p300 wt contains a HAT domain which was 
active in these assays in the context of the full-length p300 protein (Kraus et al., 1999).
The failure of AvJ-p300 wt to activate v-Jun target promoters could have several causes. 
One possibility is that the chimaeric protein has no HAT activity. This would not be 
expected, as DNA sequencing of RCAS-AvJ-p300 wt showed that the p300 HAT domain 
was fused in-frame with the v-Jun bZip region, and was not mutated during the PCR and 
cloning process. Additionally, fusion of the equivalent domain of the highly similar CBP 
protein to the Gal4 DBD created a protein with in vitro HAT activity (Martinez-Balbas et 
a l, 1998).
However, differences between p300 and CBP may render a p300 HAT domain fusion such 
as AvJ-p300 wt transcriptionally inactive. The p300 domain used lacks protein regions 
which interact with other co-activators such as PCAF and SRC-1. These interactions may 
be necessary for transcriptional activation of v-Jun target promoters by p300. This would 
not be unprecedented. It has been shown that, while p300 and PCAF both co-activated 
transcription by MyoD, the HAT activity of PCAF, but not p300, was essential for co­
activation (Puri et al., 1997). This suggests that, at some promoters, p300 may activate 
transcription by the recruitment of PCAF and other HAT proteins. The HAT activity of 
AvJ-p300 wt and mt could be determined by an in-gel HAT assay or similar method. Any 
HAT deficiency of AvJ-p300 wt would provide a probable explanation for the failure of 
this protein to activate the transcription of a v-Jun target promoter.
However, it may be found that AvJ-p300 wt has a functional HAT domain but does not 
activate transcription. A Gal4-CBP HAT domain fusion protein activated transcription 
from five Gal4 binding sites located upstream of the adenovirus AdML and E4 promoters, 
but not the E1B promoter (Martinez-Balbas et al., 1998). It may be that AvJ-p300 wt could 
similarly activate only a sub-set of TRE-containing promoters. Assessment of the effect of 
AvJ-p300 wt expression on other known v-Jun target genes may determine whether this is 
the case. However, given the failure of AvJ-p300 wt to induce cell transformation, it seems
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unlikely that the chimaeric protein would activate the transcription of putative v-Jun 
effector genes such as HB-EGF.
A further possibility is that transcriptional activation of v-Jun target promoters is mediated 
not by p300, but by other co-activator proteins such as CBP, PCAF or SRC-1. As 
described in Chapter 1.3.1.2 and 1.3.2.2, various HAT proteins are known to bind c-Jun 
and nuclear hormone receptors, possibly as co-activator complexes. However, the specific 
roles of these proteins in transcriptional activation of c-Jun and v-Jun target genes are not 
known.
Despite the high degree of sequence conservation between p300 and CBP, examples are 
known where the two proteins have distinct functions. The use of ribozymes which 
specifically cleave p300 or CBP mRNA showed that p300, but not CBP, was required for 
transcriptional activation and cell differentiation in response to retinoic acid (Kawasaki et 
al., 1998; Kawasaki et al., 1999). However, both proteins contributed to retinoic acid- 
induced growth arrest and apoptosis. It was shown that p300 was required for activation of 
the p21 promoter, while CBP was specifically involved in activation of the p27 promoter 
(Kawasaki et al., 1998). A similar study in human cells indicated a role for p300, but not 
CBP, in ionising radiation-induced apoptosis (Yuan et al., 1999).
These results suggest that, despite the similarity of p300 to CBP, the two proteins are 
involved in different processes and co-activate different sets of promoters. It may be that v- 
Jun and ligand-activated AvJ-hER wt activate transcription via the recruitment of CBP or 
other HAT proteins, rather than p300. Fusions of the v-Jun bZip domain to other HAT co­
activator proteins may therefore be able to activate transcription from v-Jun target 
promoters, possibly leading to cell transformation.
Alternatively, the deficiency of AvJ-hER mt in hormone-dependent transcriptional 
activation may be due to a failure to recruit not HAT co-activators, but other factors such 
as TAFu or SWI/SNF proteins. Determination of the histone acetylation status of the bkj 
promoter in estradiol-treated AvJ-hER wt and mt CEFs, for example by ChIP assays, could 
potentially reveal whether transcriptional activation by AvJ-hER wt is dependent on the 
activities of HAT co-activators, or other proteins.
5.3.5 Cell transformation as a result of v-Jun target gene 
activation.
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As described in Chapter 5.3.3, hormone-dependent transcriptional activation and cell 
transformation by AvJ-hER wt are mediated by the ER-a AF-2 domain. The failure of AvJ- 
hER mt and the AvJ-p300 proteins to induce cell transformation is proposed to be due to 
their inability to activate v-Jun target promoters. The relationship between transcriptional 
activation of v-Jun target genes and cell transformation is further supported by parallel 
observations with AV2. This protein consists of the v-Jun bZip domain fused to the VP16 
TAD, and has been shown to bind TREs and CREs (Schuur et al., 1993).
The AV2 protein strongly activated the bkj promoter (Figure 4.8). AV2 had previously 
been shown to activate transcription only very weakly compared with v-Jun (Schuur et al.,
1993). However, this comparison was performed using the -73/+63 ColCAT promoter. 
While Schuur et al reported some degree of activation of this promoter in CEFs by v-Jun 
and AV2, other reports have shown the collagenase promoter to be a negative 
transcriptional target of v-Jun ((Hussain et al., 1998; Kilbey et al., 1996), Chapter 3 of this 
work). While the reason for this discrepancy is not clear, Figure 4.8 clearly shows that 
recruitment of the VP 16 TAD to the bkj promoter induced a high level of transcription.
The expression of other v-Jun target genes in AV2 CEFs, such as collagenase or HB-EGF, 
has not been investigated. As described in Chapter 4.3.4, expression of AV2 induced cell 
transformation, as assayed by cell morphology, rate of cell proliferation, and anchorage- 
independent growth. This supports the relationship between activation of v-Jun target 
genes and cell transformation.
Comparison between Figure 4.8 and Table 4.1 reveals a negative correlation between the 
efficiency of bkj promoter activation and of cell transformation by v-Jun, AV2 and ligand- 
activated AvJ-hER wt. The significance of this relationship is not known. A previous report 
assayed the efficiency of transcriptional activation and cell transformation by a panel of c- 
Jun mutant proteins containing various deletions within the delta domain (Havarstein et al.,
1992). A negative correlation between transcriptional activation and cell transformation 
was observed. However, the -73/+63 ColCAT promoter was again used to assay 
transcription. As this is a negative target of v-Jun, a higher level of activation of this 
promoter by a mutated c-Jun protein could indicate a lesser degree of transcriptional mis- 
regulation compared to v-Jun. Indeed, the use of some of these mutant c-Jun proteins in a 
screening panel revealed a positive correlation between their activation of HB-EGF and
160
reversion-induced LIM protein, and their efficiency of cell transformation (Fu et al., 1999; 
Fu et al., 2000).
Others have reported that estradiol-bound AvJ-hER wt induced anchorage-independent 
growth with a similar efficiency to v-Jun (Kruse et al., 1997), and that AV2 induced cell 
transformation with a significantly decreased efficiency compared to v-Jun (Schuur et al.,
1993). While the relative abilities of these proteins to induce cell transformation may vary 
between studies, it is clear from Figure 4.8 and Table 4.1 that all three constructs induced 
the activation of a v-Jun target gene and anchorage-independent growth with a high 
efficiency compared to negative controls. It may be that a threshold level of activation of 
v-Jun target genes is sufficient to induce cell transformation. It is equally possible that bkj 
is not a v-Jun effector gene, and that the level of activation of genuine effector genes 
correlates more closely with the efficiency of anchorage-independent growth. 
Determination of the expression of putative effector genes such as HB-EGF in these cells 
may help to resolve this issue.
It is also possible that, like v-Jun, AV2 and ligand-activated AvJ-hER wt repress certain 
target genes. While ligand-activated AvJ-hER wt did not repress transcription from the c- 
jun promoter, this negative target of v-Jun was nevertheless down-regulated by another 
mechanism, possibly specific protein degradation (see Chapter 5.3.2). While it would be 
expected that negative transcriptional targets of v-Jun, such as collagenase, would not be 
repressed by ligand-activated AvJ-hER wt and AV2, other targets may be down-regulated 
by indirect mechanisms. It is not known whether putative v-Jun effector genes such as 
SSeCKS and SPARC are down-regulated by v-Jun at the level of transcription, or whether 
they are indirect targets. Proteins such as these may be found to be down-regulated in AV2 
and estradiol-treated AvJ-hER wt CEFs. However, this would not necessarily contradict the 
hypothesis that activation, rather than repression, of direct transcriptional v-Jun target 
genes is the primary cause of cell transformation.
Cell transformation by v-Jun, AV2 and ligand-activated AvJ-hER wt may be a result of 
altered target promoter selection, as well as increased transcriptional activation, compared 
to c-Jun. As described in Chapter 1.1.7.1, c-Jun bound preferentially to TREs and a sub-set 
of CREs, depending on the flanking sequence. However, analysis of DNA sequences 
bound by the v-Jun bZip domain revealed that v-Jun bound preferentially to CREs, rather 
than TREs (Kataoka et al., 1994). Also, interaction of c-Jun with other transcription factors 
can alter its affinity of binding to non-consensus TREs (see Chapter 1.1.7.2). The binding
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and activity of v-Jun at such promoters have not been investigated. However, based on the 
relative preferences of the proteins for binding to TREs and CREs, there are likely to be 
differences between the spectra of target promoters bound and regulated by c-Jun and v- 
Jun.
The v-Jun bZip domain would be expected to recruit the ER-a AF-2 domain or VP 16 TAD 
to the same set of target promoters as the v-Jun TAD. This may contribute to cell 
transformation by AV2 and ligand-activated AvJ-hER wt. Indeed, while fusion of the ER-a 
hormone-binding domain to the v-Jun bZip domain created AvJ-hER, which induced 
hormone-dependent cell transformation (Kruse et al., 1997), fusion of the same ER-a 
region to the bZip domain of c-Jun created a protein with an altered activity. This TAM67- 
ER protein induced transcriptional activation from a TRE-containing promoter, but not cell 
transformation, in the presence of estradiol (Kim et al., 1996). Indeed, expression of 
TAM67-ER inhibited transformation by Ras and Raf in a hormone-independent manner. 
This suggests that target promoter selection, as well as activation, is important for the 
induction of cell transformation by v-Jun.
Emerging technologies such as micro-array analysis may determine whether AV2 and 
ligand-activated AvJ-hER wt alter the expression of the same set of target genes as v-Jun. 
Analysis of common mis-regulated targets may facilitate the identification of v-Jun 
effector genes. Identification of these genes, and study of the effect of v-Jun on their 
regulation, would improve our understanding of the relationship between transcriptional 
regulation and cell transformation by v-Jun.
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